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Summary
The generation o f neocartilage grafts ex vivo shows promise for the repair o f articular 
cartilage defects. This thesis describes (1) the metabolism and macromolecular 
organisation o f grafts produced utilising a Transwell culture system at biochemical 
and microscopic levels, (2) the effect of chondrocyte de-differentiation, induced by 
monolayer expansion, on resultant graft tissue architecture, and (3) how addition o f 
exogenous hyaluronan o f varying molecular weights, during and post graft generation 
effect chondrocyte metabolism, with a view to explaining effects of hyaluronan 
administration in viscosupplementation procedures. Grafts generated from primary 
chondrogenic sources were o f hyaline nature with distinct zonal stratification as found 
in native articular cartilage evidenced by cell morphology, matrix organisation and 
immunohistochemical composition. Graft tissue produced from immature sources was 
more synthetically active than those produced from mature sources. Passage 
expansion o f chondrocytes in monolayer culture caused progressive reduction in graft 
thickness, loss o f zonal architecture, and a more fibrocartilaginous tissue histology, 
consistent with a de-differentiating chondrocyte phenotype. Grafts subjected to 
exogenous hyaluronan o f smaller molecular weight than that typically found in native 
aggrecan aggregates (500kDa-lOOOkDa) had an increased release o f proteoglycan 
from graft tissue. Addition o f hyaluronan with significantly higher molecular weight 
than endogenous hyaluronan resulted in an increased retention o f proteoglycan within 
graft tissue, suggesting that high molecular weight hyaluronan in 
viscosupplementation procedures may be facilitating the retention o f newly 
synthesised ‘repair aggrecan’ in pathological cartilage, slowing down the rate of 
cartilage destruction through loss o f proteoglycan from the tissue. Futhermore, the 
addition o f 490kDa (similar molecular weight to endogenous hyaluronan) showed a 
marked increase in the amount o f aggrecan synthesised. Collectively, this data 
suggests that viscosupplementation procedures should incorporate a mixture o f 
hyaluronan ranging between 490kDa-3000+kDa in order to provide optimal benefits 
o f aggrecan retention and biosynthesis to osteoarthritic patients receiving this 
treatment modality.
XXIII
1 INTRODUCTION
1.1 Articular cartilage morphology
Ideally, tissue engineered cartilage grafts should show similarities to native cartilage 
in cellular distribution, collagen organisation and at a macromolecular level. It is 
important to take all these aspects into consideration when generating cartilage grafts. 
Cartilage is extensively distributed within the foetus, and often considered to be an 
‘embryonic tissue’. Through a process termed endochondral ossification, cartilage 
provides a template in which skeletal elements can develop, leading to skeletal 
maturity. In adults, there is a restriction in cartilage distribution but it is still located 
in a variety o f sites including trachea, nasal septum, and the focal point for this project 
‘the articulating join t’(Archer & Francis-West., 2003).
Articular cartilage is an avasular, aneural, alymphatic connective tissue that lines the 
ends o f bones in diarthroidal joints, providing a frictionless surface that has impact 
absorbing properties (Buckwalter and Hunziker., 1999). Cartilage contains one type 
o f cell, the ‘chondrocyte’. The chondrocyte is responsible for synthesising the 
extracellular matrix o f articular cartilage. A large percentage o f the extracellular 
matrix is composed o f collagens (see section 1.2), proteoglycans (see section 1.4) and 
water. Collagen constitutes up to 60% dry weight of articular cartilage and 
proteoglycans, immobilised within the extracellular matrix via a collagen framework, 
constitute 10-15% wet weight o f articular cartilage. Depending on the load status of 
the cartilaginous tissue water can contribute 65-80% of the total cartilage weight 
(Jackson et al., 2001).
1.1.1 Chondrocytes
There is only one cell type found within articular cartilage and it comprises only 2-5% 
of the tissue volume, this being the ‘chondrocyte’. The chondrocytes are 
cytoplasmically isolated, and consequently cell-cell contact is improbable. These 
cells are responsible for the synthesis o f extracellular matrix molecules including 
collagens, proteoglycans and non-collagnous proteins forming a unique, ordered
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structure (Buckwalter and Hunziker., 1999). Chondrocytes are largely nourished by 
diffusion from adjacent synovial fluid, which fills the joint cavity. Additionally, 
small amounts o f nutrients are derived from blood vessels that course through the 
calcified cartilage close to the bone (Schumacher et al, 1994). As a result o f 
chondrocytes being locked within an extracellular matrix they are unable to move. 
They do not actively change their shape except during hypertrophy, but they may be 
passively deformed during compressive loading (Skaggs etal., 1993).
Typically chondrocytes can vary in shape from a spheroidal to a flattened form. 
Factors that influence the shape, size and characteristics o f a chondrocyte are the type 
o f cartilage in which the chondrocyte is present, the actual position of the chondrocyte 
within the tissue, the age of the organism in which it is present and the cellular density 
o f the tissue (Buckwalter & Hunziker., 1999).
Chondrocytes contain cellular organelles similar to those found in other cells, e.g. a 
nucleus containing the DNA content o f the cell, endoplasmic reticulum, golgi 
apparatus, lysosomes and mitochondria. There are low levels o f mitochondrion, as 
chondrocytes are unique in that they exist in a low oxygen tension environment and 
most energy requirements are obtained through glycolysis (Bulkwalter & Hunziker., 
1999).
The chondrocyte contains a cytoskeleton consisting o f three types o f protein elements; 
microfilaments, microtubules and intermediate filaments. The cytoskeleton o f 
chondrocytes is important in maintaining the chondrogenic phenotype, cell division, 
inside-out and outside-in signalling mechanisms. The action o f a chondrocyte on the 
extracellular matrix depends on the stimuli received and vice versa, therefore a 
feedback loop o f signals from the extracellular matrix to the chondrocyte and the 
chondrocyte to the extracellular matrix is maintained (Benjamin et al., 1994). Some 
chondrocytes also have short processes or microvilli cilium extending into the cell 
matrix which sense mechanical change within the extracellular matrix conveying the 
information back to the cell (Buckwalter and Hunziker., 1999).
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1.1.2 Zonal Organisation in Articular Cartilage
Four zones of articular cartilage can be identified (Figure 1.1), due to morphological 
changes in both the chondrocytes and matrix from the articular surface to the 
subchondral bone. There is variance between species and among joints in the relative 
size and appearance of each of the zones. Chondrocytes from different zones vary in 
size, shape and metabolic activity (Schumacher et al, 1994). The arrangement of the 
cells within these zones is maintained by the collagen fibre organisation known as 
'Benninghoff Arcades’ (Benninghoff., 1925).
Figure 1.1 Histological section through mature (18 month) bovine native articular 
cartilage depicting the zonal organisation of chondrocytes. Alcian blue and 
haematoxylin/eosin. Scalebar=200pm
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(A) Tangential layer / Superficial Zone
Superficial Zone
Figure 1.2 Histological section showing the superficial zone of mature (18 month) 
bovine native articular cartilage, an amorphous material at the top most surface and 
underlying flattened ellipsoid chondrocytes. Alcian blue and haematoxylin/eosin.
Scalebar=50|im
The superficial zone typically consists of an acellular layer and a cellular layer 
(Figure 1.2). The acellular, most superficial region is referred to as the lamina 
splendens (Jackson et al, 2001) which is composed of an amorphous material 
(Jurvelin et al, 1996). The lamina splendens consist of fine fibrils running parallel to 
the articular surface and contains little polysaccharide. It is the thinnest zone and the 
so-called skin of articular cartilage that acts as a barrier against the movement of 
molecules between the synovial fluid and cartilage (MacConaill 1951) (Jackson et al, 
2001).
The deeper cellular region of this zone contains disc shaped chondrocytes (flattened 
ellipsoid chondrocytes) interspersed within a matrix of fine collagen fibrils aligned 
parallel to the surface (Schumacher et a l, 1994). Fibronectin and collagen 
concentrations (Buckwalter and Hunziker., 1999) are high in this layer in contrast to a 
low concentration of proteoglycans found within this region. However, a novel 
proteoglycan is synthesised by the superficial zone chondrocytes o f articular cartilage 
called Superficial Zone Protein (SZP) and was first identified by Schumacher et a! in 
1994.
This zone has great tensile strength in comparison with deeper zones found in 
cartilaginous tissue (Jackson et a l, 2001). The superficial layers have been described 
as a ‘tension resisting diaphragm’ (Meachim & Stockwell., 1979) manifested by the
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tendency o f articular cartilage to curl when released from the subchondral bone 
(Broom & Poole., 1982).
(B) Transitional zone / Intermediate zone
Intermediate Zoni?
Figure 1.3 Histological section showing the intermediate region of mature (18 month) 
bovine native articular cartilage depicting randomly dispersed chondrocytes. Alcian blue and
haematoxylin/eosin. Scalebar=50pm
The transitional zone as the name implies is an intermediate between the superficial 
zone and the radial zone (Figure 1.3). The chondrocytes in this region are slightly 
larger, spheroidal in appearance, prehypertrophic and widely spaced. The 
chondrocytes have a higher concentration of synthetic organelles than those found in 
the superficial layer, synthesising a matrix with a higher proteoglycan concentration. 
Both the water and collagen concentrations decrease within this region in comparison 
to the superficial zone, but the fibrils that are present have a larger diameter and they 
are not arranged in any clear orientation (Buckwalter and Hunziker., 1999). Unique 
to this area o f cartilage is a molecule known as Cartilage Intermediate Layer Protein 
(CILP see section 1.5.3) (Lorenzo et al., 1998).
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(C) Radial zone / Deep zone
Figure 1.4 A histological section of the deep region of 18 month bovine articular 
cartilage clearly showing the columnar organisation of the chondrocytes. Alcian blue and
haematoxylin/eosin. Scalebar=50pm
This zone contains fairly large, spheroidal chondrocytes that are arranged into 
columns orientated perpendicularly to the surface of the articular cartilage tissue. The 
course of large diameter collagen fibrils follows the orientation of the chondrocyte 
columns. The collagen fibres pass into the so-called tidemark, a smooth undulating 
junction between the radial layer and the calcified cartilage. This zone contains the 
lowest concentration of water and the highest concentration of proteoglycans 
(Buckwalter and Hunziker., 1999).
(D) Calcified cartilage layer
This zone separates the radial zone and the subchondral bone. The chondrocytes 
located within this region are rounded and contained within uncalcified lacunae. 
Some cells appear completely surrounded by calcified cartilage suggesting an 
extremely low metabolic activity (Buckwalter and Hunziker., 1999). The collagen 
fibrils are anchored within a calcified matrix (Poole 1997).
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1.1.3 Circumferential Differentiation
The description of zones shows the horizontal matrix subdivisions that occur within 
articular cartilage. There is also a circumferential differentiation apparent within 
articular cartilage (Figure 1.5). ‘Circumferential differentiation’ refers to the distance 
from a chondrocyte to distinct regions within the extracellular matrix, which provide 
the biochemical and biomechanical microenvironment of the chondrocyte 
(Buckwalter et al., 1990).
KEY
□  CHONDROCYTE
|  PERICELLULAR MATRIX
□  TERRITORIAL MATRIX
□  MI E HI L RHIf ORIAL MATRIX
Figure 1.5 A diagram showing circumferential differentiation between chondrocytes, 
and certain regions within the extracellular matrix (Adapted from Buckwalter & Hunziker
1999).
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(A) Pericellular Matrix
The pericellular matrix (PCM) is the immediate environment surrounding the 
chondrocyte. This immediate environment along with the chondrocyte has been 
termed the ‘chondron’ (Benninghoff., 1925) (Poole 1997).
The shape o f a chondron reflects the collagen architecture of the interterritorial 
matrix, and this varies significantly with depth from surface to deep zones in articular 
cartilage. Chondrons may contain a single chondrocyte or several chondrocytes 
(Youn et al., 2006). A chondron containing one chondrocyte shows matrix polarity. 
The articular pole o f a single chondron is densely compact and faces towards the 
surface o f articular cartilage. The basal pole tapers towards the tidemark, and has the 
ability to form interconnections between adjacent chondrocytes via an unknown 
mechanism (Lee & Loeser., 1998). The volumes o f chondrons within the deeper 
zones are higher than those found at the surface, but the ratio o f PCM to chondrocyte 
remains constant regardless o f zonal positioning (Lee & Loeser., 1998).
The PCM plays an important role in governing the local environment o f the 
chondrocyte. This region is enriched with hyaluronan and a range o f glycoproteins 
including link protein, which may imply that this is the preferential distance for 
involvement in aggrecan-link protein complexes (Poole 1997) (section 1,4.1). The 
PCM contains constituents found in other regions e.g. aggrecan, biglycan, fibronectin, 
Types II, IX and XI collagen, but it is generally defined by the unique presence o f 
type VI collagen (Youn et al., 2006). Therefore, the PCM can serve as a transducer 
of signals potentially through interactions o f type VI collagen with integrins or 
hyaluronan with CD44 (Youn et al., 2006) between both the extracellular matrix and 
the chondrocyte. Receptors known to be present on chondrocyte membranes and 
potential extracellular matrix molecules in which these receptors can bind are 
depicted in Table 1.1.
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RECEPTORS EXPRESSED ON THE 
SURFACE OF CHONDROCYTES
EXTRACELLULAR MATRIX MOLECULES 
THAT BIND TO CHONDROCYTE 
RECEPTORS
CD44 Hyaluronan (Knudson & Knudson 2004)
CD44 plus GAG chain Collagens, fibronectin, laminin 
and Chondroitin sulphates (Goodison et al., 1999, 
Greenfield et al., 1999)
Annexin V 
{Formally anchorin cIT)
Type II & X collagen (Lucic et al., 2003, Kirsch 
et al., 1992)
Integrins
Pi, a2p2)
Types II & VI collagens (Durr et al., 1993)
Integrins 
(asPi, a3p2)
Fibronectin (Durr et al., 1993, Salter et al., 1992)
Table 1.1. Receptors found on chondrocyte membranes and the molecules with which
these receptors have the ability to bind.
(B) Territorial Matrix
The territorial matrix (TM) is the region surrounding the pericellular matrix. There is 
a more concentrated amount o f chondroitin sulphate-rich proteoglycans present within 
this region (Meachim & Stockwell., 1979). In the middle and deep zones o f articular 
cartilage the pericellular matrix is separated from the territorial matrix by a fibrous 
capsule (Lee & Loeser., 1998). Potentially the territorial matrix could have an 
influence on the pericellular matrix activities.
(C) Interterritorial Matrix
The interterritorial matrix (ITM) surrounds the territorial matrix. It is the largest 
fraction o f cartilage matrix, consisting mostly o f aggregating proteoglycan (aggrecan) 
and type II collagen (Youn et al., 2006). The largest collagen fibres predominate 
within this region, and their compacted organisation and alignment defines the 
collagen arcades described previously by Benninghoff 1925. Meachim and Stockwell 
in 1979 reported that this region was more concentrated in keratan sulphate rich 
proteoglycans (Poole 1997).
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1.2 Collagens
There are twenty eight members o f the collagen family that have been identified to 
date. Collagens are a major component of articular cartilage extracellular matrices 
(iconstituting 20% w/w) that provide a structural role and strength to withstand 
tensional forces. Therefore, it is important to take into consideration the desired 
distribution o f the collagens present in native cartilage whilst engineering this tissue. 
Collagens are made up o f a number of polypeptide chains that individually form left- 
handed helices. These chains wind around each other in a right handed super triple 
helix and are held together by hydrogen bonds (Stryer 1995). The triple helical 
structure in collagen arises from an unusual abundance o f three amino acids {glycine, 
proline and hydroxyproline) forming a characteristic motif; Gly-X-Y. The amino 
acid proline is a cyclic structure found in the bends and folds o f proteins and glycine 
is the only amino acid with a side chain that can fit into the crowded centre o f a triple 
stranded helix. Hydroxyproline has been found to stabilise collagen, as the proportion 
of hydroxyproline containing chains increase, helix melting temperatures increase 
(Slatter et al., 2003).
Collagens are separated into four classes; Fibril forming, Network forming, Fibril 
associated collagens with an interrupted triple helix (FACITs) and other groups (e.g. 
transmembrane, beaded filaments and anchoring fibrils for basement membranes). 
The collagens present in articular cartilage and their associated classes are discussed 
below.
1.2.1 Heterotypic Fibrils of Articular Cartilage
Types II, IX and XI collagens aggregate together forming organised matrix fibrils 
(Figure 1.6), where type II constitutes the bulk o f the fibril, and both type IX and XI 
collagens are found co-distributed on the fibrils contributing to the organisation and 
mechanical stability o f the type II fibrillar network. Other structural macromolecules 
such as fibromodulin and decorin participate in fibril assembly, but only the 
collagenous constituents will be discussed here (Oldberg et al., 1989 & Pringle & 
Dodd., 1990).
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KEY
■ ■ Type II collagen fibrils
H i Type IX Collagen molecule
■ ■ Type XI Collagen molecule
Figure 1.6. Organisation of major collagens in articular cartilage (Personal communication
with Vic Duance)
(A) Type II Collagen
The major collagen predominantly, but not exclusively found in hyaline cartilage is 
the fibril forming type II collagen. Type II collagen is a product of a single gene, 
COL2A1 and two forms of COL2A1 mRNA are expressed due to variable splicing of 
the primary transcript. One form contains and the other lacks a cysteine rich exon 2 
coding domain (Ryan et al., 1990). The two splice variant pro-collagens show 
different tissue distributions (Sandell et al., 1991); the type IIA is a transient 
embryonic form found in pre-chondrogenic mesenchyme and perichondrium and the 
type IIB dominant form is found in mature cartilage (differentiated chondrocytes). It 
has been found that IL-lp down regulates the COL2A1 gene inhibiting production of 
newly synthesised collagen (Chadjichristos et al., 2003)
The biosynthesis o f type II fibres follows the normal pathway o f secreted proteins. 
Firstly, they are synthesised as precursors called pro-collagens by ribosomes on the 
surface o f the rough endoplasmic reticulum. Pro-collagens contain a large central 
triple helical domain linked to N- and C- propeptides, by a short sequence, the 
telopeptides. A growing pro-collagen chain is transported into the luminal space of
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the rough endoplasmic reticulum where it is processed by a series of reactions: 
glycosylations, hydroxylations and formation of interchain disulphide bonds between 
the N-and C-terminal propeptide sequences aligning the three polypeptide chains 
before the formation o f the triple helix. The pro-collagen is then secreted to the 
extracellular space where the N- and C-terminal propetides are removed by enzymes 
(Lodish et al ,1999).
After the removal of the propeptides the fibrils pack together side by side with a small 
gap separating the head of one molecule with the tail of another collagen molecule. 
There are non triple helical segments present at the ends of each fibril containing 
lysine/hydroxylysine residues. Covalent cross links form between two lysine or 
hydroxylysine residues at the C-terminus of one collagen fibril with two similar 
residues at N-terminus of adjacent collagen molecules. This creates a striated effect 
where the collagen molecules are displaced from one another by 67nm stabilising the 
packing o f collagen forming an extremely strong fibril (Figure 1.7) (Lodish et 
al., 1999)
COLLAGEN CROSS-LINKING KEY
• ----------- • = Covalent Cross links
N o r C = Terminal domains of fibrils
Figure 1.7. Schematic of the striated effect created by collagen cross-linking (Adapted
from Lodish et al., 1999)
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In mature cartilage, type II forms fibrillar networks with thicker fibrils in the deep 
layers o f cartilage and finer fibrils enriched in the surface (Aydelotte & Kuettner., 
1988). The collagenous fibres form a stable network that counteracts the
hydrodynamic pressure generated by the highly hydrodynamic proteoglycan 
aggregates.
(B) Type IX Collagen
Type IX collagen (Figure 1.8) is a FACIT (Fibril Associated Collagen with an 
Interrupted Triple-helix) found covalently bound to type II collagen on the surface of 
heterotypic fibrils located in articular cartilage. It was found that a single amino acid 
substitution in the C-terminus region of type II collagen altered the affinity o f type IX 
for type II collagen (Steplewski et al., 2005).
Type IX collagen is composed of three disulphide bonded polypeptide chains 
[al(lX )] [a2(IX)] [a3(IX)] that form together three triple helical domains (COL-1,-2 
and -3) interrupted by non-helical sequences (NC-1,-2,-3 and -4) (Figure 1.8) 
(Muller-Glauser et al., 1986, Wu & Eyre., 1984 and Van der Rest., 1985). Rotary 
shadowing studies revealed a distinctive kink towards one end of the molecule within 
the NC3 domain, and the presence of a globular domain (NC4) at the end of the kink 
(Irwin et al., 1985). It may exist in both long and short forms depending on the 
presence or absence of a large globular domain (NC4) at the amino terminal of the 
al(IX ) chain (Wu & Eyre., 2003, Savontaus et al., 1998, Swiderski and Solursh., 
1992).
NC-4
COL-3
NC-3
COL-2
339 RESIDUES
NC-2
COL-1
NC-1
KEY
Collagenous Domain 
Non-Collagenous
Figure 1.8. Structural organisation of a type IX collagen molecule (Adapted from Eyre et al.,
2006).
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It is a unique member o f the collagen family due to several distinct characteristics; 
one o f the collagen helices (COL-3) has a high content o f both proline and 
hydroxyproline resulting in an extremely stable helix with an elevated melting 
temperature (Irwin et al., 1985). Another unique feature o f type IX collagen is the 
apparent linkage o f chondroitin sulphate and sometimes dermatan sulphate to the 
[a2(IX)] polypeptide chain in the NC-3 domain (Irwin et al., 1985, Muller & 
Glauser., 1986, Huber et al., 1986 and Irwin and Mayne 1986). The attachment o f a 
GAG chain is both tissue and species specific, substitution has been observed the 
vitreous o f the eye (in both chick and bovine) (Yada et al., 1990, Bishop et al., 1992, 
Ring et al., 1995) and in chick cartilage (Vaughan et al, 1985, Bruckner et al., 1985, 
McCormick et al., 1987), but GAG substituted type IX collagen has been found to be 
a minor component in human and bovine articular cartilage (Diab et al., 1996).
In articular cartilage, type IX collagen functions in the regulation o f type II collagen 
fibril diameter, its presence appears to reduce the fibril diameter o f heterotypic fibril 
aggregates (Wotton et al, 1988). Type IX collagen is responsible for stabilising the 
fibrillar network as it is arranged along the surface o f type II collagen fibrils, its N- 
terminal domain projects from the fibril surface encouraging interactions with other 
matrix components (Leppanen et al., 2007). Type IX collagen is known to decrease 
with an increased age (Duance & Wotton., 1991), a reduction o f type IX collagen 
affects the organisation o f cartilage components at a molecular level, having a 
profound effect on the integrity o f the cartilage matrix, leading to cartilage 
degradation as occurs in osteoarthritis (Hu et al., 2006) and rheumatoid arthritis 
(Jaalinoja et al., 2008).
(C) Type XI Collagen
Type XI collagen (Figure 1.9) is a fibrillar collagen found partially buried within 
heterotypic collagen fibrils located in articular cartilage. Type XI collagen is a 
heterotrimeric molecule containing three polypeptide chains [al(X I)] [a2(XI)] 
[a3(XI)] that form together two triple helical domains (COL-1 and -2) interrupted by 
non-helical sequences (NC-1,-2 and -3) (Morris & Bachinger 1987). The NC2 
domain is a hinged region within the molecule. The a l  and a2 chains resemble type
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V collagen, whereas the a3 is highly homologous to an over-glycosylated [al(II)] 
chain (Morris & Bachinger 1987 & Vaughan-Thomas et a l,  2001).
The cross-linking bonds formed by type XI collagen molecules are homopolymeric 
and molecules cross-link head to tail. There are three modes of interaction; [al(X I)] 
N-telopeptide to [a3(XI)] C-terminal helix, [a2(XI)] N-telopeptide to [al(X I)] C- 
terminal helix and [a3(XI)] N-telopeptide to [a2(XI)] C-terminal helix (Wu & Eyre.,
1995). Also, a cross-link was identified between the amino-terminal of the a l(X I) 
triple helix and the al(II)/a3(X I) C-telopeptide, forming a potential linkage of the 
type XI collagen homopolymer with the type II collagen within the heterotypic fibril 
(Duance et a l, 1999).
NC-1COL-1
KEY
Collagenous Domain Non-Collagenous Domain
Figure 1.9. Structural organisation of a type XI collagen molecule 
(Adapted from Duance et al., 1999)
The most N-terminal domain consists of a module rich in basic residues, also found in 
FACIT collagens and is characterised by a P-stranded structure, which constitutes the 
proline/arginine-rich protein (PARP) (Neame et al., 1990). Nucleotide sequencing 
demonstrated that PARP is a fragment of the NH2 terminal non-collagenous (NC-3) 
domain of collagen [a2(XI)] chain (Zhidkova et al., 1993 & Rousseau et a l,  1996). 
Between the PARP module and the short triple helix, there is a highly acidic domain 
that presents a poor sequence conservation among the three chains and is variable in 
length (it is referred to as the variable region) (Rousseau et a l, 1996).
Six isoforms of type XI collagen can be generated from splicing in the [al(XI)] chain; 
alternative splicing of this region has also been demonstrated within the [a2(XI)] 
chain (Rousseau et a l, 1996). BMP-1 can be held responsible for a variety of
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processing o f these chains (Medeck et al., 2003). The functional significance of such 
structural diversity is yet to be elucidated, but the presence o f these isoforms may 
indicate important roles o f type XI collagen at different stages o f development and 
growth (Duance et al., 1999).
The al(X I) and a2(XI) chains within the COL1 domain contain heparin binding sites 
(Smith and Brandt., 1987) (aggrecan can also bind through the same site), these 
binding sites can be exploited providing a method for the column purification of type 
XI collagen preventing contamination with type II collagen (Smith & Brandt., 1987). 
Type XI collagen has been reported to interact with components o f cartilage 
extracellular matrices. Along with type IX collagen, type XI collagen potentially 
makes the surface of heterotypic collagen fibrils in cartilage highly interactive.
It has been proposed that type XI collagen plays a role in fibril formation and its 
incorporation into heterotypic fibrils could be responsible for limiting fibril diameter 
(Yingst et al., 2008). Type XI collagen could potentially limit fibril diameter by: (1) 
having a heavily glycosylated triple helix in comparison to type II collagen, resulting 
in a more bulkier molecule that could interfere with the intermolecular spacing and 
molecular packing, (2) its non-collagenous sequence projects out up to the surface o f 
heterotypic fibrils, regulating fibril diameter by steric hindrance (Rousseau et al.,
1996), and (3) the alternative splicing o f the N-terminal domains may enable 
interactions to occur with other matrix molecules which stabilise the fibrils at a 
certain diameter (Duance et al., 1999).
16
1.2.2 Minor collagens present in cartilage
The most predominant collagen in articular cartilage is type II collagen. All other 
collagens present in cartilage are found in smaller quantities in comparison to type II 
collagen. Therefore, the collagens discussed below (Table 1.2) are referred to as 
minor collagens.
Collagen (Type) Information
Fibril Forming
Type I • Enriched in the ‘lamina splendens’ of the superficial region (Duance 
1983), and is not present in the mid or deep regions of articular 
cartilage (Stanescu et al., 1976 & Eyre et al., 1978).
Type III • Copolymerises and links to type II collagen (Young et al., 1995 & 
Eyre 2002).
• Found pericellularly throughout cartilage depth at a variety of ages, 
ranging from young to old (Wotton & Duance., 1994).
• Identified in both normal (Wotton and Duance 1994) and 
osteoarthritic (Aigner et al., 1993) human articular cartilage.
• Osteoarthritic state: Found concentrated in the superficial and 
transitional zones (Teshima 2004).
Type V • Present in articular cartilage, but not epiphyseal cartilage its role is 
unknown (Eyre et al., 1978).
• Located in the pericellular region of the matrix (Furuto et al., 1991 & 
Bland & Ashhurst., 1996).
• Shares sequence homology to 2 chains of type XI collagen 
twww.rockland-inc.com/commerce/misc/eci.iso).
Network Forming Collagens 
These collagens self assemble into networks and have longer non-collagenous domains than fibril 
forming collagens (Kadler et al., 1996). The monomers associate at their C-termini to form dimers and 
at their N-termini to form tetramers. The triple helical domains intertwine to form supercoiled 
structures.
Type X • Short chain, non-fibril-forming collagen that is a product of 
hypertrophic chondrocytes (Kielty et al., 1985).
• Possible involvement during the endochondral ossification process 
(Morris & Bachinger 1987).
• Human osteoarthritic cartilage shows moderate mRNA expression of 
type X collagen in the deep zones (Aigner et al., 1993).
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1 ihril associated collagens with interrupted triple helix (I 1 ( l l\)
The FACIT family do not form fibrils themselves, but are found attached to the surface of pre-existing 
fibrils of the fibril forming collagens (Shaw & Olsen 1991). The FACIT group share sequence 
similarities, their most conserved region being their COL1 domain. They are thought to bind collagen 
fibril surfaces via their COL 1/NCI domains (Eyre 2002).
Type XII • Located at the surface of type II fibrils associated in a non-covalent 
fashion, distributed in areas of cartilage with more organised fibril 
orientation potentially playing a role in promoting alignment or 
stabilising organisation (Gregory et al., 2001).
• Also found in: tendon, ligament, perichondrium and periosteum 
tissues that are rich in type I collagen; type XII collagen localises to 
the surface of type I fibrillar collagens (Bland & Ashhurst., 1996).
Type XIV • Localised uniformly throughout articular cartilage, but absent in 
growth plate cartilage (Watt et al., 1992).
Other Small groups in Cartilage (Headed hi laments)
Type VI • Heterotrimer of three distinct a chains that arrange themselves to 
contain short triple helical domains and extended globular termini, 
consisting of a larger globular domain at its C-terminal and smaller 
one at its N-terminal (Soder et al., 2002).
• The microfibrils formed are of beaded appearance. The helical 
segment is unusual in that the Gly-X-Y sequence is interrupted 
approximately twenty four times with segments unable to form triple 
helices providing flexibility to the molecule (Knupp et al., 2001).
• Self-assembles into disulphide-bonded dimers and tetramers, 
polymerising into a filamentous network that is mostly concentrated 
around cells in the pericellular matrix (Eyre 2002).
• Binds integrins on the chondrocyte membrane via RGD-sequences in 
the a l  and a2 chains, and binds other proteins of the pericellular 
matrix such as other collagens, decorin, fibromodulin, hyaluronan, 
and fibronectin providing an interface between the rigid 
interterritorial matrix and the chondrocyte (Marcelino et al., 1995).
• Involvement in cell anchoring, maintenance of chondrocyte integrity 
and matrix cell signalling (Poole et al., 1992).
• The microenvironment surrounding Type VI collagen might also be a 
central factor for formation of chondrocyte clusters, a characteristic 
feature of osteoarthritis (OA) (Soder et al., 2002).
Table 1.2. The minor collagens present in articular cartilage
18
1.3 Glycosaminoglycan (GAGs)
There are six glycosaminoglycans (GAGs) and they are divided into two groups 
depending on their disaccharide unit composition. One group is the 
‘galactosaminoglycans’ that include both chondroitin sulphate (CS) and dermatan 
sulphate (DS), and the other group referred to as the ‘glucosaminoglycans’ include 
heparan sulphate (HS), heparin (Hep), hyaluronan (HA) and keratan sulphate (KS). 
All glycosaminoglycans are un-branched linear polymers o f repeated disaccharide 
units o f varying lengths that covalently attach to a protein core forming a 
proteoglycan, with hyaluronan being an exception to this rule. Each disaccharide unit 
has at least one negatively charged carboxylate or sulphate group. Therefore, GAGs 
form a long string o f negative charges that repel other negatively charged molecules 
and attract cations (Bulkwalter and Hunziker 1999). As a result o f being highly 
charged molecules, GAGs function as a water adsorbent attracting water molecules 
from the surrounding environment to maintain a hydrated matrix.
Glycosaminoglycans provide essential roles in vertebrates as intracellular adhesives, 
signalling molecules, anti-coagulants and structural elements (Williams et al., 2006). 
The GAGs found in cartilage include hyaluronan, chondroitin sulphate, keratan 
sulphate and dermatan sulphate and are discussed in more detail below. 
Concentrations o f these molecules vary among sites within articular cartilage. Factors 
contributing towards this variability are age, cartilage injury and disease (Bulkwalter 
and Hunziker 1999).
1.3.1 Galactosaminoglycans
(A) Chondroitin Sulphate
Chondroitin sulphate (CS) is an important structural component o f articular cartilage 
that provides much resistance to compression by attracting water molecules. It is 
made up o f alternating sugars o f N-acetylgalactosamine (galNAc) and glucuronic acid 
(GlcA) (Figure 1.10). There are eight possible isomers o f CS made from repeating 
disaccharide units that utilise three possible combinations o f estersulphation (Figure 
1.10). The most common forms found in nature include a non-sulphated chondroitin
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sulphate molecule referred to as chondroitin-O-sulphate (C-O-S), and monosulphated 
CS molecules {sulphated at either carbon -4 or -6 o f the N-acetylgalactosamine unit) 
referred to as chondroitin-4-sulphate (C-4-S) and chondroitin-6-sulphate (C-6-S), 
respectively. Several other less common CS isomer repeat disaccharides also occur in 
nature. CS type E contains disaccharides with ester sulphate substituted in both 4- 
and 6-position of N-acetylgalactosamine residue. Four CS isomers have also been 
identified that contain ester sulphate substitution at the 2-position of the glucuronic 
acid residue with various sulphation patterns occurring on the N-acetylgalactosamine 
residue at positions 4- and 6-. The most highly sulphated isomer of CS contains 
sulphate in all three available positions (Caterson et al., 1990).
Chondroitin Sulphate
□  Sulphation position ■  Carbon number
r
coo-
o h ) n h c o c h 3
Glucuronic acid N-acetylgalactosamine
V. J  n
Figure 1.10. A diagrammatic representation of a Chondroitin Sulphate disaccharide unit.
The glycosaminoglycan CS can link to a hydroxyl group within a serine residue of 
certain proteins to form proteoglycans. The glycosylated serines o f the proteins to 
which the CS chains can attach are often followed by a glycine residue neighboured 
by acidic regions, although this motif does not always predict glycosylation. 
Alterations o f sulphation patterns in chondroitin sulphate chains on proteoglycans 
have been associated with both ageing and degeneration o f articular cartilage.
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Sauerland & Steinmeyer (2007) reported that sulphation patterns o f CS chains in 
bovine articular cartilage explants were also altered following mechanical loading. 
The internal region o f the CS chain showed an increase in sulphation at both carbon 4 
and 6 o f the N-acetylgalactosamine unit and simultaneously less CS chains terminated 
with galNAc 4 and 6 sulphation following an applied mechanical load.
The loss o f CS from articular cartilage is a major consequence osteoarthritis, and 
there is a marked increase o f CS chain length present in the synovial fluid following 
both exercise and osteochondral injury (Brown et al, 2007). Chondroitin sulphate 
may exert both limited chondroprotective and anti-inflammatory effects on articular 
cartilage that could provide long term benefits on the osteoarthritic process.
Utilising an avian model, the effect o f CS on IL-1-induced expression o f genes related 
to catabolic and anabolic inflammatory aspects in chondrocytes cultured in hypoxic 
alginate beads was determined (Legendre et al., 2007). It was found that avian CS 
could repress expression o f genes encoding proteolytic enzymes involved in cartilage 
degradation. It also inhibited IL -ip induced expression o f the pro-inflammatory 
genes iNOS and COX-2 and restored TGF-p receptors I and II mRNA levels 
(Legendre et al., 2007). It was also demonstrated in a long term bovine explant 
culture system that glucosamine and chondroitin sulphate treatment down-regulated 
mRNA expression for inflammatory mediators and matrix degrading enzymes while 
increasing TIMP-3 transcripts (Chan et al., 2007). Therefore, glucosamine and 
chondroitin sulphate have become widely used as a dietry supplement for 
osteoarthritic treatment.
Chondroitin sulphate is also showing potential in the field o f cartilage tissue 
engineering, as it can be used as a biopolymer to develop a novel bio-adhesive that 
enables integration between native cartilage and a tissue engineered implant (Wang et 
al., 2007). The CS is chemically modified with methacrylate and aldehyde groups on 
the polysaccharide backbone to chemically bridge biomaterials and tissue proteins via 
two fold covalent links (Wang et al., 2007).
(B) Dermatan Sulphate
Dermatan sulphate (DS) also known as Chondroitin Sulphate B, was originally called 
mucopolysaccharide and has been found to accumulate in many o f the
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mucopolysaccharidosis disorders. It is very similar in structure to CS, but some o f the 
glucuronic acid residues are epimerized to L-iduronic acid (IdoA).
1.3.2 Glucosaminoglycans
(A) Keratan Sulphate
Keratan sulphate (KS) also known as keratosulphate is found in cornea, cartilage and 
bone and is a highly hydrated molecule in joints that can act as a cushion. It has many 
features in common with complex oligosaccharides found in glycoproteins and 
contains oligosaccharide branches, but it is still considered a GAG as it consists of 
repeating disaccharides o f N-acetylglucosamine linked to galactose (Heinegard and 
Paulsson 1984).
Keratan sulphate can be found in both an N-linked form (in the cornea), or an O- 
linked form (in cartilage). In the N-linked form keratan sulphate attaches through an 
asparagine residue in the amino acid consensus sequence Asn-X-Ser/Thr, where X is 
any amino acid except proline. O-linked attachment occurs through the consensus 
sequence Glu-Glu/Lys-Pro-Phe-Pro-Ser (Barry et al, 1995) where keratan sulphate 
attaches via the serine residue.
Keratan sulphate chains increase with ageing (Theocharis et al., 1985) as do the level 
of KS sulphation (Greiling & Baumann 1973). The concentrations o f circulating 
cartilage-derived KS in serum are higher in adult patients with osteoarthritis 
(Wakitani et al., 2007). Measuring serum KS levels could be used as a diagnostic 
marker in joint disease (Thonar et al., 1987).
(B) Hyaluronan
Hyaluronan (HA) forms strikingly viscous solutions and is unlike any other GAGs, as 
it does not contain sulphate groups, epimerize or occur in proteoglycan form but it is 
found in a free form (Kjellen and Lindahl 1991 & Stern et al., 2006). Its highest 
concentrations are found in connective tissues and its lowest concentrations in blood 
and it has a relatively high turnover rate. The HA polymer is made up from repeating
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disaccharide units o f [D-glucuronic acid (l-P-3) N-acetyl D-glucosamine (l-P-4)]n 
(Meyer & Palmer, 1934) (Figure 1.11). The HA polymer forms stiffened helical 
configurations that are stabilised by hydrogen bonds parallel within the chain axis 
(Laurent and Fraser., 1992). Under normal physiological conditions, hyaluronan 
consists o f 2,000-25,000 disaccharides, which corresponds to polysaccharides with 
relative molecular masses of 106-107 and polymer lengths o f 2-25 pm (Toole 2004). 
The large molecular mass hyaluronan is highly negatively charged and can adsorb 
vast amounts o f water exerting a swelling pressure on surrounding tissues (Underhill 
e ta l ., 1998).
Hyaluronan
COOH
OH
OH
NHCOCH:OH
N-acetylglucosamineGlucuronic acid
Figure 1.11. A diagrammatic representation o f a hyaluronan disaccharide unit.
Hyaluronan molecules bind to HA binding proteins (referred to as hyaladherins), 
such molecules include: CD44, RHAMM, LYVE-1, TOLL4 and extracellular matrix 
PGs e.g. aggrecan and versican (Stem et al., 2006). HA-binding proteins interact 
with hyaluronan via common structural domains o f approximately 100 amino acids 
termed link modules, proposed to be related to C-type lectin modules owing to their 
similar topological function (Seyfried et al., 2006). Hyaluronan interacts with the 
surface o f chondrocytes in two ways: (1) through receptor (CD44, RHAMM) binding
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at the surface o f the chondrocyte and (2) through hyaluronan synthases (Toole., 
2004).
(i) Hyaluronan Biosynthesis
Hyaluronan is synthesised in a different manner to other GAGs. It is synthesised in 
the plasma membrane o f cells such as chondrocytes, fibroblasts and synoviocytes by 
enzymes referred to as hyaluronan synthases. The HA chain grows by the addition of 
sugars to the reducing end o f the polymer, whereas the non-reducing end translocates 
into the pericellular matrix during synthesis (Laurent and Fraser., 1992 & Laurent and 
Fraser 1986). This enables an intimate relationship o f HA with the cell surface and 
can readily participate in the creation of a pericellular hydrated zone around the cells 
(Toole., 2004). In some cases HA can be released from the cell surface, but the 
release mechanism has not been clarified (Laurent and Fraser 1992). In comparison 
other GAGs are synthesised by the addition o f sugar units to the non-reducing end of 
their polymers within the endoplasmic reticulum and Golgi apparatus without the aid 
o f hyaluronan synthases (Laurent and Fraser 1992 & Laurent and Fraser 1986).
There are at least three synthases in mammals being; HAS-1, HAS-2 and HAS-3 that 
produce hyaluronan products o f varying lengths (Stem et al., 2006). Membranes 
from cells expressing HAS-1 or HAS-3 synthesise hyalyronan o f 0.2-20 MDa (Brinck 
et al., 1999) and cell membranes expressing HAS-2 generate hyaluronan polymers o f 
more than 2 MDa (Itano et al., 1999). Interestingly, hyaluronan has wide biological 
roles some o f which are size dependent; this could potentially imply that hyaluronan 
functions are diversely regulated through control o f the activities and expression o f 
HAS isoforms (Itano et al., 2004). It has been found that alterations at two conserved 
amino acid residues in streptococcus equisimilis hyaluronan synthase (Changes at K48 
within membrane domain 2 to either Arg or Glu and E327 in membrane domain 4 to 
either Lys, Asp or Gin) decreased the length o f hyaluronan produced (Kumari et al., 
2006).
The over expression o f HAS-2, leads to over expression o f HA, enhancing anchorage- 
independent growth and tumorigenicity (Kosaki et al., 1999). It has been suggested 
that the three HAS isoforms differ from each other in expression profiles during 
embryonic development (Itano et al., 2004).
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(ii) Hyaluronan Degradation
Hyaluronan has a high rate o f turnover as the polymers are funnelled through three 
catabolic pathways (Stem et al., 2006). The three different pathways are discussed 
below:
1. C ellular T urnover
Hyaluronan catabolism in cartilage explant studies revealed that unlike proteoglycan 
fragments, HA degradation products are found neither in culture medium nor within 
the tissue, suggesting an alternative mode o f removal (Nicoll et al., 2002). Local HA 
turnover is dependent on receptor (CD44, RHAMM) mediated endocytosis and 
delivery to low pH intracellular organelles to be degraded by a series o f enzymes 
(Chow et al., 2006). These enzymes are referred to as hyaluronidases. High 
molecular weight HA is cleaved progressively by a series o f enzymes in which the 
product o f one becomes the substrate for another, producing HA fragments o f a 
decreasing size (Lepperdinger et al., 1998, Csoka et al., 2001). It has been shown that 
G1 aggrecan fragments (section 1.4) can also be internalised and degraded in this 
pathway (Embry Flory et al., 2006). There are six hyaluronidase sequences in the 
human genome which are clustered in groups of three at two chromosomal sites 
(Table 1.3) (Csoka et al., 2001).
C hrom osom e G ene P ro tein
3p21.3 HYAL1 Hyal-1
HYAL2 Hyal-2
HYAL3 Hyal-3
7q31.3 HYAL4 Hyal-4
SPAM1 PH-20
HYALP1 None
Table 1.3. Six hyaluronidase sequences located in the human genome, and the proteins
in which these genes encode.
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Three o f these genes do not play a role in hyaluronan turnover in articular cartilage as 
HYALP1 in humans is a recently identified pseudogene that may be active in other 
species. PH-20 is a testicular hyaluronidase important during egg fertilisation by 
sperm and Hyal-4 is restricted to placenta and skeletal muscle with preliminary 
evidence indicating that Hyal-4 is a chondroitinase with no activity against HA 
(Csoka et al., 2001). The hyaluronidases actively involved in the turnover of HA in 
cartilage are Hyal-1, Hyal-2, and Hyal-3, with Hyal-2 being the most predominantly 
expressed hyaluronidase in human articular cartilage (Chow & Knudson., 2005). Not 
much is known about Hyal-3, but strong hybridization patterns have been found in 
mammalian testis and bone marrow. These two tissues retain a stem cell-like state for 
the life o f an animal, suggesting that Hyal-3 maybe important in stem cell regulation 
(Csoka et al., 2001).
Hyal-2 is a glycosylphosphatidylinositol (GPI)-linked enzyme attached to the external 
surfaces o f the plasma membrane. It is constitutively expressed and not regulated by 
catabolic agents (Chow & Knudson., 2005). This enzyme has unusual substrate 
specificity cleaving high molecular weight HA polymers to intermediate size 
fragments o f approximately 20kDa (Lepperdinger et al 1998 & Stem., 2004). The 
HA fragments are then delivered to early endosomes and to lysosomes where 
fragmentation continues {through the action o f acid active Hyal-1) generating 
predominantly tetrasaccharides (Stem et al., 2004 & 2006).
Hyal-1, a 57kDa protein {single polypeptide chain o f 49kDa with approximately 8kDa 
post translational glycosylation), is an acid active lysosomal enzyme that utilizes HA 
of any size as a substrate, generating predominantly tetrasaccharides and also cleaves 
chondroitin sulphate to a limited extent. There are two isoforms o f  Hyal-1, the first 
form found in plasma and the second form with a higher specific activity is found in 
urine. The second form is a 45kDa protein with approximately 100 amino acids 
deleted at the carboxyl terminal resulting in two polypeptide chains bound by 
disulphide linkages (Csoka et al., 2001). Primary chondrocytes in monolayer culture 
have the ability to degrade exogenous hyaluronan (Williams et al., 2005). The two 
isoforms o f Hyal-1 have been detected in chondrocyte cultures, the first form is 
predominant in the culture medium (higher molecular weight form) and the smaller 
form is found in the cell layer (Csoka et al., 2001). The modulation of native 
hyaluronidase activity may offer a new approach to improve the quality and quantity 
of hyaluronan in articular joints (Williams et al., 2005).
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2. Scission of Hyaluronan by Free Radicals
The scission of HA can occur via free radicals under oxidative conditions promoted 
by divalent cations (Stern et al., 2006).
3. Tissue Turnover
Hyaluronan is released from tissue matrices and mobilised from these sites through 
lymphatic vessels to lymph nodes. The final degradation steps occur either in the 
liver, kidney or possibly the spleen. This pathway involves unique receptors such as 
the HA receptor for endocytosis (HARE), also stabling-2, lymphatic vessel 
endothelial HA receptor (LYVE)-l and layilin (Stern et al., 2006). In the liver, liver 
endothelial cells carry specific receptors for the endocytosis o f HA. Following 
endocytosis, the HA is transported to lysosomes that contain enzymes for HA 
degradation (e.g hyaluronidase, p-glucuronidase and P-N-acetylglucoaminidase). 
Hyaluronan degradation products are the two monosaccharide units that make up the 
HA polymer. The pathway which the monosaccharides follow during degradation is 
shown in Figure 1.12 (Laurent and Fraser 1992).
Hyaluronan breakdown
Glucuronic Acid (GIcA) N-acetylglucosamine
Regular degradation 
Pathway for GIcA
N-acetylglucosamine-6-phosphate
DeacetylatedIn vivo acetate becomes 
oxidised to C 0 2 and H20
N-glucosamine-6-phosphate
Deaminated
Fructose-6-phosphate
Glycolytic Pathway
Figure 1.12. The pathway followed during hyaluronan degradation by the monosaccharides 
that constitute a hyaluronan polymer (Adapted from Laurent & Fraser 1992)
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(iii) Functions of Hyaluronan
Hyaluronan appears to be a simple molecule, but has an extraordinarily large array o f 
functions, some o f which are contradictory (Table 1.4). It is hard to determine the in 
vivo functions of hyaluronan, as functions may be gained or lost upon extraction 
(Stern et al., 2006). Hyaluronan plays an important role in development, 
differentiation and inflammation (Seyfried et al., 2006).
Levels o f hyaluronan have been found to rapidly increase as a survival mechanism in 
response to acute stress, shock, septicaemia, extensive bums and in sepsis, as well as 
increasing during tumour invasion (Csoka et al., 2001). It functions as a lubricant 
(providing visco-elastic properties separating most tissues that slide along each 
other), a shock absorber and semi-permeable barrier regulating metabolic exchange 
between cartilage and the synovial fluid.
It plays an important structural role in cartilage as the proteoglycan, aggrecan, binds 
to hyaluronan chains stabilised by a link protein. Without this interaction 
proteoglycans would not be retained within cartilage. This interaction influences the 
hydration properties of tissues. The network of hyaluronan chains evolved within a 
tissue regulates the distribution and transport of plasma proteins. Hyaluronan forms a 
pericellular coat around cells which enables cells to participate in cell adhesion, 
migration and proliferation (Sugahara et al., 2006).
Hyaluronan has been reported to protect cartilage against PG loss and chondrocyte 
cell death caused by free radicals (it can also reduce anti-fas-induced apoptosis o f OA 
chondrocytes (Julovi et a l, 2004). Cartilage degradation induced by catabolic 
stimulants, i.e. IL-1 (Yasui et al., 1992) and fibronectin fragments (Kang et al., 1999) 
can also be reduced by hyaluronan in vitro (Roth et al., 2005)
Various sized hyaluronan polymers are known to trigger different functional 
responses. High molecular weight hyaluronans have many functions including being 
space-filling molecules, anti-angiogenic, immunosuppressive with abilities to impede 
differentiation (possibly by suppressing cell-cell interactions, or ligand access to cell 
surface receptors) (Stem et al., 2006). Small molecular weight hyaluronans could 
potentially be generated during biosynthesis by HAS enzymes or could just be 
degradation products of hyaluronidases. They appear to act as endogenous ‘danger 
signals’ mediating cell signalling effects (Powell & Horton., 2005). The smaller 
fragments are inflammatory, immuno-stimulatory and angiogenic (Stem et al., 2006).
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They are capable o f activating macrophages (Kumari et al., 2006) competing with 
high molecular weight hyaluronan for HA receptors and can induce proteolytic 
cleavage o f the CD44 HA receptor from the surface of tumour cells promoting tumour 
migration (Sugahara et al., 2006).
High Molecular Weight 
Hyaluronan
Low Molecular Weight 
Hyaluronan
500-73OkDa HA: counteracts IL-ip induced 
effects, decreasing MMP-3 expression, decreasing 
nitric oxide synthase production of nitric oxide 
and increasing proteoglycan synthesis (Monfort et 
al., 2005).
Tetrasaccharides HA4: Anti-apoptotic 
actions and inducers of heat shock proteins (Stem 
et al., 2006). Suppress proteoglycan sulphation 
(Solursheia/., 1980).
800kDa HA. Addition to bovine explant 
cultures and in vivo rabbit joints inhibited IL-ip 
production of MMP-1, -3 and 13 and the catabolic 
action of fibronectin fragments. Therefore having 
the effect of preventing breakdown of type II 
collagen and proteoglycan. It was found that 
aggrecan breakdown was delayed, but not 
completely blocked (Julovi et al., 2004 & Kang et 
al., 1999).
Hexasaccharides H A6: Induce HAS-2 in 
chondrocytes (Knudson & Knudson 2004). 
Induce nitric oxide synthase to produce nitric 
oxide (nitric oxide is produced during 
inflammation, infection, disease or tissue damage) 
(Iacob & Knudson., 2006) and activates a specific 
profile of transcription factors that are observed in 
cartilage e.g Retenoic acid receptor (RAR), 
Retenoid X receptor (RXR), SP-1, MMP-3, Type 
I collagen and Comp. It was demonstrated that 
high molecular weight HA could suppress HA6 
signalling (Ohno et al., 2005).
120-1260kDa HA: Did not induce 
production of nitric oxide (Iacob & Knudson., 
2006)
8-50kDa HA: Induces angiogenesis 
(Sugahara et al., 2006)
1000-5OOOkDa HA: suppresses HA 
synthesis (Lueke and Prehm 1999) and inhibits 
phagocytosis (Forrester & Balazs 1980).
lOkDa HA: Displaces proteoglycans from cell 
surfaces (Solursh et al., 1980).
Table 1.4. The large array of contradictory functions identified to date by both high and
low molecular weight hyaluronans.
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1.4 Proteoglycans
Proteoglycans are complex macromolecules that are widely distributed in all 
connective tissues in varying amounts. They have a large degree o f variability 
providing them foundation to fulfil a diversity o f biological roles. They consist o f a 
core protein o f varying size to which a few to several hundred polyanionic 
glycosaminoglycan chains covalently attach via their reducing terminals and radiate 
out from the core (Heinegard & Paulsson 1984). A major source of structural 
variation occurs within the glycosaminoglycan chains that are attached to the core 
protein. The number o f GAG chains, their length and sulphation patterns can change 
to suit different biological requirements (Hardingham & Fosang 1992). 
Proteoglycans are classified into a number o f structurally and functionally diverse 
families including: Hyalectins, Small Leucine Rich Proteoglycans, cell surface 
proteoglycans and basement membrane proteoglycans (Vertel 1995). In this section 
proteoglycan families shall be discussed, with a focus on the proteoglycans relevant to 
this research project, paying particular attention to those present in articular cartilage.
1.4.1 Hyalectins
Members o f the hyalectin family include aggrecan (present in cartilage, aorta, 
intervertebral disc and tendon), versican (present in fibrous and fibrocartilaginous 
tissues), brevican and neurocan (both predominantly found in adult brain). They are 
grouped into this family alternatively named for their common G1 and G3 domains. 
This family share the capability o f interacting with hyaluronan via a proteoglycan 
tandem repeat (PTR) unit contained within their G1 domain at their amino termini. 
This region is termed the hyaluronan-binding region (HABR). Other hyaluronan 
binding proteins such as link protein, tumour necrosis factor stimulated gene-6 (TSG- 
6) and the cell surface receptor for hyaluronan (CD44) all expressed in cartilage, 
have been found to contain sequence homologies similar to the G1 domain or a single 
proteoglycan tandem repeat (PTR) loop. This family may also be referred to as the 
hyaluronan-binding proteins or the lecticans (Heinegard & Paulsson 1984).
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(A) Aggrecan
Aggrecan is a large proteoglycan that is one of the major constituents of cartilage 
extra-cellular matrices and is entrapped by a 3D latticework of fibrillar collagens. 
The core protein o f an aggrecan monomer (Mr 210-250kDa) is divided into multiple 
structural regions that serve unique functions (Figure 1.13). These regions consist of 
three globular domains (i.e. Gl, G2 and G3) and interglobular domains (i.e. 
interglobular domain (IGD), chondroitin sulphate (CS) and keratan sidphate (KS) 
glycosaminoglycan attachment regions). A clear relationship has been determined 
between the structure of aggrecan and its function. The structure of aggrecan is not 
constant, but varies with species, age and site origin (Knudson and Knudson 2001).
GAG ATTACHMENT REGION
KS CS1 CS2
KEY
Core Protein & &Chondroitin Sulphate (CS) Keratan Suphate
Globular Domain (G)
Epidermal Growth Factor-Like Domain
0 Immunoglobin Fold Lectin-Like Domain
0 Proteoglycan Tandem Repeat Complement regulatory Protein-Like
Figure 1.13. An Aggrecan Monomer (Adapted from Roughley 2006)
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(i) Globular Domain 1 (Gl) to Globular Domain 2 (G2)
The amino terminus o f an aggrecan monomer is where the G l domain is located. 
The G l domain contains 3 sub-domains consisting of disulphide bonded loops: loop 
A having sequence homology with the immunoglobin superfamily, loops B and B ’ 
that share sequence homology with each other and form a double looped structure 
m otif referred to as the proteoglycan tandem repeat (PTR) (Figure 1.13 & 1.14).
The PTR provides the functional site for the binding o f aggrecan to hyaluronan. Due 
to the hyaluronan binding capacity o f the PTR it is referred to as the hyaluronan- 
binding region (HABR). Therefore, G l domains of up to one hundred aggrecan 
monomers can non-covalently associate with a central filament o f hyaluronan (typical 
Mr 0.5-1.0 x 106 Da), self assembling into supramolecular aggregates of 
approximately 200 x 106 Da.
These aggregates are stabilised by a glycoprotein referred to as link protein (Figure 
1.14). The link protein can retard degradation o f hyaluronan in proteoglycan 
aggregates (Rodriguez & Roughly 2006) and is structurally similar to the G l domain 
of an aggrecan monomer, consisting o f a PTR region that can also associate with a 
central filament of hyaluronan, and an immunoglobulin fold that interacts with the 
immunoglobin fold o f aggrecan’s G l domain (Hardingham & Fosang 1992). The 
capacity for aggregation is determined by extracellular pH, age and the diseased state 
of the tissue (Roughley 1980).
(ii) Globular Domain 2 (G2) to Globular Domain 3 (G3)
The G l and G2 domains are separated by a linear interglobular domain. The 
functions o f the G2 domain are yet to be determined, but it is known to contain two 
homologous PTR regions that show no hyaluronan binding properties (Vertel 1995, 
Hardingham and Fosang 1992).
Extending from the G2 to the C-terminal G3 domain is a glycosaminoglycan 
attachment region containing three adjacent domains; a keratan sulphate rich domain 
(KS) and two adjacent chondroitin sulphate rich domains (CS1 and CS2). This GAG 
attachment region shows a high degree o f variability among species. A short proline- 
rich hexapeptide repeat sequence on the protein core proximal to the CS domain and 
located nearer to the N-terminal has been shown to contribute to keratan sulphate
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substitution and has been designated the KS domain. The KS domain is responsible 
for the covalent attachment o f up to 30-60 keratan sulphate glycosaminoglycan 
chains, each chain being of 20-25 repeats per aggrecan monomer. Within the CS 
domain there are approximately 120 serine-glycine repeat sequences on the core 
protein recognised for the covalent attachment of up to 100-150 chondroitin sulphate 
glycosaminoglycans chains o f 40-50 repeats per aggrecan monomer (Vertel 1995, 
Knudson and Knudson 2001). The chondroitin sulphate chains in human articular 
cartilage are o f shorter length in the CS-2 in comparison to those found in the CS-1 
domain (Rodriguez et al., 2006). The covalent attachment of CS, KS chains and 
shorter N- and O-linked oligosaccharides contribute to 90% of aggrecan’s mass. 
(Knudson and Knudson 2001).
Glycosaminoglycans are highly sulphated and contain negatively charged carboxyl 
groups, as a result negative charge concentrates within the extracellular matrix. 
Immobilising a negative charge attracts positive counter ions, and increases the 
chance o f attracting water molecules forming a highly hydrated resilient tissue o f 
expanded volume. This enables the formation o f a resilient layer on the epiphyses of 
long bones acting as a protective measure for the joint, providing cartilage with its 
characteristic resistance to compressive loads and mechanical stress (Murdoch 2002).
(iii) Globular Domain 3 (G3)
The C-terminus comprises o f the G3 domain that consists o f a number o f protein 
motifs: epidermal growth factor (EGF) like repeats, a C-type lectin motif, a 
complement regulatory protein (CRP) and a short tail peptide (Knudson and Knudson 
2001, Day et al., 1999). Alternative splicing o f the mRNA encoding these motifs 
creates G3 domains o f varied properties. The G3 domain has been reported to interact 
with other components within the extracellular matrix such as tenascin, fibulins and 
cell surface proteoglycans. The ligands for the G3 domain are not generally found in 
mature cartilage but in developing cartilaginous regions o f the body. This suggests an 
important role for G3 in the assembly o f the extracellular matrix and possibly an 
involvement in a repair process. An increase in age causes an increase of the 
population o f aggrecan monomers that lack the G3 domain, most likely due to 
proteolytic cleavage in matrix turnover (Knudson and Knudson 2001).
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Figure 1.14. Interactions involved in the aggregation of aggrecan {Adapted from 
Hardingham and Fosang 1992).
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(iv) Proteolytic Cleavage o f Aggrecan
There are many families o f proteases such as matrix metalloproteinases (MMPs) and 
aggrecanases that can cleave along the length of the aggrecan core protein (<discussed 
in section 1.6). Aggrecanases cleave aggrecan preferentially in the chondroitin 
sulphate-2 domain (CS-2) and secondarily in the interglobular domain (IGD). Data 
indicates that covalently bonded chondroitin sulphate enhances ADAMTs-4 mediated 
cleavage within the CS-rich region (Miwa et al., 2006). Also matrix 
metalloproteinase-13 cleaves preferentially within the CS rich region, but apparently 
by a CS independent mechanism (Miwa et al., 2006).
However, IGD cleavage is more deleterious for cartilage biomechanics as it releases 
the entire CS containing portion o f aggrecan. It was found using knockin mice that 
blocking aggrecanolysis in the aggrecan IGD protected against cartilage erosion and 
showed potential for cartilage repair (Little et al., 2007).
(B) Versican
Versican is a large fibroblastic proteoglycan that is not expressed in articular cartilage 
except during an osteoarthritic condition (Nishida et al., 1994), therefore it can be 
utilised as a marker to determine if  tissue engineered cartilage is o f a 
fibrocartilaginous phenotype instead o f the desired cartilaginous phenotype.
The amino terminal o f versican contains a hyaluronic acid binding domain followed 
by a central region that consists o f glycosaminogycan attachment sites. The C- 
terminus portion includes two epidermal growth factor-like repeats, a lectin-like 
sequence and a complement regulatory protein-like domain (Zimmermann & 
Ruoslahti 1989).
Recently it has been demonstrated that versican through the attachment o f chondroitin 
sulphate chains has an involvement in the early developmental stages o f cartilage. 
Versican positively regulates mesenchymal cell condensations and the onset of 
chondrocyte differentiation during chondrogenesis (Kamiya et al., 2006).
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1.4.2 Small Leucine Rich Proteoglycan
Small leucine rich proteoglycans (SLRPs) are synthesised either as glycoproteins 
containing N-linked oligosaccharides or as proteoglycans containing 
glycosaminoglycan side chains (Iozzo 1999). The core protein of SLRPs contain a 
cysteine rich region followed by a main portion of leucine rich repeats that participate 
in protein-protein interactions flanked by disulphide loops on both sides. Apart from 
chondroadherin, these proteins contain divergent amino-terminal extensions with 
features unique for different proteins (Figure 1.15).
SLRPs are divided into four classes (I-IV) depending on evolutionary protein 
conservation, gene organisation, the number of leucine rich repeats within the core 
protein central domain and the presence of distinct cysteine rich clusters at the N- 
terminal with varying consensus sequences (Iozzo 1999). Class I SLRP members 
(Table 1.5) include decorin, biglycan and asporin. Class II SLRPs (Table 1.6) 
comprise of 5 members; fibromodulin, lumican, proline arginine-rich and leucine-rich 
repeat protein (PRELP), keratocan and osteoadherin, of which all except keratocan 
and osteoadherin are expressed in cartilage (Grover et al., 1995). Members of the 
Class III SLRPs (Table 1.7) include epiphycan, mimecan and opticin. 
Chondroadherin is a class IV SLRP.
Numbers of leucine rich repeats vary 
depending on SLRP class
_________ A _________
Cysteine motif Leucine Repeats
KEY
Divergent amino termini extensions with 
features unique for different proteins
Leucine-rich repeat region
C-terminal cysteine residuesCysteine rich consensus sequence motif
(differs depending on SLRP class)
Figure 1.15. General structure of a Small Leucine Rich Proteoglycan (SLRP) (Iozzo
1999)
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Class 1 SLRPs
In general, the amino termini of Class 1 SLRPs contains the cysteine rich consensus sequence motif [CX3CXCX6C (C= Cysteine residue and X= intervening amino acid spacing]. 
Their central regions consist of 10-12 leucine rich repeats flanked by cysteine regions (Iozzo 1999). All Class I SLRPs (Asporin being an exception) are  primarily substituted with 
chondroitin sulphate (CS) / dermatan sulphate (DS) chains that show variation with age and between connective tissues (Roughley etal, 1993).
Location Structure Function
Decorin
The most abundant SLRP found in 
cartilage and its levels appear to 
increase with aging showing a 
greater need for decorin in adults 
(Melching 1989, Roughley etal., 
1994). The distribution of decorin 
within cartilage decreases with 
depth from the surface.
The glycoprotein core of decorin harbours 12 leucine-rich 
sequence motifs flanked by cysteine-rich regions with 4 at 
the N-terminus and 2 at the C-terminus. it also has either 2 
or 3 asparagine-bound oligosaccharides {at asparagines 
residues 181, 232 and273 respectively) (Hausser 1998). 
The decorin proteoglycan appears to have horseshoe like 
dimensions and due to this unusual structure decorin can 
partake in a multiple of functions.
The horseshoe structure of decorin enables it to bind 
various ligands including; TGF p, fibronectin and various 
collagen molecules. It is presum ed that the concave 
surface of decorin binds gap zones of collagen fibres 
maintaining fibril-fibril spacing via the GAG side chain at 
the N-terminus (Yamagudu 1990, Knudson & knudson 
2001).
Biglycan
Biglycan has been identified at the 
surface and pericellular regions of 
cartilage and at higher 
concentrations in the deeper layers 
(Poole e ta l, 1996, Miosge e ta l, 
1994). Biglycan requirement 
appears to be greatest in juveniles 
(Roughley e ta l, 1994).
This SLRP is com posed of a  38kDa core protein. At 
the amino terminus there are two chondroitin 
sulphate/derm atan sulphate attachment sites. The 
non-proteoglycan form of biglycan constitutes a minor 
proportion of biglycan in newborn, but is a major 
component in adults (Roughley e ta l, 1993). More C- 
terminal of this region there is a cysteine rich region 
followed by a leucine rich region containing 10 
repeating units (Neame et al, 1989).
Biglycan has been demonstrated to interact with some of the 
molecules in which decorin can interact such as TGFp. There is 
conflicting data as to whether biglycan can interact with fibrillar 
collagens or not. Biglycan doesn't interact with collagen under all 
conditions and primarily it interacts with type VI collagen. In 
Schwarm rat chondrosacoma tissue, both biglycan and decorin 
have been demonstrated to interact with matrilin-1 forming 
complexes acting as a linkage between collagen type VI microfibrils 
to both collagen type II and aggrecan (Wiberg et al,2003). Biglycan 
has been indicated as a positive regulator of bone formation and 
bone mass (Xu etai, 1998).
Asporin
Partially purified from human 
articular cartilage and meniscus. Its 
RNA levels are expressed in aorta, 
uterus, heart, liver and to a  greater 
extent in osteoarthritic cartilage 
(Lorenzo e ta l, 2001).
Asporin contains a putative pro-peptide, 4 amino- 
terminal cysteines, 10 leucine rich repeats and 2 C- 
terminal cysteines. Asporin is not a  proteoglycan, a s  it 
doesn’t contain a consensus sequence for GAG 
attachm ent and it comprises of a  long stretch of aspartic 
acid residues in its amino terminal (Lorenzo etal, 2001).
The aspartic acid repeat polymorphism in asporin inhibits 
chondrogenesis and potentially contributes to calcium 
phosphate deposition in osteoarthritis (OA) (Lorenzo et al, 
2001, Kizawa e ta l, 2005, Ikegawa S 2006). Asporin has not 
been found to play a major role in the susceptibility to 
rheumatoid arthritis, but it may influence the disorder (Torres 
e ta i, 2007).
Table 1.5. Members o f Class I Small Leucine Rich Proteoglycans located in cartilage
Class II SLRPs
In general, th e  am ino termini of C lass  II S L R P s contain  su lp h a ted  ty rosine re s id u es  and  th e  cyste ine  rich c o n se n su s  se q u e n c e  motif [CX3CXCXgC]. Their 
central d o m ains consist of 10 leucine rich re p e a ts  (Iozzo 1999). All C la ss  II SL R Ps, with th e  excep tion  of PRELP (that h a s  heparin  su lp h a te  a tta ch m en t
sites) a re  primarily substitu ted  with poly lactosam ine o r keratan  su lp h a te  (KS) chains.
Location Structure Function
Fibromodulin
Cartilage, tendon, skin, sclera 
and cornea (Oldberg et al.,
1989). In articular cartilage 
high levels of fibromodulin have 
been located to the 
interterritorial matrix region with 
decreasing concentrations from 
articular surface with depth 
(Hedlund etal., 1994).
Fibromodulin can contain up to 4 KS chains, within its 
leucine rich region through N-glycosidic linkages to 
asparagine residues (Plaas etal., 1990). Fibromodulin in 
juveniles and young adults exists in a proteoglycan form 
possessing KS chains, the size of these chains decrease 
with age. In mature cartilaginous tissues fibromodulin does 
not possess KS chains or non-sulphated polylactosamine 
chains, but possesses the same number of N-linked 
oligosaccharides (Roughley et al., 1996).
Fibromodulin is localised along the surface of 
collagen fibrils and may possibly regulate fibril 
diameter (Hedbom & Heinegard 1993). It has 
also been shown to inhibit type I collagen 
fibrillogenesis through more than one binding 
domain within fibromodulin (Font ef al., 1998).
Lumican
The major location is the cornea, 
but it does have a wide spread 
distribution including muscle, 
kidney, lung, intestine and 
connective tissues including 
articular cartilage (Melching and 
Roughley 1989, Ying etal., 
1997).
In adult cartilage, lumican exists predominantly in 
a glycoprotein form lacking KS chain attachment, 
whereas the juvenile form of the molecule is a 
proteoglycan form (Grover etal., 1995, Melching 
etal., 1997).
Colocalises with fibrillar collagens in the corneal 
stroma, regulating assembly and diameter of 
collagen fibres (Blochberger et al., 1992, Neame et 
al., 2000). Modification of lumican with KS may 
contribute to corneal transparency (Chakravarti et al. 
1998 review).
Lumican has been shown to interact with type II 
collagen (Sztrolovics etal, 1999).
Proline Arginine-rich 
and leucine-rich 
repeat protein 
(PRELP)
Articular cartilage (predominantly 
in the territorial matrix) and at 
certain basement membranes.
Also present in kidney, skin, aorta, 
sclera, liver, skeletal muscle, 
cornea and tendon.
It is the only member of the SLRPs with a  basic 
amino-terminal region that is rich in proiine and 
has clusters of arginine residues.
Binds the heparan sulphate proteoglycan perlecan via its 
jositively charged amino terminal (Bengtssonn et al. 2000 
& 2002) and binds collagens type I and type II through its 
leucine-rich repeat domain suggestive that PRELP 
functions as a molecule for anchoring basement 
nembranes to underlying connective tissues (Bengtssonn 
etal. 2002).
Table 1.6. Members of Class II Small Leucine Rich Proteoglycans located in cartilage
Class III SLRPs
In general Class III SLRPs contain the N-terminal cysteine rich consensus sequence [O^CXCXgC] and have slightly smaller central domains consisting
of only six leucine rich repeats (Iozzo 1999).
Location Structure Function
Epiphycan / 
PG-Lb / 
DSPG3
Epiphysis (Johnson et al., 1997), 
cartilage, ligament and placental tissue 
(Deere et al., 1996).
The core protein of bovine epiphycan is 
approximately 46kDa and substitution of 
dermatan sulphate/chondroitin sulphate of 
variable size ranging from 23-34 kDa at two 
serine residues have been found within its N- 
terminal acidic region. All glycosylations 
except one N-linked oligosaccharide occur in 
the N-terminal domain of the protein core.
Epiphycan functions as an immediate 
marker for chondrogenesis and has an 
involvement in the organisation of the matrix 
growth plate, especially the zone of flattened 
chondrocytes where it is abundantly located 
(Johnson et al., 1999).
Mimecan / 
Osteoglycin
Found in sclera and cornea, but can 
also be found in non-ocular tissues 
as a non-sulphated glycoprotein. 
(Funderburgh eta l., 1997, Madisen 
etal., 1990).
Exhibits only ~ 40% protein sequence 
identity to epiphycan (Shinomura and 
Kimata 1992)
Mimecan has been demonstrated to 
regulate collagen fibrillogenesis in vivo 
(Tasheva et al., 2002). Mimecan is also a 
secretary product found in osteoarthritic 
cartilage (De Ceuninck etal., 2005).
Opticin / 
Oculoglycan
Located in ocular tissues, cartilage, 
ligament, skin, muscle, and testes 
(Pellegrini et al., 2002).
At its amino terminal region there are 0 -  
linked oligosaccharides (Reardon et al., 
2000) and heparin binding consensus 
sequences (Cardin & Weintraub 1989)
Been reported to bind to collagen fibrils 
(Pellegrini et al., 2002).
Table 1.7. Members of Class III Small Leucine Rich Proteoglycans located in cartilage
Chondroadherin (a class IV SLRP) is a cell binding protein that is expressed at high 
levels in certain zones o f articular cartilage within the territorial matrix, also detected 
in bone, tendon, bone marrow, and chondrosarcoma cells (Tasheva et al., 2004). 
Principal features o f this Class IV SLRP are that it contains a series of ten leucine rich 
repeats and most N terminal o f these repeats is a cysteine residue (Cys63) that is not 
disulphide bonded, but probably involved in hydrogen bonding. Chondroadherin 
lacks both amino and COOH terminal extensions outside the cysteine motifs. Two 
major isoforms o f this proteoglycan generated as a result o f cleavage within the C- 
terminal region have been isolated from bovine articular cartilage (Neame et al., 
1994).
Chondroadherin has been found to bind two sites on collagen type II and has also 
been shown to mediate adhesion o f isolated chondrocytes (Camper et al., 1997). Both 
type II collagen and chondroadherin have been found to interact with chondrocytes 
via the same receptors, but the interaction o f the two different molecules with the 
receptor give rise to different cellular responses (Mansson et al., 2001).
1.4.3 Superficial Zone Protein (SZP) / Proteoglycan 4 / Lubricin
This proteoglycan was first described by Schumacher et al and identified in the 
culture medium from thin slices o f superficial bovine articular cartilage (Schumacher 
et al, 1994). The molecular weight o f this proteoglycan is approximately 345kDa 
and it is specifically synthesised by chondrocytes located within the superficial zone 
of articular cartilage (Schumacher et al., 1994). SZP is not synthesised by 
chondrocytes located in the mid or deep regions therefore functions as a specific 
marker for chondrocytes o f the superficial zone region (Schumacher et al., 1994). 
Accumulation o f SZP in articular cartilage has been shown to increase in response to 
bone morphogenetic protein-7 (BMP-7) and growth factors (Khalafi et al., 2007).
The molecule is substituted with keratan sulphate and chondroitin sulphate mostly at 
the amino or carboxy-terminal, or at both termini therefore it can be categorized as a 
proteoglycan (Schumacher et al., 1999). Very little SZP is incorporated in the matrix 
surrounding the chondrocytes; most diffuses out o f the tissue and can be detected in 
the synovial fluid (Schumacher et al., 1994, Schumacher et al., 1999). Not only has 
SZP been located at the surface o f articular cartilage, it has also been found in the
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synovial membrane (Schumacher et al., 1999 and at the surface of fibrocartilaginous 
regions o f tendon with an increased presence with age (Rees et al., 2002).
The amino acid composition of SZP is highly conserved between human and bovine 
species and has been found homologous to the precursor protein megakaryocyte- 
stimulating factor (MSF) (Schumacher et al., 2005). SZP is a multifunctional 
proteoglycan. Its core protein within the central region is composed of large and 
small mucin-like repeat domains composed o f the sequences KEPAPTTT/P (76-78 
repeats) and XXTTTX (6-8 repeats), respectively. The mucin-like domains are likely 
to be substituted with O-linked oligosaccharides, which provide lubricative and 
cytoprotective properties. The mid region is flanked by cysteine rich N- and C- 
terminal domains, which are homologous to somatomedin B and haemopexin 
domains o f vitronectin, respectively. The potential growth promoting, cytoprotective 
properties have been associated with the N-terminal domain and both matrix binding 
and aggregating properties have been associated with the C-terminal domain 
(Flannery et al., 1999).
1.5 Other Extracellular Matrix Macromolecules
There are a number o f molecules within the extracellular matrix that are not collagens 
or proteoglycans that have been identified in articular cartilage. Some o f these are 
discussed in detail below.
1.5.1 Cartilage Oligomeric Matrix Protein (COMP)
The acidic oligomeric protein COMP is a member o f the thrombospondin gene family 
o f extracellular glycoproteins, and recently has been termed thromospondin 5 (TSP-5) 
(Kipnes et al., 2003). It is a product of a unique gene and is not formed by the 
alternative splicing of the thrombospondin gene (Oldberg et al., 1992).
Cartilage Oligomeric matrix protein is a non-collagenous glycoprotein expressed 
predominantly in articular cartilage (Hedbom ef al., 1992), tendon (DiCesare et al.,
1994) and ligament. In adult cartilage, COMP has been shown to be primarily located 
within the interterritorial matrix (Kipnes et al., 2003). Its expression has also been
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found to be predominantly located in the proliferative region of the growth plate 
(Shen et al., 1995, Ekman et al., 1997) indicating a role for COMP in developing 
cartilage.
The structure of COMP has been identified as a pentameric bouquet like protein 
(~524kDa) composed of five identical subunits (Figure 1.16). Each subunit contains 
an a-helical structure located at its N-terminus which is responsible for the 
stabilisation of the pentameric structure due to disulphide bonds occurring between 
residues 20-83 (Efimov et al., 1994). Each COMP subunit contains 2 N-linked 
oligosaccharides which differ between immature and mature cartilage. The N- 
terminal is followed by a flexible region of 4 type 2 epidermal growth factor (EGF) 
domains and 7 thrombospondin (TSP) type 3 calcium binding domains and a C- 
terminal globular domain (Oldberg et al, 1992).
The Structure of a Single Subunit from a Cartilage Oligomeric Matrix Pentameric Protein
n h 2
C-Terminal
KEY
a- Helical pentam erization domain
♦
❖
Epidermal Growth Factor Like dom ains
Calcium binding Epidermal Growth Factor 
Like dom ains
□Calcium binding throm obospondin Type III rep ea ts
C-terminal Globular dom ain
Figure 1.16. Schematic diagram representing one o f the five subunits found on a COMP 
pentameric protein adapted from Spitznagel et al., 2004.
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Crystal structure analysis o f the recombinant coiled coil domain of COMP revealed 
that within the pentameric a  helical bundle there was a hydrophobic channel, 73 A 
long with a diameter o f 2-6 A potentially responsible for the binding o f hydrophobic 
molecules (Ozbek et al., 2002). This is suggestive that COMP plays a role in storage 
and delivery o f regulatory molecules in metabolism (Ozbek et al., 2002).
COMP mediates primary chondrocyte attachment of matrix components and has a 
role in organising matrix assembly in cartilage (Misumi et al., 2001). It had been 
suggested that it plays a role influencing the organisation of collagen fibrils via its C- 
terminal domain with collagen types I, II and IX. COMP binds collagen type I/II and 
pro-collagen I/II in the presence o f Zn2+ and with the non-collagenous domains of 
type IX collagen (Holden et al., 2001). This has a stabilising function on the collagen 
network in cartilaginous tissues. Potentially COMP can bind with its five C-terminals 
to five different collagen molecules, possibly indicating that COMP has an 
involvement in the organisation o f collagen molecules into microfibrils (Halasz et al., 
2007).
The fact that COMP and its proteolytic fragments are released into the synovial fluid 
and serum on joint degradation, suggest a structural role for COMP in the assembly 
and maintenance o f the extracellular matrix (Spitznagel et al., 2004). COMP is 
utilised as a biomarker for cartilage turnover, proving to be a valuable parameter as a 
prognostic factor as levels o f COMP are elevated during rheumatoid arthritis (RA). 
COMP has also been used as a marker to monitor therapy response in patients with 
RA (Skoumal et al., 2004).
There have been over sixty mutations identified to occur in COMP (Lachman et al., 
2005, Chen et al., 2008). Mutations occur in the calcium domains and the C-terminal 
domains therefore disrupting the interaction o f COMP with collagens. Two related 
skeletal dysplasias in man have been identified; pseudoachondroplasia (PSACH) and 
multiple epiphyseal dysplasia (MED) (Holden et al., 2001, Rosenburg et al., 2001, 
Spitznagel et al., 2004).
1.5.2 Matrilins
Four members o f the glycoprotein matrilin family have been identified to date; 
matrilin-1, -2, -3 and -4. The first member to be discovered was matrilin-1, originally
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called cartilage matrix protein (Paulsson and Heinegard 1981). Matrilins have the 
ability to form both homotypic and heterotypic oligomers and there are seven novel 
matrilin isoforms (Frank et al., 2002). Comparative genomics o f the syndecans has 
defined an ancestral genomic context associated with matrilins in vertebrates 
(Chakravarti & Adams 2006). Recently, mutations in the human gene encoding 
matrilin-3 have been associated with different forms o f chondrodysplasias (Nicolae et 
al., 2007)
All four matrilins are expressed in cartilage (Nicolae et al., 2007). Matrilin-1 is 
expressed mainly in cartilage and matrilin-3 has a similar distribution, while both 
matrilins -2 and -4 occur in a wide variety o f extracellular matrices (Deak et al.,
1999). In rabbit knee joints matrilin-1 was found within deeper epiphyseal cartilage 
and remained confined to the residual epiphyseal cartilages indicating that articular 
and epiphyseal cartilage are different from the earliest o f  developmental stages 
(Kavanagh & Ashhurst 1999).
All matrilins contain common structural motifs; they have two von Willebrand Factor 
A (vWFA)-like domains separated by varying numbers o f epidermal growth factor 
(EGF)-like domain(s) {varying from one in matrilin-1 to ten in matrilin-2) and a 
coiled-coil a-helical motif (Aszodi et al., 1999 & Deak et al., 1999).
Matrilins are similar in their structures, but versatile in their functions. They are 
matrix adapter proteins that mediate interactions between collagen-containing fibrils 
and other matrix constituents, such as aggrecan (Wagener et al., 2005 & Nicolae et 
al., 2007). They participate in the formation o f fibrillar or filamentous structures and 
are often associated with collagens (Wagener et al., 2005 & Nicolae et al., 2007). 
Matrilin-1 has been found to form complexes with both decorin and biglycan 
molecules acting as a linker with abilities to connect type VI collagen to both collagen 
type II and aggrecan (Wiberg et al., 2003). These linkers have also been shown to 
connect a number o f pro-collagen molecules to collagen type VI scaffolds (Wiberg et 
al., 2003).
Both matrilins-1 and 3 have been found to be major components o f the pericellular 
matrix and chondrocyte sensitivity to changes in the microenvironment induced by 
cyclic loading can be adjusted by altering the content o f matrilins in the pericellular 
matrix, supporting a critical role o f the pericellular matrix in chondrocyte mechano- 
transduction (Kanbe et al., 2007).
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All matrilins except matrilin-4 are capable of mediating cell attachment. Matrilins-1 
and -3 have been found to facilitate cell attachment in a dose dependent manner, but 
higher doses o f these matrilins are required for cell attachment to reach plateau values 
similar to those obtained using fibronectin (Mann et al., 2007).
1.5.3 Cartilage Intermediate Layer Protein
The cartilage intermediate layer protein (CILP) gene is mapped to chromosome 15 
(locus q22) (Nakamura et al., 1999) and it encodes a proform o f two polypeptides. 
The precursor protein, contains a putative signal peptide o f 21 amino acids and is 
synthesised as a single polypeptide chain that is processed into two polypeptides upon 
or preceding secretion. The amino terminus corresponds to non-collagenous CILP 
protein. CILP has been identified as a single 92kDa polypeptide chain that contains 
30 cysteine residues, 1 thrombospondin-like repeat and 6 N-glycosylation sites (10% 
o f its total molecular mass being attributed to N-linked oligosaccharides) (Lorenzo et 
al., 1998). At the C-terminal, 460 amino acids show 90% similarity to pig 
ectonucleotide pyrophosphohydrolase (NTPPHase); this region is preceded by a furin 
protease consensus cleavage site (Lorenzo et al., 1998). The NTPPHase contains 10 
cysteine residues and 2 putative N-glycosylation sites.
CILP is a synthetic product o f chondrocytes and it is restricted to cartilaginous tissues 
with specific distribution in the middle layer o f the tissue with deposition in the 
interterritorial matrix (Lorenzo et al., 1998). It is not observed in the superficial or 
the deep regions o f articular cartilage (Lorenzo et al., 1998). Interactions o f CILP 
with other extracellular matrix molecules have not been identified.
Increased synthesis o f CILP has been shown in lumbar disc disease and in early OA 
(Mori et al., 2006 & Seki et al., 2005). In early OA, CILP distribution changes from 
a predominantly interterritorial location to a pericellular location (Lorenzo et al.,
1998).
CILP/NTPPHase secretion into the matrix around chondrocytes has been shown to 
increase with age. In this extracellular site it may generate inorganic pyrophosphate 
and contribute to age-related calcium pyrophosphate dihydrate crystal deposition 
disease (Masuda et al., 2001 and Yamakawa et al., 2002).
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1.5.4 Tenascins
Tenascins are large multi-subunit glycoproteins that are found in numerous tissues. 
There are five types o f tenascins that have been identified to date these being; 
tenascin-R {predominantly found in the central nervous system having an impact on 
neurite outgrowth and synaptic function (Chiquet-Ehrismann 2004a & b), -X {found 
in connective tissue around blood vessels), -W {found in the extracellular matrix o f 
bone, muscle and kidney (Chiquet-Ehrismann 2004 a & b)), -Y and C {produced by 
osteoblasts, cartilage, perichondral cells and fibroblasts (Chiquet-Ehrismann 2004 a 
&b)).
There are several distinct isoforms o f Tenascin-C and its expression has been found in 
large concentrations in articular cartilage, suggesting a tissue specific function. The 
smaller 220kDa isoform of tenascin-C is found in normal chondroid matrix and the 
expression o f a larger 320kDa isoform is found in chondrosarcoma (Ghert et al., 
2002). Therefore, alternative isoforms o f tenascin-C may lead to therapeutic 
approaches for chondrosarcoma (Ghert et al., 2002).
The overall glycoprotein structures o f the tenascin family are the same, although 
tenascin-C is the only one in the family known to form hexabrachions (Jones & Jones
2000). Tenascin-C contains six monomers each terminating in a globular domain that 
radiate from a central complex, existing as a disulphide linked multimer. Each 
monomer o f the hexabrachion, at the N-terminal contains a group o f hydrophobic 
residues and eight cysteine residues thought to be responsible for association o f the 
six monomers into a homohexamer. C-terminal to this region are epidermal growth 
factor-like (EGF-like) repeat modules that show sequence homology with type II units 
found in fibronectin and several other proteins (Gulcher et al., 1991).
Tenascins have been found to have adhesive and anti-adhesive properties. Evidence 
for adhesive domains within tenascin is that it can interact with chondroitin sulphate 
proteoglycans or with RGD-sensitive integrins (Gotz et al., 1996, Xiao et al, 1997, 
Grumet et al., 1996, Elefteriou et al., 1999). Tenascin-C has been found to be 
modulated by mechanical stress, having an increased expression in tissue surrounding 
tumours, wounds and inflamed tissues (Latijnhouwers et al., 1998, Chiquet- 
Ehrismann et al., 2003 & 2004, Dang et al., 2006). Here it may possibly regulate cell 
morphology, growth and migration by activating diverse intracellular signalling
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pathways (Chiquet-Ehrismann 2004 a & b). It has been demonstrated that tenascin-C 
can interfere with the binding o f syndecan-4 to fibronectin and block cell adhesion 
stimulating tumour cell proliferation (Huang et al, 2001). It has been suggested that 
tenascins may act as ‘avoidance molecules’ that could act as steric blockers o f cellular 
receptors for other extracellular matrix components (Sage and Bomstein, 1991).
1.6 Degenerative Changes in Articular Cartilage
A major degenerative pathology of cartilage is arthritis. Arthritis is a multifactorial 
disease with genetics, obesity, joint injury, sex and age all being possible contributors. 
A central event in both osteoarthritis and rheumatoid arthritis is the depletion of 
cartilage extracellular matrices via enzymes; this also occurs to a lesser extent during 
the course o f normal matrix turnover.
There are several enzyme families termed matrix proteases which are responsible for 
matrix erosion. They include Cathepsins (Soderstrom et al., 1999, Fosang et al., 1992 
Rantakokko et al., 1996, Deiss et al., 1996 and Wex et al., 2001), A Disintegrin and 
Metalloproteinase (ADAMs) (Wolfsberg et al., 1998, Black et al., 1997, Primakoff & 
Myles., 2000 and Hartmann et al., 2002), A Disintegrin and Metalloproteinase 
(reprolysin type) with Thrombospondin motifs (ADAMTs) (Kuno et al., 1997, 
Flannery et al., 1999, Somerville etal., 2003, Tang et al., 2001, Abbaszade 1999, Cal 
et al., 2002., Bomstein 1992, Amer 2002, Tortorella et al., 1999, 2000a & 2000b), 
and Matrix Metalloproteinases (MMPs) (Van Wart et al., 1990, Gomis-Ruth et al., 
1996, Fosang et al., 1992, Little et al., 2002).
Members o f the ADAMTs family (ADAM Ts-1, ADAMTs-4 (Aggrecanase-1), 
ADAMTs-5 (Aggrecanase 2) and ADAMTs-9) have been shown to cleave at various 
positions along the core protein of aggrecan, the major proteoglycan found in 
cartilage (Tortorella et al., 1999, 2000b, Abbaszade et al., 1999 and Flannery et al.,
1999). Matrix Metalloproteinases (MMPs) that have been found to cleave aggrecan 
to date include MMP-1,-2, -3, -7, -9, -10 and -13 (Fosang et al., 1992, Little et al., 
2002 and Flannery et al., 1992) and the collagenases (MMP-1, -8, -13 and -14) have 
been found to efficiently degrade fibrillar collagens (Somerville et al., 2003). Altered 
mechanical stresses induce chondrocytes within cartilage to make inflammatory
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cytokines resulting in synthesis, secretion, and activation of these cartilage degrading 
matrix proteases.
Inhibitors o f the MMPs have been identified, and are called Tissue Inhibitors o f 
Metalloproteinases (TIMPs) (Henriet et al., 1999). Recent studies have shown that 
they also have the ability to inhibit aggrecanase activity (Hashimoto et a l , 2001 and 
Gendron et al., 2003). Cystatins are known inhibitors of Cathepsins (Auerswald et 
al., 1996 and Sawicki & Warwas 1989); alterations in the Cathepsin / cystatin balance 
result in uncontrolled proteolysis as seen in disorders such as osteoarthritis 
(Soderstrom et al., 1999). Consequently, these enzymes are a target for therapeutic 
intervention, with much research focusing on discovering various inhibitors with 
chondro-protective abilities.
1.6.1 Osteoarthritis
Osteoarthritis (OA), also known as osteoarthrosis, arthrosis, and degenerative joint 
disease is the most common age-related disorder o f articular cartilage joints and bone 
tissue although in certain cases it has been found to affect juveniles. OA can affect 
different joints including hands, feet, spine, knees and hips and is characterised by 
progressive degeneration and loss o f articular cartilage. There is no cure for this 
common disease and current treatments only modify the symptoms o f the disease to 
alleviate pain and minimise joint damage (Dodge and Jimenez, 2003).
Factors that contribute to OA include obesity, joint injury and a persons’ sex 
(O’Conner 2006, Pearson-Ceol 2007). A higher disease incidence occurs with 
increasing age, although OA is not an inevitable part o f ageing. Occasionally OA can 
be found in multiple members o f the same family implying a genetic role. Genetic 
mutations in ECM components of cartilage predispose the joints to OA either through 
failure of matrix integrity or of whole joint functioning. Genes associated with 
abnormal development of skeletal structures are found at 
(http://www.ncbi.nlm.nih.gov/omimT Early stage OA cannot be detected using 
radiographs as significant alterations must occur before its detection, therefore it is 
essential to identify early onset biomarkers associated with this disease (Kato et al., 
2007).
48
The early stages o f osteoarthritis are non-inflammatory. Initially, articular cartilage 
attempts to repair and remodel itself rather than enter a degradation process, 
reinitiating the synthesis o f some extracellular matrix proteins characteristic of early 
developmental stages. Increased expression levels of aggrecan, link-protein, type II 
collagen (some o f the type II collagen is present in its embryological form, Type IIA) 
and type X collagen (a marker for hypertrophy) have been observed (Hardingham and 
Fosang 1992). The chondrocytes are stimulated to undergo cell replication which is 
the converse o f normal non-diseased, non-proliferating chondrocytes (Sandell & 
Adler 1999) and they start to synthesis more ECM molecules. This remodelling of 
articular cartilage compromises the ability o f cartilage to resist compressive loads. 
Altered mechanical stresses induce chondrocytes within the cartilage to make 
inflammatory cytokines resulting in the activation o f matrix proteases. An 
inflammatory reaction is also observed within the synovial membrane, and the 
volume o f synovial fluid increases showing changes in the lubrication properties 
during this disease as the fluid has a reduced viscosity (Gerwin et al., 2006). Matrix 
proteases increase both proteoglycan and collagen degradation. The initial loss of 
proteoglycan is from the superficial zone and its degradation compromises the ability 
of cartilage to imbibe water and resist compressive loads.
During the later stages o f OA cellular changes in cartilage morphology occur, cells 
divide in their lacunae and become hypertrophic forming cells clusters (von der Mark
1995). Remodelling o f chondrons within the deep zones occur, where there is a 
characteristic decline in pericellular fibrillar collagens (i.e type IX collagen) and an 
increase in type VI collagen forming a type VI rich glycocalyx to accommodate the 
increasing number of chondrocytes attempting to repair (Poole 1997). Eventually 
cartilage can be worn away exposing the underlying subchondral bone; joint space 
narrowing is also evident. The formation o f osteophytes and thickening o f the 
subchondral plate is observed in bone (Martel-Palletier et al., 1999)
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1.6.2 Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic, chronic inflammatory autoimmune disease. 
The immune system attacks normal tissue components as if they were invading 
pathogens, attacking the lining o f joints causing them to be swollen, stiff and painful. 
The pathology o f RA extends throughout the synovial joint, and in severe cases 
involves many other organs (e.g. skin, blood vessels, heart, lungs and muscle). There 
is a 3 fold predominance o f RA in women that may be attributed to hormonal factors 
(Masi et al., 2006).
The cellularity o f the synovial membrane increases from 1-2 to 6-8 cells thick, 
comprising mostly macrophages, as it is infiltrated with cells from the blood during 
RA. The synovial fluid o f the diseased joint also becomes more cellular in 
comparison to the acellular fluid that is usually present under normal conditions. It 
becomes predominantly enriched with neutrophils but there are also macrophages, T- 
lymphocytes and dendritic cells present.
The major site of irreversible tissue damage originates at the junction o f the synovium 
lining the joint capsule with the cartilage and bone, a region termed the pannus. 
Pannus cells migrate over underlying cartilage and into the subchondral bone, causing 
erosion o f these tissues (Feldman et al., 1996). Fibroblast-like synoviocytes (FLS) 
are a cell population central to the development o f the pannus. It was found that p21 
was involved in regulating cell cycle, playing a role in repressing FLS migration. The 
loss o f p21 expression that occurs during RA, may contribute to the excessive 
invasion and subsequent joint destruction that takes place during RA (Woods et al., 
2006).
Many pro-inflammatory cytokines (including TNFa and IL-lp), chemokines, and 
growth factors are expressed in diseased joints from cells within the pannus and 
synovial lining; inhibition o f these molecules may provide a treatment in RA (Chu et 
al., 1992). Cytokines cause synthesis, secretion and activation o f matrix proteases 
(i.e. MMPs, ADAMTs 4 and 5) responsible for degradation o f cartilage and bone 
within the joint. Destruction o f cartilage as seen in rheumatic disease is now 
considered to be mostly due to the activity o f matrix metalloproteinase enzymes 
(MMPs), produced by activated macrophages and fibroblasts in response to pro- 
inflammatory cytokines such as IL -ip  and TNF a  (Feldman et al., 1996).
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Recently it was established that TL-23 p l9  was expressed in the synovium o f RA 
patients, but not in OA patients. IL-1 p and to a lesser extent TNF a  were found to 
induce and regulate IL-23 p l9  expression from RA FLS via NF kappa p and AP-1 
pathway. IL-23 p i 9 promoted an inflammatory response in RA, inducing IL-8 and 
IL-6 which was repressed by the addition of inhibitors for both NF kappa P and AP-1 
(Liu et al., 2007). Inflammatory conditions can affect the activities o f 
glycosyltranferases, thereby modifying glycan chain synthesis. This can have 
detrimental effects when the function o f glycoproteins present within a matrix is 
influenced (Yang et al., 2007).
At present there are no cures for RA, just symptom modifying treatments which 
reduce pain and minimise joint destruction. In the past, inhibitors of TNF a  have 
been utilised as a treatment, but frequency and degree o f response was restricted. 
Recently it has been reported that a promising treatment of RA involves the use o f 
three novel biological compounds; rituximab (anti-CD20), abatacept (cytotoxic T- 
lymphocyte antigen 4 immunoglobin) and tocilizumab (anti-interleukin 6 receptor) 
(Smolen et al., 2007). RA FLS gene expression profiles may provide an insight into 
disease pathogenesis and have utility in diagnosis, prognosis and drug responsiveness 
(Galligan et al., 2007).
1.6.3 Cartilage Defects
Cartilage defects are localised lesions o f cartilage, either generated as a result o f OA 
or joint trauma. A cartilage defect can be regarded as a bioactive chamber. Natural 
repair can hypothetically occur from the surrounding cartilage walls, the calcified 
zone, the bone marrow and migrating cells from the synovial fluid (Brittberg 1999). 
Cells adjacent to wound margins undergo cell death, then after 24 hours there is an 
increase in cell proliferation, cluster formation and increased matrix synthesis and 
catabolism. This response is short lived and is not sufficient to repair the defect 
(Redman et al., 2005).
There are two types o f articular cartilage defects, partial thickness defects and full 
thickness defects. Partial thickness defects do not penetrate the subchondral bone and 
are unable to heal spontaneously often undergoing progressive degeneration to 
osteoarthritis (OA). Full thickness defects penetrate through the zone o f calcified
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cartilage and into subchondral bone and elicit an intrinsic repair response generating a 
fibrocartilaginous repair tissue. With time there is marked degeneration o f repair 
tissue and a continued degeneration o f native articular cartilage (Redman et al., 2005).
1.7 Current Cartilage Repair Strategies and Techniques
Current, non-operative treatments that are applied for pain reduction during arthritis 
include; anti-inflammatory medications, viscosupplementation, activity modifications, 
bracing and the use o f orthotics (Simon & Jackson et al., 2006). A number of surgical 
procedures such as joint realignment may provide pain relief for patients for a number 
o f years. The only effective treatment for pain reduction and knee disability is 
prosthetic joint replacement, although this does not provide permanent functionality, 
as prostheses have a limited life span.
1.7.1 Viscosupplementation
Viscosupplementation, approved in the late 1990’s involves 3-5 injections of 
exogenous high molecular weight hyaluronan (HA) to the intra-articular space o f 
arthritic joints over several weeks. High molecular weight injections used to date 
include: (1) Hyalgan {naturally derived sodium hyaluronate with average molecular 
weight (Mwt) 500-730kDa), (2) Supartz {naturally derived sodium hyaluronate with 
average Mwt 630-1120kDa, Seikagaku corpororation, Tokyo), (3) Orthovisc {Sodium 
hyaluronate with average Mwt 1900-3000kDa. Anika Therapeutics, Woburn MA) and 
(4) Synvisc {hylan G-F20, chemically modified with an average Mwt > 6000kDa, 
Genzyme) (Goldberg & Buckwalter 2005).
These injections improve the visco-elastic properties o f the synovial fluid 
encouraging lubrication, shock absorbance, the formation o f a semi permeable barrier 
and decreased inflammatory and proliferative processes that occur within diseased 
synovium. Degradation by active oxygen species may reduce the protective 
properties o f HA (Roth et al., 2005).
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Currently, intra-articular HA injections are indicated as symptom modifying 
treatments only. However, there is substantial evidence suggesting that HA can also 
have disease modifying activity in certain patient populations, as pain relief has been 
found to last considerably longer than the half life of the injected HA. In an animal 
trial, the half life o f hyalgan injections were estimated to be as short as 18-24 hours 
but pain relief lasted for 26 weeks or more (Goldberg & Buckwalter 2005).
Adverse effects associated with hyaluronan injections are a mild pain and swelling at 
the injection area. There was a rare report of a pseudoseptic knee, where a patient 
developed a severe inflammatory reaction against chicken proteins present in the high 
molecular weight HA injection (Hamburger et al., 2003).
1.7.2 Debridement and Lavage
Debridement and lavage procedures have been employed in the treatment of cartilage 
defects. Cartilage in and around a chondral defect is abnormal and unstable. 
Debridement is the arthroscopic excision o f  this damaged cartilage. Debridement 
itself has been shown to improve symptoms for up to 5 years or more (Smith et al., 
2005). Lavage is the irrigation o f a joint during arthroscopy which removes debris 
and appears to alleviate pain. Both o f these treatments can be successful in treating 
the early stages o f OA, but they do not induce repair. When both debridement and 
lavage are used in conjunction with each other the pain relief lasts longer (Redman et 
al, 2005).
1.7.3 Microfracture
Microfracture (Steadman et al., 2001) is a procedure introduced by Steadman 20 
years ago that stimulates intrinsic repair (Smith et al., 2005). It is a marrow 
stimulating technique that is similar to abrasion arthroplasty and Pridie drilling 
(Redman et al., 2005). This technique has acceptable clinical results o f up to 5-7 
years and has been found to have better results with patients less than 35 years o f age 
(Smith et a l, 2005). During this technique damaged tissue is debrided down to the
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subchondral bone. The subchondral bone is perforated by small awls, approximately 
2-3mm apart inducing bleeding (Redman et al., 2005).
Invading mesenchymal stem cells from the bone marrow space have the potential to 
differentiate into chondrocytes, but can produce a fibro-cartilaginous tissue containing 
collagen type I. Therefore, there is an unpredictable outcome of the nature and 
quality o f the repair tissue produced from patient to patient utilising this technique 
(Redman et al, 2005).
1.7.4 Mosaicplasty
Mosaicplasty (also known as osteochondral transfer (OATS)) is a procedure that was 
first described in 1993 (Hangody et al., 1997 & 1998). It can be carried out 
arthroscopically or with an open joint to treat both chondral and osteochondral defects 
(Smith et al., 2005). Autologous osteochondral cylindrical plugs are taken from 
regions considered to be relatively non-load bearing, usually the peripheries o f both 
femoral condyles at the level o f the patellofemoral joint (Smith et al., 2005). 
However, no harvest site is truly non-load bearing; for this reason donor sites shall be 
referred to as low-load bearing sites.
Different sized plugs are mosaically transplanted to a debrided full depth defect in 
order to fill the defect. An advantage o f this technique is that defects are filled 
immediately with mature hyaline cartilage. The disadvantages are that cell death can 
occur at the wound margins o f the donor site, and at the margins o f the ostoechondral 
plug leading to failure o f lateral integration. Tissue from the low load bearing regions 
may have difficulties withstanding the stresses found in a high load bearing area 
(Redman et al., 2005). An additional problem is the variation in thickness o f the 
osteochondral plugs from the donor site cartilage in comparison to the cartilage found 
at the defect site (Smith et al, 2005).
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1.8 Culture Systems for Cell Based Therapies in Tissue 
Engineering.
There has been recent interest in the use o f cell based therapies and tissue engineering 
long lasting hyaline-like cartilaginous replacement tissue for damaged areas of joints. 
However, this has proved problematic as the engineered tissue must have similar 
mechanical properties to native articular cartilage and also have the ability to integrate 
with native tissue.
Tissue engineering itself implies problems: (1) currently there are many experimental 
models utilised to generate articular cartilage; both structural and macromolecular 
properties o f engineered tissue vary depending on the culture system used; and (2) the 
initial cell source used to engineer cartilage could be at a different stage of 
development, come from a different origin or even a different species giving rise to 
conflicting results and complicating the understanding of tissue engineering cartilage. 
Culture systems enable in vitro cultivation o f tissues and cells, allowing the analysis 
of chondrocytes and their extracellular matrix. Culture systems that have been 
utilised to date for cell based therapies in tissue engineering are discussed below.
1.8.1 Cartilage Explant Culture System
The cartilage explant culture system provides a model to analyse chondrocytes that 
are resident to their native matrix and their extracellular matrix ex vivo (Flannery et 
al, 1999). The cartilage explants are cultured in a rich medium, often supplemented 
with serum, metabolites and growth factors. The cartilage explant system provides a 
model system for analysis o f mechanical compression effects (Sah et al, 1989), 
proteoglycan synthesis and catabolism, matrix degradation initiated by cytokines such 
as IL-1 and potential protective properties o f varying factors (Flannery et al, 1999). 
Chondrocytes within cartilage explant cultures maintain their differentiated state. 
Therefore, some o f the tissue’s architecture can be preserved within the explant. The 
chondrocytic cells o f the explants remain viable for both short and long term 
incubation periods ranging from six hours to six weeks (Maroudas and Kuettner 
1990).
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1.8.2 Monolayer Culture System
A human chondrogenic cell source for use in tissue engineering is o f limited supply. 
Therefore an unavoidable measure is to multiply the cells utilizing a process termed 
‘passaging’ within a monolayer culture.
The initial step is the enzymatic isolation o f chondrocytes harvested from a low load 
bearing region o f a patient. This procedure proves problematic, as all cell-matrix 
inter-relationships and cell surface molecules are abolished, altering the metabolic 
activity and growth rate o f the chondrocytes from what would be observed in native 
cartilage (Maroudas and Kuettner 1990). Hayman et al in 2006 analysed the effects 
different enzymatic procedures inflicted upon an isolated chondrocyte. They reported 
that a longer collagenase digestion step was preferable for obtaining a high cell yield, 
but a shorter collagenase digestion step was required to yield chondrocytes with gene 
expression closest to native chondrocytes.
The isolated chondrocytes within a media suspension are placed into flasks and 
allowed to multiply in an alien 2-dimensional culture system without the crucial 
influences o f physiological cell-cell and cell-extracellular matrix interactions. As a 
result the chondrocytic phenotype is challenged and chondrocytes undergo a process 
called de-differentiation that is characterised by the transition o f a chondrocytic 
phenotype to a more fibroblast-like phenotype.
To try minimising the occurrence o f de-differentiation, one study has investigated the 
effects of culturing bovine articular chondrocytes on different substrates including: 
tissue culture plastic, fibronectin, type I collagen and type II collagen. It was reported 
that chondrocyte expansion on protein monolayers may not be an effective solution to 
prevent de-differentiation (Brodkin et al, 2004).
As a result o f this process there are alterations in chondrocyte morphology, gene 
expression, matrix formation and cytoskeletal organisation. The expression of 
collagen type I increases, and collagen type II decreases. The addition o f factors that 
encourage chondrogenic behaviour during the expansion procedure may prove 
beneficial. Improving the basic knowledge o f alterations that occur to the 
chondrocyte and cellular signalling during this process may provide an insight for 
future intervention preventing this un-wanted de-differentiated characteristic.
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1.8.3 Three Dimensional Culture systems
The re-differentiation o f de-differentiated chondrocytes can by encouraged by placing 
expanded chondrocytes from monolayer cultures into a 3-dimensional bio-mimetic 
culture environment that encourages the chondrocytes to lay down an extracellular 
matrix, generating a tissue. Culture systems that can be used for such a purpose 
include; (A) pellet, (B) alginate, (C) agarose, and (D) the use of scaffolds. Although a 
limitation o f stimulating re-differentiation, is the induction o f hypertrophic 
differentiation that leads to the undesired effect o f endochondral ossification.
(A) Pellet Culture
In a pellet culture system, chondrocytes are pelleted in the base o f a tube and cultured 
in this fashion (Boyer et al., 2003). The chondrocytes are less likely to de­
differentiate in comparison to monolayer culture, and cell recovery is not as 
problematic as it is with agarose cultures. The initial amount o f extracellular matrix is 
essentially zero. The chondrocytes synthesise a matrix around themselves, forming a 
ball o f cells and matrix that remain suspended in culture medium. If  the culture 
period o f pellet cultures is prolonged then the centre may differentiate further and 
begin to express bone markers and become mineralised (Naski & Ornitz 1998).
It has been shown in high-density bovine chondrocyte pellet cultures that the 
production of cartilage proteoglycan and collagen can be stimulated by extracellular 
ATP and UTP (Croucher et al, 2000).
(B) Alginate Culture
The use of an alginate culture system to encourage re-differentiation of de­
differentiated chondrocytes has been reported utilising many different species 
including: human (Gagne et al., 2000 & Schulze-Tanzil et al., 2002), rabbit (Yoon et 
al., 2002) and bovine (Dommet al., 2002). Low oxygen tensions have been reported 
to induce the re-differentiation o f de-differentiated cells in alginate cultures (Domm et 
al, 2002).
57
(C) Agarose Culture
An advantage o f agarose cultures is that they can three dimensionally immobilize 
cells and maintain the differentiated phenotype of chondrocytes, enabling them to 
deposit a characteristic matrix after modulation in monolayer (Makarand & Sittinger 
2002). The major advantage o f these gels is a rather even distribution o f cells while 
their mechanical behaviour is not suitable for transplantation (Sittinger et al., 1999). 
The cultures may be exposed to catabolic stimulants, mechanical loading, enzyme 
inhibitors or drugs.
(D) Scaffolds
Scaffolds have been utilised as a tool to provide growth and integration for engineered 
articular cartilage in a 3-dimensional biomimetic environment. They function as a 
delivery vehicle enabling the distribution o f cells to a site o f injury, minimizing cell 
loss in transferral and enabling the treatment o f relatively large defect areas. 
Scaffolds may also be cut into a required shape and provide guidance for desired in 
vitro and in vivo tissue development. Ideally scaffolds would biodegrade at the same 
rate that the implanted chondrocytes produce their framework (Mahmoudifar and 
Doran 2005). The use o f scaffolds is superior to conventional 2D monolayer cultures 
as they help encourage and maintain the chondrogenic phenotype (Heng et al, 2004). 
The nature of the tissue developed and molecules synthesised depends on the cell 
source, the type o f scaffold used and the chosen factors applied to the scaffold system. 
A recent development in scaffold technology utilises a senate scaffold that actually 
monitors in vivo loading from within the joint over extended periods o f time, having 
the ability to monitor healing (Geffre et al., 2008).
There have been numerous matrix scaffolds that have been applied in tissue 
engineering cartilage. Matrices tested to date include protein based matrices (fibrin, 
collagen and gelatin), carbohydrate based polymers (polylactic acid, polyglycolic 
acid, hyaluronan, agarose, alginate and chitosan) and synthetic polymers (carbon 
fibres, polyethylene trephthalates and polytetrafluroethylene) (Hunziker 2001). The 
naturally occurring bioactive materials utilised as matrices may have problems with 
immunogenicity (Brittberg 1999). Therefore, smart scaffolds have been developed
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incorporating inflammatory inhibitors or antibiotics. The slow controlled release o f 
bioactive molecules encourages adaptation and maturation of new cartilage in hostile 
in vivo conditions, preventing early infections following surgery (Risbud and Sittinger 
2002).
1.8.4 Autologous Chondrocyte Implantation
Autologous Chondrocyte Implantation (ACI) is a technique utilised for treating 
articular cartilage defects and the procedure has been employed for the last two 
decades. Initially, ACI was described by Brittberg et al 1994, using a truly 
committed chondrocyte cell source. This cell based therapy was approved by the 
USA Food and Drug Association in 1997, and is the only cell based therapy permitted 
to date. There are many factors that can determine the effectiveness o f ACI 
including; defect size, previous associated surgeries (.Re-operation is frequent after 
ACI and is associated with a less satisfying outcome (Henderson et al, 2006)) and 
defect location as cartilage thickness and properties can vary with its positioning 
within the knee.
The ACI technique has been applied across a variety o f species including rabbit 
(Brittberg 1996), canine (Breinan et al., 1997), goat (Dell’Accio et al., 2003) and 
human (Brittberg et al., 2004). In humans, this procedure seems to be more beneficial 
for the treatment of femoro-tibial defects and less successful in the patello-femoral 
region (Brittberg et al., 1994). Contradictory results have been reported using a 
canine model in comparison to rabbit, goat and human systems. It was perceived that 
in canines there were no significant differences between defects that were treated or 
untreated with autologous chondrocytes, indicating that the ACI procedure did not 
contribute to the repair response observed. These findings may be due to species 
differences (Breinan et al., 1997).
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The Steps Involved In Autologous Chondrocyte Implantation (ACI) Procedure
1. Initially, a cartilage biopsy is taken from a low load bearing region of the 
knee (Figure 1.17). In essence this can prove to be detrimental as removal of 
cells from a donor site would instigate cell death at the wound margins 
creating another cartilage defect.
Figure 1.17. Cartilage biopsy being taken from a low load bearing region {Kindly donated by
Genzyme).
2. Chondrocytes are enzymatically isolated from the cartilage biopsy. There is a 
limitation on chondrocyte numbers that can be obtained from a patient; 
unfortunately high cell seeding densities are required for this procedure. 
Therefore, the harvested chondrocyte numbers are multiplied in monolayer 
culture. It is a disadvantage to have to multiply the chondrocytes as they have 
a tendency to de-differentiate due to cytoskeletal modification in the 2D 
monolayer culture environment, altering their chondrogenic phenotype 
(Vacanti et al., 2001). The passaged cells appear to be more fibrous in nature 
lacking the appropriate material and organisational properties o f a 
chondrocyte. Addition of factors to stimulate re-differentiation can prove 
problematic as they can then induce hypertrophic differentiation o f the 
chondrocytes.
3. At the defect site cartilage is debrided back to the healthy tissue, without 
puncturing the subchondral bone, as bleeding is an inevitable consequence of
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surgery and it is well documented that blood induces cartilage damage 
(Sawatzky et al., 2005).
4. A covering in the form of a periosteal patch (taken from the medial tibia) or a 
biodegradable membrane (e.g collagen type I/III membrane) is sutured to the 
wound margin. The use of a periosteal covering has been reported to provide 
a shield preventing wear and tear, possibly providing a source of potential 
stem cells and growth factors that promote the chondrogenic phenotype and 
enhance chondrocyte proliferation (Brittberg et al., 1999). It has been shown 
that periosteum alone, without the use of injected autologous chondrocytes is a 
suitable treatment for defects (Breinan et al., 1997). This may be due to an 
opening in the subchondral bone allowing the periosteum to exert paracrine 
effects on invading mesenchymal stem cells from the bone marrow space 
(Brittberg et a l, 1999). It has been reported that the use of a periosteal 
covering leads to graft hypertrophy post-implantation, and this is avoided by 
using a collagen type I/III membrane (Steinwachs & Kreuz 2007). One 
disadvantage is the loss o f periosteal / collagen membranes during the 
recovery period (Driesang & Hunziker 2000).
5. The cultured chondrocytes are injected within a suspension under the sutured 
covering (Figure 1.18). The injected chondrocytes within the defect 
synthesise and lay down a matrix, generating a graft over time that to a certain 
extent covers the defect.
Figure 1.18. A suspension of cultured chondrocytes injected underneath a periosteal covering (Kindly
donated by Genzyme).
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The ACI procedure is capable o f forming durable hyaline-like tissue in vivo. 
However, the reparative tissue consists o f mixed morphologies, ranging between a 
hyaline-like and fibro-like cartilage. Integration of new tissue with surrounding 
matrix can prove unsatisfactory (Hunziker 1999, 2002). Autologous chondrocyte 
repairs composed o f fibro-cartilage showed more morphologic abnormalties and 
became more symptomatic earlier on than hyaline or hyaline like cartilage repair. 
The hyaline articular cartilage repair had biomechanical properties comparable to 
surrounding cartilage and superior to those associated with fibrocartilage repairs 
(Henderson et al., 2006).
Moriya et al, 2007, evaluated the reparative cartilage generated one year following 
ACI treatment for full thickness defects in human Osteochondritis dissecans femoral 
condyles. The reparative tissue was reportedly o f mixed morphologies and 
hypertrophy o f the periosteum occurred. The reparative tissue stained for type II 
collagen in the deep to mid regions o f the grafts, but did not stain well at the surface. 
The glycosaminoglycan concentrations within reparative tissues were lower than 
those found in native, being 76.6pg/mg +/- 4.2 pg /mg and 108pg/mg +/- 11.2 pg/mg, 
respectively. When utilising a cell source it is important to take into consideration its 
cell viability. It has been reported that periosteum viability significantly decreases 
following implantation to a rabbit knee and chondrocyte viability did not significantly 
decline post-implantation (Emans et al., 2006).
1.8.5 Transwell Culture Systems
The Transwell culture system was first utilized by Kandel et al in 1995. Rabbit 
chondrocytes were seeded in monolayer fashion onto Millipore filter inserts (Figure 
1.19) and maintained over a culture period to produce neo-cartilage grafts ex vivo. 
The Kandel group investigated if the neo-cartilage grafts generated could be used to 
treat cartilage defects i.e. full thickness defects into the subchondral bone or intra- 
chondral defects. The in vitro neo-cartilage tissue produced was placed into a rabbit 
defect in the presence or absence o f a fixative. It was found that the absence of an 
adhesive was more productive than the presence o f an adhesive, enhancing grafts to 
remain in position within full thickness defects. However, maintaining graft
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positioning within intra-chondral defects was poor and required further analysis 
(Kandel et al., 1995).
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Figure 1.19. Schematic of Millicell filter insert.
Generating grafts ex vivo using a Transwell culture system shows potential benefits in 
comparison to autologous chondrocyte implantation. The surgical procedure could be 
simplified as it can be performed arthroscopically, reducing surgical morbidity and 
recovery time. There are no requirements for a periosteal flap or covering, so there is 
a reduction in damage to the surrounding cartilage. It can also be used to treat larger 
degenerative defects. The Transwell culture system is an ideal test model as all non- 
gaseous molecules produced during time o f culture can be monitored. Therefore, the 
Transwell culture system is an excellent model to evaluate the efficiency of novel 
therapeutics for future research into cartilage metabolism in health and disease.
1.9 Signalling molecules involved in chondrogenesis and in vivo 
cartilage homeostasis and their potential in tissue engineering  
applications.
At a glance articular cartilage appears to be a relatively simple tissue, having no 
innervation, blood or lymphatic supply and containing only one cell type; ‘The 
chondrocyte,’ making this tissue a likely candidate for tissue engineering. Yet the 
structural simplicity o f articular cartilage is superficial and there are extreme 
complexities that must be taken into consideration whilst engineering this tissue.
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To engineer cartilage ex vivo, it is important to understand the initial development of 
cartilage in vivo (termed chondrogenesis) and the functions o f the growth factors, 
signalling molecules, effector proteins and cell to cell interactions involved in this 
process and the importance o f applying the right factor at the right moment. This 
knowledge could then lead to the manipulation of a culture system to encourage the 
ideal conditions for articular cartilage engineering (i.e. re-differentiation o f de­
differentiated chondrocytes and prevention o f chondrocyte hypertrophy) resulting in 
the production o f neocartilage tissue with increased type II collagen and proteoglycan, 
decreased type I and type X collagen, with delayed expression o f alkaline phosphatase 
and calcium mineral accumulation (Liu et al., 2007).
Adkisson in 2001 used an in vitro Transwell culture system to analyse human 
chondrocyte activity in a serum free environment. It was found that: (i) juvenile 
chondrocytes produced neocartilage discs with collagenous matrices and 
chondrocytes lacked cellular hypertrophy, (ii) Pre-adolescent chondrocytes 
recapitualated embryonic development in the absence of embryonic factors, but (iii) 
adult chondrocytes failed to produce grafts in serum free conditions. This emphasises 
the fact that an understanding o f factors required to generate neocartilage grafts would 
be advantageous (Adkisson et al., 2001).
1.9.1 Chondrogenesis
The sequential events (labelled A-D) involved during chondrogenesis are discussed 
below, and are represented by a chondrogenic timeline (Figure 1.20).
(A) Com m itm ent (Stage 1)
Mesenchymal cells (also referred to as precursor cells) originating from the 
mesodermal germ layer of the blastocyst o f a developing embryo are encouraged to 
differentiate and commit themselves to the chondrogenic lineage with the aid o f 
growth factors such as IGF-1. Previously, these precursor mesenchymal cells have 
been referred to as chondroblasts. This is incorrect as the mesenchyme cells at this 
stage can differentiate into either chondrocytes or osteoblasts depending on the factors
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to which they are subjected. It is thought that both BMP-2 and 4 support the 
transition o f mesenchyme into the chondrogenic lineage, but they may also support 
proliferation and hypertrophy o f chondrocytes (Sandell & Adler., 1999).
(B) Condensations {Stage 2)
The committed mesenchyme condense and compact into nodules differentiating to a 
chondrogenic phenotype. Pre-cartilaginous condensations express SOX 9, a marker 
for chondrogenesis in less mature chondrocytes.
(C) Proliferation (Stage 3)
The chondrocytes start proliferating rapidly, secreting cartilage specific extracellular 
matrix molecules. Both FGF-2 (Jingushi et al.,2006, Miot et al., 2006) and IGF-1 
(Takahashi et al., 2005) have been found to stimulate proliferation. FGF-2 may also 
inhibit chondrocytes from progressing to the hypertrophic state (Sandell & Adler., 
1999, Tchetina et al., 2006). Cells proliferating and beginning to hypertrophy release 
a protein called Indian hedgehog (Ihh). The released Ihh protein binds to a protein 
within the perichondrium called patch, initiating the hedgehog signalling pathway 
resulting in increased Parathyroid Hormone Related Protein (PTHrp) secretion from 
perichondrial cells within close proximity to undifferentiated mesenchyme. Prior to 
the chondrocytes expressing Indian hedgehog protein they express PTHrp receptors. 
The released PTHrp binds to the receptors within the mesenchyme setting up a 
negative feedback loop (Figure 1.20) blocking the differentiation o f remaining cells 
and increasing proliferation.
(D) H ypertrophy and Calcification {Stage 4)
Chondrocytes stop dividing and increase in volume, becoming hypertrophic. 
Hypertrophic chondrocytes alter the matrix in which they synthesize, secreting both 
type X collagen and fibronectin to surrounding extracellular matrix. They also start to 
produce an alkaline phosphatase enzyme essential for mineralization. BMP-6 is 
present in both pre-hypertrophic and hypertrophic cells enabling mineralization by 
calcium carbonate (Sandell & Adler., 1999). The matrix becomes calcified which is
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less hydrated than hyaline cartilage creating a restriction of nutrient diffusion and 
waste elimination.
(E) Endochondral Ossification {Stage 5)
The hypertrophic chondrocytes die via apoptosis leaving cavities that are invaded by 
blood vessels and bone forming cells. Eventually cartilage is replaced by bone in a 
process termed endochondral ossification.
Chondrogenic Timeline
(C)
P ro life ra tio n
(D)
H y p ertro p h ic
C h o n d ro c y te s
(B)
C o n d e n sa tio n s
(A)
U n d ifferen tia ted  
M e se n ch y m e  (Prior 
to comm itm ent)
P re -h y p e rtro p h ic
C h o n d ro c y te s
Secreted Ih h Q  binds to patch 
protein in perichondrium
PTHrp receptors on chondrocytes 
( 3 )  prior to  Ihh expression bind PTHrp
Binding of Ihh initiates hedgehog Signalling 
Pathway leading to the release of PTHrp
PROTEIN
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0  Parathyroid Hormone Related Protein (PTHrp) release 
Indian hedgehog protein (Ihh) release 
PTHrp receptor expression (Chondrogenic Timeline)
1 Secrete Indian hedgehog protein (Chondrogenic Timeline)
KEY:
Figure 1.20. Embryological development of cartilage. The sequence of events are labelled 
A-D and discussed above. Arrows indicate a negative feedback control mechanism involved 
in the regulation of cartilage development (Adapted from Sandell & Adler, 1999).
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1.10 Aims of the project
The objective was to evaluate the organisation of scaffold-free neocartilage grafts 
produced utilising an in vitro Transwell culture system that was originally described 
by Kandel et al in 1995 and use this system to investigate the effects o f different Mwt 
HA on chondrocyte metabolism. The aims to achieve this objective were;
(1) To investigate the effects an increased cell density and culture duration have 
on neocartilage graft production and determine the optimal culture conditions 
{i.e. cell density and culture period) to be applied in future experimentation.
(2) After determining the optimal culture conditions, to compare neocartilage 
grafts produced using either an immature or mature chondrogenic source.
(3) To examine the effect passage expansion o f chondrocytes from both immature 
and mature sources, in monolayer culture, followed by re-differentiation in a 
high cell seeding density culture system, has on resultant graft tissue 
architecture.
(4) To investigate the effects different molecular weight hyaluronan {ranging 
from 5kDa -  3000+kDa) have on; (1) normal neocartilage graft metabolism 
and (2) IL-1 induced neocartilage graft matrix degradation, determining the 
possible mechanisms o f action involved with a view to potentially improve 
neocartilage grafts for tissue engineering applications.
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2.0 GENERAL METHODS AND MATERIALS
2.1 Materials
All chemicals and materials utilized in this project were obtained from Sigma-Aldrich 
Chemical Corporation, UK unless otherwise stated. Pronase (7u/ml) from 
Streptomyces griseus was obtained from Roche Diagnostics, Collagenase Type II 
(lOOu/ml) prepared from Clostridium Histolyticum was obtained from Lome labs, 
Worthington Biomedical Corporation,UK. Dulbecco’s Modified Eagles Medium 
(DMEM) without Sodium Pyruvate with 4500mg/ml Glucose with pyridoxine, 
Gentamycin (lOOOx stock) and heat inactivated Foetal Bovine Serum (FBS) were 
obtained from Invitrogen, UK. Biopore filter inserts (12 mm, 0.4pm pores) were 
obtained from Millipore, Bedford, MA. Recombinant human TGFp2 was obtained 
from Peprotech, UK. 40pm Cell strainers were obtained from BD Falcon, Belgium. 
Phosphate buffered Saline (PBS) tablets were obtained from Oxoid. Tissue culture 
plates were obtained from Coming. Histobond microscope slides for both histology 
and immunolabelling were obtained from RA Lamb. For Immunolabelling analysis 
Cryo-protect/Cryo-M-Bed tissue mountant was obtained from Bright/UK. 
DakoCytomation pen, FITC secondary antibody, Goat and swine serum were 
obtained from Dakopatts Ltd, UK. Keratanase was obtained from AMS 
Biotechnology, UK. Propidium Iodide (0.5pg/ml) Molecular probe was obtained 
from Invitrogen, UK and Vectorsheild was obtained from Vector Laboratories Ltd, 
UK. Mayers haematoxylin and Eosin (Aqueous 1%) were obtained from RA lamb. 
The 96 well multiplates were obtained from Elkay Laboratory products UK, Ltd, 
Basingstoke,UK. Powdered DMMB was obtained from Serva. Formic acid was from 
BDH. Lactate assay kit was obtained from Trinity Biotech. The Combiplate 8 Eliza 
plates were obtained from Thermoelectron Corporation. Ethylenediaminetetraacetic 
Acid Disodium Salt Dehydrate, Acetic Acid, Xylene, Ethanol, sodium hydroxide, 
hydrochloric acid, perchloric acid, dialysis tubing and propan-2-ol were all obtained 
from fisher.
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2.2 Preparation of scaffold free neocartilage graft production 
utilising an in vitro Transwell culture system. 
2.2.1 Isolation of articular chondrocytes
Cartilage grafts were tissue engineered using a modification of the method described by 
Kandel et al., 1995. Articular cartilage shavings were harvested from either 7 day 
(immature) or 18 month (mature) bovine metacarpophalangeal joints. Full depth 
cartilage was harvested and chondrocytes isolated using well-established asceptic 
techniques. Full depth cartilage was digested in 7 units/ml pronase in Dulbecco’s 
modified Eagle medium (DMEM) containing 50pg/ml gentamycin and 5% (v/v) heat 
inactivated FBS for 3 hours at 37°C. The cartilage shavings were washed with an 
arbitrary volume of DMEM containing 50pg/ml gentamycin, then further digested in 
100 units/ml collagenase type II in DMEM containing 50pg/ml gentamycin and 5% 
(v/v) heat inactivated FBS overnight at 37°C.
The overnight digest was filtered through a cell strainer and the cell suspension was 
centrifuged at 470g for 5 minutes. The supernatant was removed and the chondrocyte 
pellet was resuspended in DMEM containing 50pg/ml gentamycin and 10% heat 
inactivated FBS. The cell suspension was again centrifuged at 470g for 5 minutes. The 
supernatant was removed and the chondrocyte pellet was resuspended in 10ml DMEM 
containing 50pg/ml gentamycin and 10% heat inactivated FBS.
2.2.2 Cell Count
Isolated cells were stained with 0.4% (v/v) trypan blue to determine percentage cell 
viability.
• Cell viability (%) = Total viable cells (unstained) /  Total cells 
(stained and unstained) x 100
69
The cells were counted using a Sigma bright-line haemocytometer and a bright field 
microscope. If the cell yield was high, then cell suspension was diluted with PBS 
prior to the cell count. This dilution factor was then taken into account when 
calculating the final cell numbers. The subsequent cell concentration per ml (and the 
total number of cells), were determined using the following calculations:
• Cells per ml = The average count o f cells per square on 
haemocytometer (5 squares counted in total, centre square and 4 
corner squares on haemocytometer grid) x dilution factor x 104.
• Total cells = Cells per ml x original volume o f fluid from which 
the sample was removed.
In all the following experiments, cells were seeded at 4xl06cells/400pl unless 
otherwise stated. Therefore, the volume of media in which the cells should be 
resuspended to make a required concentration of cells was calculated. After this the 
10ml cell suspensions were centrifuged and made to the appropriate volumes with 
DMEM containing 50pg/ml gentamycin and 10% heat inactivated FBS.
2.2.3 Seeding chondrocytes onto M illipore filter inserts and culture 
maintenance using a Transwell culture system
In the following experiments, unless otherwise stated, cells were seeded at 4x106 
cells/400pil onto 0.6cm2 MillicellCM filter inserts (0.4pm pores) pre-coated with 40pl of 
0.5mg/ml chick type II collagen, and each filter insert positioned into a well of a 24 well 
tissue culture plate (Figure 2.1).
MILLIPORE FILTER
Figure 2.1.
Schematic depicting the 
positioning of a millipore 
filter insert into a 24 well 
culture plate.
Filter membrane
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A schematic o f the compartmental organisation of a Transwell culture system is shown 
in Figure 2.2. Outside of the filter insert, within the well of the culture plate, 600pl 
DMEM containing 50pg/ml gentamycin and 20% heat inactivated FBS was pipetted. 
The seeded chondrocytes were left to settle for 48 hours at 37°C in a humidified 
atmosphere containing 5% CO2 .
A WELL WITHIN A 24 WELL 
TISSUE CULTURE PLATE
F itter I n e r t
O utside M edia 
(600,4)
C artilage G raft produced 
w here chondrocytes are 
in itially  seeded
Insert M edia 
(400,il)
Figure 2.2. A Transwell culture system used to generate neocartilage grafts
Culture M aintenance of the Transwell culture system
• The first feed consisted of removing both the insert and outside media from the 
culture system following a 48 hour incubation period. DMEM containing 
50pg/ml gentamycin and 20% heat inactivated FBS supplemented with 
lOOpg/ml ascorbate and 5ng/ml TGF02 was applied to both the filter insert 
(400pl) and outside o f the well (600pl). The cultures were maintained at 37°C 
in a humidified atmosphere containing 5% C 0 2.
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•  After the first feed cultures were maintained by a media change thrice weekly o f 
DMEM containing 50|ig/ml gentamycin and 20% heat inactivated FBS 
supplemented with lOOpg/ml ascorbate and 5ng/ml TGFB2. 600pl was pipetted 
to the outside well and 400pl into the inner insert. The cultures were maintained 
over a 4 weeks culture period unless otherwise stated at 37°C in a humidified 
atmosphere containing 5% CO2.
Media was collected following each feed and stored at -20°C until further analysis.
2.2.4 Harvesting scaffold free neocartilage grafts
Following a 4 week culture period the neocartilage grafts were harvested. This did 
not require an asceptic technique. The cartilage grafts were prized from the Millipore 
filter insert membrane using a tweezers. The grafts were washed with PBS and 
blotted dry. The weight (mg) o f the graft was then recorded and grafts for 
biochemical analysis were placed at -20°C, grafts for histological analysis were fixed 
using 4% paraformaldehyde (4°C) and grafts for immunohistochemical analysis were 
fixed using 95% ethanol until further analysis.
2.3 Immunofluorescent labelling and histological analyses of 
scaffold free neocartilage grafts
2.3.1 Immunofluorescent labelling
Circular 6mm tissue graft samples were harvested and stored at 4°C in a 95% ethanol 
solution. Prior to section cutting, individual tissue samples were put on rotation at 4°C 
in a PBS and 5% (w/v) sucrose solution (~5hours) to cryo-protect the grafts, then 
samples were snap frozen onto cryostat chucks in Cryo-M-Bed tissue mountant. 
Cryosections (12pm thickness) were cut using a Bright 5030 cryostat (Bright, UK). The
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sections were mounted onto HistoBond microscope slides and stored at -80°C until 
required. An area around each individual section was circumscribed with a water 
repellent ring using a DakoCytomation pen. The sections were then wet in 0.05M 
phosphate buffered saline (PBS) (pH 7.4) containing 0.1% (v/v) Tween20 
(Polyoxyethylene-Sorbitan Monolaurate) for 10 minutes. The sections were transferred 
to a humidified labelling box and pre-treated with appropriate enzymes to expose the 
neoepitope of interest or to improve antibody penetration (Table 2.1). This involved a 
pre-treatment with a cocktail o f 0.4U/ml chondroitinase ABC and 0.4U/ml keratanase in 
a lOOmM Tris Acetate solution (pH7.4) at 37°C for 1 hour to enzymatically de- 
glycosylate the sections. The sections were then washed in 0.05M PBS (pH7.4) 
containing 0.1% (v/v) Tween20 (3x5 minutes). Blocking serum at 1:20 dilution was 
applied to the sections for 30 minutes at room temperature. Sections that were to be 
stained with monoclonal antibodies were blocked using goat serum and those to be 
stained with polyclonal antibodies were blocked with swine serum. The blocking serum 
was removed and primary antibodies applied at appropriate concentrations (Table 2.1) 
overnight at 4°C. As a negative control, the primary antibody was omitted and replaced 
with an appropriate (Mouse/Rabbit) ‘naive’ immunoglobin (10|ng/ml) with or without 
the enzymatic digestion step. Non-specific binding o f the secondary antibody was 
checked by omitting the primary antibody and replacing it with 0.05M PBS (pH7.4) and 
0.1% (v/v) Tween20.
Following an overnight incubation, the sections were washed in 0.05M PBS (pH7.4) 
containing 0.1% (v/v) Tween20 (3x5 minutes). An appropriate FITC-conjugated 
secondary antibody (Table 2.1) recognising either mouse or rabbit species was applied 
at a 1:50 dilution for 1 hour at room temperature to individual sections. The sections 
were then washed in 0.05M PBS (pH7.4) containing 0.1% (v/v) Tween20 (3x5 
minutes). Propidium Iodide (0.5p,g/ml) was applied to sections for 5 minutes for nuclei 
staining, and then the sections were again washed in 0.05M PBS (pH7.4) containing 
0.1% (v/v) Tween20 (3x5 minutes). Sections were mounted under a coverslip 
(22x50mm) using vectashield fade retarding mountant, the coverslips were held into 
place using nail varnish. Sections were viewed and photographed using an Olympus 
fluorescence microscope.
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Specificity Antibody
(clone ;dilution)
Pre­
treatment
Blocking
serum
Secondary
antibody
Source/Reference
Type I 
collagen
Anti-type I 
(poly; 1:100)
ABC/K Swine Swine
anti-rabbit
FITC
Fitzgerald Industries Int
Type II 
Collagen
CIICI 
(mono; 1:5)
ABC/K Goat Goat
Anti-mouse
FITC
DSHB/ Holmdahl et al 
(1986)
Aggrecan
IGD
6B4
(mono 1:20)
ABC/K Goat Goat
Anti-mouse
FITC
Caterson et al (2000)
Versican
(HA binding region)
12C5
(mono 1:5)
ABC/K Goat Goat
Anti-mouse
FITC
DSHB/Asher et al (1991)
Unsulfated
chondroitin
1B5
(mono 1:500)
ABC/K Goat Goat
Anti-mouse
FITC
Couchman et al (1984) 
Caterson et al (1985)
C hondroitin-
4-sulfate
2B6
(mono 1:20)
ABC/K Goat Goat
Anti-mouse
FITC
Couchman et al (1994) 
Caterson et al (1985)
C hondroitin-
6-sulfate
3B3
(mono 1:20)
ABC/K Goat Goat
Anti-mouse
FITC
Caterson et al (1985)
Decorin
(core protein)
28.4
(mono 1:20)
ABC/K Goat Goat
Anti-mouse
FITC
Bidanset et al (1992)
Biglycan
(core protein)
PR8A4 
(mono 1:20)
ABC/K Goat Goat
Anti-mouse
FITC
Roughley et al (1993)
K eratan
sulfate
5D4
(mono 1:20)
None Goat Goat
Anti-mouse
FITC
Caterson et al (1983)
Superficial 
zone protein
(SZP)
3A4 
(mono)
None Goat Goat
Anti-mouse
FITC
Schumacher et al., 1999 
Flannery et al., 1999
Table 2.1. The required conditions for specific antibodies utilised in the 
immunolabeling of chief extracellular matrix molecules.
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2.3.2 Histological Analysis
For histology, circular (6mm diameter) tissue samples were fixed in cold 4% 
paraformaldehyde, and processed for paraffin wax using standard methods. Wax 
sections o f the cartilage grafts (8|nm in thickness) were cut using a microtome (LKB 
rotary microtome). Sections were dewaxed and dehydrated by putting them in 
descending alcohol concentrations as follows: xylene (2 min), xylene (2 min), 100% 
alcohol (1 min), 100% alcohol (1 min), 95% alcohol (1 min), 70% alcohol (1 min). The 
sections were then washed in running water (1 min) followed by staining for 
proteoglycan in 1% (w/v) alcian blue 8GX stain pH 2.5 (20 min). The sections were 
washed in running water (lm in) for the second time followed by a staining with 
Mayer’s haematoxylin stain (1 min). The sections were then washed and blued by 
applying running tap water for the third time (3 min). A 1% (v/v) eosin stain was 
applied to the sections (2 min) followed by a wash in running tap water (20 sec). The 
sections were then re-hydrated and placed in an ascending alcohol concentration as 
follows: 70% alcohol (20 sec), 95% alcohol (45 sec), 100% alcohol (1 min), 100% 
alcohol (2 min), xylene (2 min), xylene (2 min). The sections were mounted under a 
coverslip using DPX mountant and allowed to dry. Tissue organisation was evaluated 
using a brightfield microscope. Neocartilage graft thickness was measured using a 
microscope equipped with digital image acquisition. Measurements o f graft thickness 
were taken at 10 arbitrary points across the diameter o f tissue for 3 sections (i.e. 30 
measurements per graft were taken).
2.4 Biochemical analysis of scaffold free neocartilage grafts
2.4.1 Proteoglycan extraction
Matrix molecules, including proteoglycans, present in neocartilage graft tissues were 
extracted by the addition o f 1ml guanidine extraction buffer (4M Guanidine HCl (a 
chaotrophic agent), 50mM sodium acetate, 0.01M ethylenediaminetetraacetic acid 
disodium salt dehydrate, 0.1M amino hexanoic (caproic) acid (pH 5.8-6.8). Fresh
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inhibitors were added prior to digest: 0.005M benzamidine HCl and 0.5mM phenyl 
methyl sulfonyl fluoride (PMSF)) to each graft for 48hours at 4°C with constant 
agitation. The 4M guanidine acts to dissociate PG aggregates by breaking any non 
covalent bonds and removing them from their native environment into solution 
(Sajdera & Hascall., 1969, Heinegard & Sommarin., 1987). The mixture was 
centrifuged and supernatant removed and dialysed three times against MilliQ™ water. 
The sulphated glycosaminoglycan content that was released by guanidine extraction 
was analysed using Dimethylmethylene Blue Assay (DMMB) (2.5.1) and the collagen 
concentration was analysed via a hydroxyproline assay (2.5.3), The residual insoluble 
grafts were further analysed.
2.4.2 Pepsin digest
Following a guanidine extraction, the residual grafts were further digested using a 
pepsin digest as to release soluble type II collagen from cartilage. Pepsin is an 
endopeptidase that hydrolyses peptide bonds. To each sample, 0.5ml of 0.5M acetic 
acid containing 1 mg/ml pepsin was added for 24hours at 4°C with constant agitation. 
The sulphated glycosaminoglycan content that was released by the pepsin digest was 
analysed using Dimethylmethylene Blue Assay (DMMB) (2.5.1) and the collagen 
concentration was analysed via a hydroxyproline assay (2.5.3), The residual grafts 
were again further analysed.
2.4.3 Papain digest
The residual grafts still remaining were completely digested via a papain digest. 
Papain is an extremely stable cysteine protease that works at elevated temperatures. It 
digests most protein substrates more extensively in comparison to other proteases. 
The addition o f 1 ml papain buffer (0.05M sodium-acetate, 0.025M EDTA pH 5.6, 
0.005M cysteine and 2pl/mlpapain) was added to each graft for 18hours at 65°C with 
occasional agitation. The sulphated glycosaminoglycan content that was released by 
papain extraction was analysed using Dimethylmethylene Blue Assay (DMMB)
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(2.5.1) and the remaining collagen concentration was analysed via a hydroxyproline 
assay (2.5.3),
2.5 Assays applied for both media and graft analysis
2.5.1 Analysisng sulphated GAG concentrations using 
Dimethylmethylene Blue Assay (DMMB)
The proteoglycan content present in grafts and media was measured as sulphated GAG 
by Dimethylmethylene Blue (DMMB) assay. It works by binding to the negatively 
charged sulphate groups on the GAG chains forming a complex which produces a 
metachromatic shift in the absorbance maxima (Farndale et al., 1986). Chondroitin 
sulphate C from shark cartilage was used as a standard ranging from 0-40pg/ml, and 
appropriately diluted samples were added at 40pl to a 96 well multiplate. 200pl of 
DMMB solution (32mg 1,9 DMMB, 20ml ethanol, 59ml 1M sodium hydroxide, 7ml 
98% formic acid and made up to 2L with water) was added to samples and absorbance 
was read at 525nm on a Labsystem Multiscan MS Spectrophotometer. All standards 
and samples were measured in triplicate with dilution factor taken into account. When 
calculating percentage proteoglycan present in grafts, GAG results were: (1) converted 
from pg to mg, (2) multilplied by 10/ 9 (as GAG constitutes 90% o f proteoglycan 
present), (3) divided by the actual graft weight (w/w), and (4) multiplied by 100.
2.5.2 Media analysis for lactate concentrations
The lactate assay was carried out using the Trinity biotech assay kit (Procedure No 
735). Lactate is a by product o f the glycolytic pathway and is utilised as a measure to 
determine the anaerobic metabolic activity that occurs in a culture system. Lactic acid 
is converted to pyruvate and hydrogen peroxide by lactate oxidase. In the presence of 
the hydrogen peroxide formed, peroxidase catayses the oxidative condensation of 
chromogen precursors to produce a coloured dye with an absorption maximum at
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540nm. The increase in absorbance at 540nm is directly proportional to lactate 
concentration. In a 96 multiwell plate 5 pi o f lactate standards of Opg/ml, 25pg/ml, 
50pg/ml, lOOpg/ml, 200pg/ml, 300pg/ml and 400pg/ml were measured in duplicate. 
5 pi o f culture medium at appropriate dilutions were measured in triplicate. To each 
well 250pl o f lactate reagent (lactate oxidase (microbial), peroxidase (horseradish), 
chromogen precursors and buffer pH  7.2) was pipetted and then the multiwell plate was 
incubated at room temperature for 10 minutes. The absorbance at 540nm was read 
using the Labsystem Multiscan MS Spectrophotometer.
2.5.3 Hydroxyproline Assay
Hydroxyproline is unique to collagen. As a result it is used in the determination to 
quantify amounts (but not types) o f collagenous protein present in tissue or a culture 
medium (Woessner.1976, Reddy & Enwemeka., 1996). The hydroxproline content 
generated by the Transwell culture system was analysed by amounts o f collagen 
retained within grafts (following a Guanidine extraction, Pepsin digest and Papain 
digest) and within the media (both insert and outside). Firstly, samples are 
hydrolysed in 6N HC1 for 24 hours at 110°C. The samples must be hydrolysed to 
generate free hydroxyproline not peptide bound for analysis. Hydroxyproline is fairly 
stable in 6N HC1 although hydrolysis does initiate the epimerizaton o f 
hydroxyproline, but in this colorimetric assay all epimers are determined together. 
After the hydrolysis process the hydrolysates are freeze dried to remove the acid. The 
freeze dried samples are then reconstituted with milli Q water in the same volume of 
media that was originally taken for hydrolysis. The reconstituted sample may contain 
a lot o f particulate material. Therefore, samples are centrifuged at 8000rpm for 10 
minutes in a microfuge to sediment insoluble material as it may interfere with the 
assay. In a combiplate 8 ELIZA plate, 30|nl o f trans-4-Hydroxy-L-proline standards; 
Opg/ml, 0.5pg/ml, 1 fig/ml, 2pg/ml, 4pg/ml, 6pg/ml, 8pg/ml, and lOpg/ml were 
measured in triplicate and 30pl o f sample at appropriate dilutions were also measured 
in triplicate. To each well o f the multiplate 70pl diluent (100ml propan-2-ol and 
50ml water) and 50pl oxidant (0.308M Chloramine T, 10ml water and 50ml stock 
buffer (Stock buffer; 0.42M sodium acetate trihydrate, 0.127M tri sodium citrate
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dehydrate, 0.025M Citric acid and 40% (v/v) Propan-2-ol)) was pipetted and the plate 
was mixed on a plate shaker for 5 minutes. The oxidant must be prepared fresh prior 
to use and will keep overnight if  stored at 4°C. The addition of the oxidant oxidises 
the water soluble hydroxyproline to the toluene soluble pyrrole molecule, this 
chemical conversion is advantageous as small amounts of hydroxproline can be 
detected in samples containing large amounts of contaminating substances. Colour 
reagent that must be prepared fresh prior to use (0.682M p- 
dimethylaminobenzaldehyde (Ehrlich’s reagent) 11.25ml (60% V/V) perchloric acid 
and 62.5ml propan-2-ol) was added to the multiplate at 125 pi. The plate was then 
mixed well on a plate shaker and then incubated at 70°C for 20 minutes. The addition 
o f p-dimethylaminobenzaldehyde reacts with the pyrrole molecules that were 
generated by oxidation and forms a complex that is detected and quantified as a 
chromophore (peach colour) at 550nm. A graph is plotted o f absorbance versus 
concentration of standards to find the function for the straight line. The function is 
then utilised to calculate the concentration o f hydroxyproline present. The content of 
hydroxylated proline residue was used to estimate collagen content o f the cartilage 
using the conversion factor o f lg  hydroyproline per 7g o f collagen. When calculating 
percentage collagen present in grafts, collagen results were: (1) converted from pg to 
mg, (2) divided by the actual graft weight (w/w), and (3) multiplied by 100.
2.6 Statistical Analysis
Data are presented as mean ± SEM. Data was checked for normality (Shapiro-Wilk) 
and equal variance using SPSS 13. Where data was normal/equal variance a one-way 
ANOVA followed by a Tukeys post hoc test was applied. Where data was not normal 
a Mann-Whitney non-parametric test was applied. Significance was assumed where 
P< 0.05 (*), P< 0.01 (**) or P< 0.001 (***).
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3.0 DETERMINATION OF THE OPTIMAL CULTURE 
CONDITIONS FOR THE GENERATION OF HIGH 
QUALITY ARTICULAR CARTILAGE GRAFTS USING IN 
VITRO TRANSWELL CULTURE SYSTEMS.
There is current interest in cartilage repair strategies with a particular focus on cell 
based, tissue engineering approaches (Kim et al., 2000, Risbud and Sittinger 2002 & 
Kuo et al., 2006). A technique initially described by Brittberg et al in 1994 called 
autologous chondrocyte implantation (ACI) is the most common cell based therapy 
permitted for clinical use to date. This procedure involves the injection of a truly 
committed autologous chondrocyte suspension into a cartilage defect under a sutured 
membrane covering (i.e. periosteal patch or biodegradable membrane).
There are several problems associated with ACI, these include: (1) loss o f the sutured 
membrane covering during the recovery period; (2) unsatisfactory integration between 
native and repair tissue (Hunziker 1999 & 2002); (3) limited cartilage resurfacing; 
and (4) the reparative tissue generated, consists o f mixed morphologies ranging 
between hyaline-like and fibro-like cartilage (Roberts et al., 2003, Henderson et al., 
2007, Moriya et al., 2007).
A potentially improved approach would be to engineer neo-cartilage grafts ex vivo 
using a Transwell culture system, and implant the developed graft within a defect site 
(Kandel et al., 1995). This technique would prove advantageous over traditional cell 
based therapies as (1) There would be no requirement o f a periosteal/collagen 
covering or a scaffold carrier as the graft would exist as a fully differentiated matrix;
(2) The initial generation o f the cartilage grafts would be highly regulated in culture, 
as most non-gaseous graft metabolites produced throughout the culture duration can 
be monitored, which is impossible to achieve in a diseased or damaged joint; and (3) 
potentially a larger degenerate area o f the joint could be repaired and resurfaced, 
arthroscopically reducing a patients rehabilitation time.
In the present study, we (i) describe the effects increased cell density and culture 
period have on the organisation of scaffold-free neocartilage graft production utilising 
an in vitro Transwell culture system at light and electron-microscopic levels (ii) 
determine the optimal culture conditions (i.e. cell seeding density and culture 
duration) required for future analyses (iii) compared the quality o f grafts generated
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from both immature and mature bovine chondrogenic sources using optimal culture 
conditions at both histological and biochemical levels.
3.1 Methods
3.1.1 Effects of cell density and culture duration on neocartilage graft 
organisation and  the determ ination of optim al culture conditions
Neocartilage grafts were produced, maintained and harvested following methodology 
described in section 2.2. A slight variation was, that chondrocytes were seeded at a 
range of cell densities (2, 4, 6 , 8 , 10 and 12 x 106 cells/insert) and cultured over 
varying periods of: 2, 4, 6  and 8  weeks.
Analyses. Graft histology was analysed as described in section 2.3.2. For 
ultrastructural investigation analysis was performed by Dr Anthony Hayes; grafts 
were processed for both scanning and transmission electron microscopy to facilitate 
an appraisal o f both topography and internal structure, respectively. For transmission 
electron microscopy, small samples o f graft tissue (~lm m 3) were fixed in 2 % 
glutaraldehyde in 0.05M cacodylate buffer, pH 7.4 containing 0.7% ruthenium 
hexamine trichloride (RHT; Sigma-Aldrich, UK) for 2 hours at room temperature. 
After washing ( 3 x 5  mins) in buffer, samples were post-fixed in 1% OSO4 in 0.1M 
cacodylate, pH 7.4 containing 0.7% RHT for 2 hours at room temperature. Samples 
were washed briefly in buffer, dehydrated in an ascending ethanol series and 
infiltrated and embedded in Spurr’s resin (Agar Scientific, UK), which was allowed to 
polymerize overnight at 70°C. Ultra-thin sections were cut through the tissue depth on 
a Reichert ultra-microtome (Leica, Germany). These were stained with uranyl acetate 
and lead citrate before examination in a Phillips EM 208 transmission electron 
microscope (Phillips Electron Optics, Holland) operating at 80kV accelerating 
voltage. For scanning electron microscopy, RHT was omitted from the fixatives to 
prevent proteoglycan retention within the tissue. After the primary fixation step, 
samples were washed in buffer and macerated in 10% NaOH with constant agitation 
for 1 week at 4°C to remove the soluble proteoglycan component, and allow a better 
appraisal o f the collagenous network. The tissue was then rinsed in buffer, passed
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through an ascending ethanol series, before drying in a Tousimis Samdri 780 critical 
point drier (Tousmis Research Corporation, USA), and sputter coating in gold on a 
EMScope sputter coater (EMScope, UK). Observation of the coated specimens was in 
a Phillips XL-20 scanning electron microscope (Phillips Electron Optics, Holland) 
operating at 40kV accelerating voltage. Collagen fibre organisation was assessed by 
staining in 0.1% (w/v) Sirius red F3B in saturated aqueous picric acid. Samples were 
then visualised using bright field Normarski differential interference contrast (DIC) 
and polarizing optics.
3.1.2 Com parison of cartilage grafts produced using either an im m ature o r 
m ature chondrogenic source.
Both immature and mature chondrogenic grafts (n=3) were generated as described in 
section 2.2. Grafts were both histologically and biochemically analysed as described 
in sections 2.3 and 2.4, respectively. The assays applied for both sulphated 
glycosaminoglycan and collagen analysis are described in section 2.5. Statistics were 
applied as described in section 2.6.
3.2 Results
3.2.1 Effects of cell density and culture duration
An immature primary chondrogenic source (7 day bovine), isolated from full depth 
native articular cartilage produced grafts o f an opaque, hyaline appearance at all cell 
densities and time points studied (Figure 3.1). The generation o f neo-cartilage tissue 
is constrained by the walls o f the culture vessel, and growth would occur 
predominantly in a vertical direction with a resultant increase in tissue thickness. A 
combination o f potential factors including cell proliferation, hypertrophy and 
progressive accumulation o f extracellular matrix material may be responsible for 
increased tissue thickness. Therefore, the effects o f both cell density and culture 
duration on the production o f neo-cartilage graft tissue were examined by the effect 
they have on tissue thickness.
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Figure 3.1. Neocartilage graft with an opaque, hyaline appearance. 
(Seeded at 6 x 106 cells and generated over a 4 weeks culture period). Bar = 2mm
Cell seeding density is known to modulate the rate chondrogenesis proceeds in vitro 
by affecting proliferation (Iwasa et al., 2003), differentiation (Watt et al., 1988, 
Seghatoleslami & Tuan., 2002), apoptosis (Kuhn et a l, 1999), matrix synthesis and 
accumulation (Iwasa et al., 2003, Williams et al., 2005). During this study it was 
determined that increasing cell number 2 fold from 2 x 106 to 4 x 106 cells yielded a 
highly significant increase (P<0.001) in the thickness o f graft tissue produced at all 
time points (Table 3.1 & Figures 3.2 & 3.3). Increasing cellularity above 4 million 
cells per insert showed only subtle increases o f variable significance in graft thickness 
(Table 3.1 & Figures 3.2 & 3.3). The effect of seeding 6 million cells/insert and 
above yielded a tissue characterised by a hypercellular appearance (Figure 3.3). 
Overall, an increased cell seeding density resulted in increased graft tissue cellularity 
(Figure 3.3)
d r a ft  Thickness (/um) TIM E PERIOD (Weeks)
CELL DENSITY 2 4 6 8
2 xlO6 cells 124.15 ±4.08 186.37 ±4.47 323.18 ±5.64 353.96 ±3.97
4 xlO6 cells 196.78 ±7.41 308.57 ±5.58 398.53 ±4.66 427.56 ± 6.29
6 xlO6 cells 185.70 ±3.54 330.51 ±4.74 424.42 ± 5.65 472.76 ±8.07
8 xlO6 cells 206.89 ±3.22 339.07 ±7.82 423.11 ±9.54 450.07 ± 5.76
10 xlO6 cells 203.95 ±2.84 370.36 ±6.08 404.59 ±4.13 434.28 ± 10.26
12 xlO6 cells 221.14 ±3.83 364.63 ± 5.44 411.84 ±4.81 484.33 ±5.46
Table 3.1. Cartilage graft tissue thickness produced over time associated with different cell seeding
densities. Data represented as mean ± SEM.
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Figure 3.2. Thickness of cartilage grafts with varying cell density and culture period.
At all cell densities, increasing culture duration from 2-8 weeks showed an increase in 
thickness of engineered grafts (Table 3.1 and Figures 3.2 & 3.3). The zonal 
proportions of the grafts appeared constant, suggesting in vitro growth occurred 
uniformly throughout the tissue during culture (Figure 3.3), an increased culture 
period encouraged chondrocytes within the basal portion of graft tissue to acquire a 
more columnar organisation (Figure 3.3).
It was concluded from this data with respect to native articular cartilage that grafts 
produced from 6 x 106 cells and above were too hypercellular, and grafts produced 
from 2 x 106 cells were too thin. Therefore, the optimum culture conditions 
considered to be most promising for engineering neocartilage tissue in future 
experiments was a cell density o f 4-6 x 106 cells over a 4 week culture period.
84
2 w e e k s  4  w e e k s  6  w e e k s  8  w e e k s
Figure 3.3. The effect of culture time and cell seeding density on neocartilage tissue histology (dashed 
lines demarcate boundaries between each cartilage zone). Neocartilage tissue generated from isolated 
immature (7 day) bovine chondrocytes. Alcian blue and haematoxylin and eosin. Scalebar = 200fim.
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Figure 3.3. The effect of culture time and cell seeding density on neocartilage tissue histology (dashed 
lines demarcate boundaries between each cartilage zone). Neocartilage tissue generated from isolated 
immature (7 day) bovine chondrocytes. Alcian blue and haematoxylin and eosin. Scalebar = 200(im.
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3.2.2 Zonal Morphology of neocartilage grafts
Histological zonal organisation was apparent in graft tissue at all cell seeding 
densities and culture periods showing a stratification into distinct zones after just 2 
weeks in culture. These zones approximated to the surface, middle and deep regions 
that characterise native adult articular cartilage in vivo (Figure 3.4).
Immature
Native
Mature
Native
Graft
Figure 3.4. Histological sectioning through a neo-cartilaginous tissue made from chondrocytes from 
an immature chondrogenic source (arrows in deep zone denote thin septa o f alcianophilic matrix that 
separate cells, organised into a columnar array) and an immature and mature native articular 
cartilage explant depicting the zonal organisation of the chondrocytes. Alcian blue and 
haematoxylin/eosin. Scalebar = 50pm.
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The surface zone o f neocartilage grafts showed weak alcian blue staining, an 
indication o f low proteoglycan content (Figure 3.4 & 3.5 (y4)). This superficial 
region was a few cells thick consisting o f flattened/discoidal chondrocytes surrounded 
by a sparse, meshwork o f collagen fibrils (Figure 3.5 (A, B & E)). In this zone, both 
cells and matrix had prominent horizontal organisation that was clearly apparent 
under Normarski DIC and polarising optics (arrows in Figure 3.5 (H & I) denote cell 
and matrix orientation).
The chondrocytes located in the mid region were small, spheroidal, pre-hypertrophic 
cells that were widely spaced in an alcian blue positive matrix (Figure 3.4 & 3.5 (A, 
C & F)). The strong alcianophilic staining within this region indicated that it 
contained higher proteoglycan content in comparison to the surface zone (Figure 3.4 
& 3.5 (A)). Ultrastructural observation showed that its extracellular matrix comprised 
of well defined pericellular, territorial and interterritorial matrix compartments 
showing similarities to native articular cartilage (Figure 3.5 (C & F)).
The deep zone consisted o f large, hypertrophic chondrocytes that were densely 
packed together and appeared to acquire a more columnar organisation with advance 
in culture period. Some cells in these columnar arrays were separated by thin septa of 
alcianophilic extracellular matrix (Figure 3.4 (denoted by arrows) & 3.5 (A, D & H)). 
Interterritorial matrices o f these septa were evident at ultrastructural levels showing 
that they consisted o f prominent longitudinal fibrils that were arranged vertically with 
respect to graft surface (Figure 3.5 (D & G)) Observation with both Normarski DIC 
and polarising optics indicated that tissue organisation in the deep zone was 
perpendicular to that occurring at the graft surface (Figure 3.5 (H, I, J)). There was 
no apparent calcified zone underlying the deep region in the neocartilage tissue as is 
observed in native articular cartilage.
3.2.3 Comparison of cartilage grafts produced using either an immature or 
mature chondrogenic source.
The optimal culture conditions required for future analysis to generate high quality 
cartilage grafts utilising an in vitro Transwell culture system were determined in 
section 3.2.1 (i.e. 4-6 x 106 cells over 4 weeks culture period).
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Figure 3.5. Histological and ultrastructural organisation of neocartilage tissue. A  Wax histology. The graft is comprised of three histologically distinct zones that 
approximate to the surface, middle and deep zones of native adult cartilage (dashed lines demarcate boundaries between each cartilage zone). Alcian blue and 
haematoxylin and eosin. B-D. Transmission electron micrographs demonstrating cell morphology and matrix organisation associated with each graft zone (top to 
bottom). E-G. Scanning electron micrographs showing topographic detail of collagenous organisation in graft zones (top to bottom). H. Nomarski differential 
interference contrast image showing distinct tissue organisations associated with each zonal strata (arrows denote predominant orientation of cells and matrix). 
Picrosirrius red. I-J. Polarised light microscope images showing: I. horizontal organisation of collagen fibre bundles at the graft surface and. J. vertical organisation 
of collagen associated with the inter-territorial matrix of deep zone chondrocytes. Scalebars represented in pm.
Neocartilaginous grafts were engineered at optimal culture conditions from both an 
immature and mature primary chondrogenic source, and the effects o f age were 
compared at a histological and biochemical level.
Sulphated glycosaminoglycan (s-GAG) analysis revealed that grafts produced from 
the immature source generated a significantly higher (P<0.05) amount of total s-GAG 
in comparison to the mature source (Table 3.2). The largest proportion of s-GAG 
produced over the 4 weeks culture period was present in the culture media and not 
retained in grafts for both immature and mature sources. Interestingly, there is always 
more sulphated GAG in the inner insert media than outside media. Importantly, of 
the total s-GAG generated by each source, a significantly higher (P<0.001) percentage 
of s-GAG is released into the media o f  the Transwell cultures using the mature 
chondrocytes (92%) in comparison to the immature (63.5%) (Table 3.2). The 
literature reports that the extracellular matrix o f  native articular cartilage is composed 
of 10-15% (w/w) proteoglycan. The grafts generated were constituted with 4.33% 
(w/w) proteoglycan in the immature (~ 4x less than native cartilage) and 1.93% (w/w) 
proteoglycan in the mature (~8x less than native cartilage) (Calculation methods 
described in chapter 2.5.1).
Age
Media Graft Residue Total 
GAG ftig)Insert Outside 4M GuHCl Pepsin Papain
Immature 765.04±23.01 119.83±5.43 445.50±124.24 14.60±1.71 48.13±8.89 1393.06±145.42
Mature 268.85±9.20 123.06±2.37 2.20±0.35 13.03±0.60 18.61±2.98 425.74±10.94
Table 3.2. Comparison of sulphated glycosaminoglycan (pg) generated by grafts produced from both 
an immature and mature bovine chondrogenic source seeded at optimal culture conditions (n=3). Data 
presented as mean ± SEM.
Grafts produced from an immature source versus a mature source are significantly 
different, and both graft weights (Figure 3.6) and thickness (Figure 3.7) support the 
above s-GAG conclusions. The grafts generated from the immature source were 
significantly heavier and thicker in comparison to those generated by the mature 
source. This indicates that the tissue formed by immature cells retains much more 
proteoglycan/aggrecan in its extracellular matrix facilitating water to be imbibed, 
causing the tissue to swell with a resultant increase in tissue thickness.
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Figure 3.6. Comparison of graft weights generated from both an immature and mature bovine 
chondrogenic source seeded at optimal culture conditions. Data presented as mean SEM and 
significance was assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***) using a paired T-test.
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Figure 3.7. Comparison of graft thickness generated from both an immature and mature bovine 
chondrogenic source seeded at optimal culture conditions. Data presented as mean SEM and 
significance was assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***) using a paired T-test.
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Grafts produced from the immature source were more strongly alcianophilic in comparison to 
grafts generated from the mature source (Figure 3.8). These histological results also support 
s-GAG conclusions that the immature source produced grafts that contained much more 
proteoglycan/aggrecan in its extracellular matrix than those produced from the mature 
source.
7 Day 18 Month
400pm
Figure 3.8. Age comparison of neocartilage grafts produced over 6 weeks duration from an immature 
or mature chondrogenic source seeded at 6 million cells (dashed lines demarcate boundaries between 
each cartilage zone). Alcian blue and haematoxylin/eosin. Bar= 400pm
Collagen analysis using a hydroxyproline assay showed that grafts produced from the 
immature source synthesised a significantly higher (P<0.05) amount of total collagen 
in comparison to the mature source (Table 3.3). It was found that more collagen was 
released to the outside media in comparison to the inner insert media for both 
immature and mature grafts. Interestingly, this is the opposite o f what is observed for 
sulphated glycosaminoglycan (Table 3.2). A significantly higher (P<0.05) 
percentage of the total collagen generated is retained within the graft extracellular 
matrix using the immature chondrogenic source in comparison to the mature, being 
68.7% and 35.4%, respectively (Table 3.3). The literature reports that the 
extracellular matrix o f native articular cartilage is composed of 20% (w/w) collagen. 
The grafts generated were constituted with 2.63% (w/w) collagen in the immature (~
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7.6x less than native cartilage) and 2.30% (w/w) collagen in the mature (~8.7x less 
than native cartilage) (Calculation methods described in chapter 2.5.3).
Age
Media Graft Residue Total
Collagenftig)Insert Outside 4M GuHCl Pepsin Papain
Immature 124.13±2.46 168.84±2.70 14.19±2.62 324.64±56.31 303.08±118.49 934.87±63.53
Mature 122.22±0.98 242.55±3.83 1.00±0.55 169.96±12.45 28.63±14.47 564.36±25.84
Table 3.3. Comparison of collagen (fig) synthesised by grafts produced from both an immature and 
mature bovine chondrogenic source seeded at optimal culture conditions. Data presented as mean ± 
SEM.
3.3 Discussion
Neocartilage grafts produced in vitro from a high density, immature, primary 
chondrogenic source using a Transwell culture system, had the ability to reconstitute a 
highly organised stratified hyaline tissue showing similarities to native adult articular 
cartilage following just 2 weeks in culture (Kandel et al., 1995) and this 
morphological stratification became more apparent with time and cell seeding density 
(Hayes et al., 2007). There are numerous theories that could potentially explain the 
distinct strata that are observed utilising this Transwell culture system; i.e. (1) the 
generation of a metabolic/morphological gradient between the graft tissue surface and 
basal region within the culture system; (2) zone specific cell sorting, (3) effects o f 
culture environment and (4) different levels o f oxygen tension throughout the graft, 
all o f which are discussed in detail below.
• Metabolic/morphological gradients (i.e. nutrient, oxygen and pH) 
generated between the surface and basal regions within a developing graft 
tissue utilising the in vitro Transwell culture system.
Oxygen tensions within grafts may be one possibility for producing graft tissue 
stratification. Oxygen tensions fall with distance from the articular surface to the
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deeper regions. This is supported by studies in our laboratory by Dr Anthony 
Hayes (unpublished observations) using the hypoxia marker pimonidazole 
hydrochloride (Hypoxyprobe™ -l; Chemicon, Millipore, UK). The oxygen 
gradient set up depends on the balance between the rate of oxygen transport 
through cartilage and the rate o f oxygen consumption by the chondrocytes. This 
is affected by cell density and distribution, cartilage thickness and the supply o f 
oxygen applied to the graft from both the surface and basal regions of the system. 
The Transwell culture system mimics in vivo native articular cartilage, as nutrients 
and oxygen are more readily available from the top o f the graft (inner insert 
media) representing in vivo the nutrient supply from the synovial fluid, and 
diffusion of nutrients is minimal at the base o f the graft (from outside media) 
representing transport from the subchondral bone, where the cells within the graft 
are densely packed and a high degree o f metabolite competition occurs.
An increased cell seeding density used in the Transwell culture system could 
diminish nutrient supply from culture media at a much quicker rate than a lower 
cell number and potentially more frequent media changes may be required when 
using higher cell numbers (Mauck et al., 2003). However, chondrocyte 
metabolism involving the uptake o f nutrients from culture media rapidly acidifies 
the media, (i.e. decreases pH) the surrounding environment o f the developing 
grafts. Due to diffusion rates to both inner insert media and outside media o f the 
Transwell culture well, potentially a pH gradient could be generated that is 
responsible for the resultant stratification within graft tissue.
Alternatively, nutrient limitation could lead to cell death. There have been studies 
within our laboratory by Dr Anthony Hayes into the cell viability o f Transwell 
cartilage grafts using a fluorescent live/dead viability kit. It was shown that the 
majority o f cells in thin (~0.25mm) living sections o f graft tissue were viable after 
4 weeks in culture. During the same 4 week time frame both necrotic and 
apoptotic cells had accumulated throughout graft matrices, but there were no 
distinct zones of cell death (Hayes et al., 2007).
• Zone specific cell sorting
Cell tracker studies in our laboratory using a live/dead™ viability/cytotoxicity kit 
showed that following a 4 week culture period, a labelled mid zone sub-
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population largely retained its intermediate position in tri-layered composites, 
indicating little inter-zonal movement o f chondrocytes. When grafts were made 
by mixing a single fluorescently labelled sub population with its unlabelled 
counterparts from adjacent zones, in all cases the chondrocytes were randomly 
distributed through-out tissue depth. Therefore, there is no evidence that zone 
specific cell sorting is responsible in the establishment of the distinct stratification 
observed by neocartilage grafts produced in vitro (Hayes et al., 2007).
• Culture environment
Alternatively, the establishment o f stratification within the grafts could be dictated 
by the culture environment produced by the Transwell culture system. Studies in 
our laboratory using bromodeoxyuridine (BrDu) to identify proliferating cells and 
the role cell proliferation has on tissue organisation have shown that high levels o f 
proliferation occur at both the graft surface and in underlying tissue. This high 
proliferative level reflects the known effects that transforming growth factor (a 
supplement in the Transwell culture system) has on chondrocyte proliferation. 
Therefore, the chondrocytes divide or differentiate according to their potential and 
position in the developing tissue. At the surface o f the developing graft the 
conditions resemble a monolayer culture. Therefore, the chondrocytes flatten out, 
proliferate and differentiate expressing molecules typical to the superficial zone. 
The deeper regions o f the developing graft contain a high density o f cells, 
therefore close contact with neighbouring cells conduct chondrogenesis and the 
formation o f spheriodal cells showing morphological similarities to those found 
within the deeper regions (Hayes et al., 2007).
Although distinct cartilaginous zones were observed within the grafts, there was no 
identifiable calcified zone. Advances were made in 1997, chiefly by the Kandel 
laboratory finding that the addition o f Phosphoethanolamine (PEA), p- 
glycerophoshate (P-GP) or adenosine triphosphate (ATP) to deep zone chondrocytes 
in Transwell culture systems encouraged calcification, producing a mineral identified 
as hydroxyapatite similar in composition and crystal size to the mineral present in 
native in vivo cartilage (Kandel et al., 1997). More recent advances involve the 
generation o f neocartilage tissue on a bone substitute calcium polyphosphate (CPP)
that has been found to improve integration with bone within cartilage defects 
(Waldman et al., 2007, Pilliar et al., 2007). The presence of the calcified zone has 
been found to increase both the tissue stiffness and interfacial shear properties at the 
cartilage-CPP interface (Allan et al., 2007).
Previously, in vitro systems utilised to study the deep region o f articular cartilage 
region had limitations. The Transwell culture system is ideal for studying the 
different properties o f chondrocytes isolated from different cartilaginous zones. 
Waldman in 2003 isolated chondrocytes from full thickness cartilage (FT), mid to 
deep region cartilage (MD) and from the deep region (DEEP) and seeded each group 
onto the surface o f a porous ceramic substrate and maintained them in culture for 8 
weeks. The tissue developed from the chondrocytes taken from full thickness 
explants accumulated the most amount o f collagen. Tissues produced from isolated 
chondrocytes from the deep region were thicker and accumulated a larger amount of 
extracellular matrix. The tissue produced by chondrocytes isolated from MD regions 
contained more proteoglycan and showed mechanical properties four times greater 
than tissue produced from deep or FT cartilage chondrocytes.
In contrast, preliminary work in our laboratory has shown a reduction in the 
differentiation potential o f chondrocytes with increasing depth from the articular 
surface utilizing a Transwell culture system (Hayes et al., 2007). Chondrocytes 
isolated from the surface zone, and to a lesser extent the mid zone have the ability to 
reconstitute the macromolecular organisation o f native cartilage tissue throughout the 
depth of the resulting graft. Chondrocytes isolated from the deep zone were unable to 
produce a stratified graft; the grafts produced were highly disorganised and stained 
strongly for collagen type I and X in addition to type II collagen. This supports the 
finding o f a progenitor cell population within the superficial zone o f articular cartilage 
(Dowthwaite et al, 2004) that allows appositional growth from the surface zone 
region (Hayes et al, 2001). These findings suggest that chondrocytes isolated from 
different zones have the ability to produce engineered tissues o f  varying properties. 
Therefore, the subpopulation o f chondrocytes used in tissue engineering could be 
dictated by the requirements at the site o f injury.
In a human knee joint, articular cartilage compensates for joint incongruence and 
differences in mechanics throughout the joint, leading to morphological variations o f 
the articular cartilage in a site specific manner (i.e. its thickness, cellularity and the 
components that contribute to its ECM). A detailed account o f the structural
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information o f native articular cartilage throughout the joint would be beneficial to 
tissue engineering, as a patient with a defect could potentially be treated with 
engineered tissue that was manipulated to consist o f the relevant properties to a site of 
injury or disease. Although, it must be taken into consideration that repair graft tissue 
must develop and function under different metabolic and biomechanical constraints in 
comparison to the original native cartilage predecessor. Therefore, the requirements 
o f the repair tissue may vary in comparison to native cartilage in order to carry out its 
healing function (Quinn et al., 2005).
This study has shown that both thickness and cellularity o f engineered grafts can be 
regulated by increasing the culture duration and cell seeding density, respectively. In 
the future, multiple neocartilage grafts o f varying properties could be generated for 
site specific treatment by: (1) applying various growth media to Transwell culture 
systems (e.g. neocartilage grafts subjected to different growth factors and serum 
concentrations)); (2) applying a mechanical load to developing neocartilage grafts as 
mechanical forces stimulate ECM synthesis (Waldman et al., 2003, 2006 & 2007, 
Miyanishi et al 2006, Kawanishi et al 2007); (3) applying low energy pulsed 
electromagnetic fields to grafts to up-regulate glycosaminoglycan synthesis and anti­
inflammatory agents (De Mattei et al., 2007); (4) the use o f different chondrocyte 
subpopulations to generate grafts (Waldman et al., 2003, Kandel et al., 1997 and 
Hayes et al., 2007); and (5) the use o f different cell sources.
In this study it was concluded from histology data that the optimal culture conditions 
for neocartilage graft generation utilising the Transwell culture system for future work 
was a cell seeding density o f 4-6 x 106 cells generated over a 4 week culture period. 
In 2007, Hayes et al reported that immunohistochemical labelling towards chief ECM 
molecules showed that Transwell neocartilage tissue generated using these optimal 
culture conditions had many similarities to immature native articular cartilage (Hayes 
et al., 2007). Type I collagen labelling was predominant at the surface o f the grafts 
and both aggrecan and type II collagen labelling were present throughout the whole 
depth o f the graft tissue, as found in native articular cartilage (Figure 3.9). No 
labelling was observed for versican, versican being a marker for fibroblastic tissue. 
All the extracellular matrix components that were present in the neo-cartilage tissue 
produced using these optimal culture conditions are discussed to a greater length in 
Table 3.4
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Extracellular matrix 
molecules present in 
native cartilage
Composition of neo-cartilage graft tissue produced 
from a 7 day bovine chondrogenic source over a 4 
weeks primary culture
Collagens
Type I Present in the surface zone, not in underlying tissue
Type II Identifiable throughout graft tissue
TypeX 4 weeks culture- The immaturity of the tissue is reflected in the fact 
that collagen type X is not detectable in grafts following 4 weeks 
culture (Schmid & Linsenmayer., 1985).
Extended culture period (>12 weeks)- Weak association of type X 
collagen within the pericellular matrix of hypertrophic chondrocytes 
of the basal zone (Schmid & Linsenmayer., 1985).
Proteoglycans
Aggrecan One of the major constituents of cartilage extra-cellular matrices 
was detectable throughout graft tissue.
Small leucine rich PG 
(i.e. Biglycan & Decorin)
Detectable throughout graft tissue. Decorin, in particular, showed a 
more prominent labelling in the surface zone that diminished with 
depth of the tissue (Miosge et al., 1994).
Surface Zone Protein (SZP) 4 weeks culture- Weakly associated with cells at graft surface 
Extended culture period (>12 weeks)- SZP became more organised 
at graft surface showing similar distribution to native articular 
cartilage (Schmacher et al., 1994).
Glycosaminoglycans
Chondroitin Sulphate (CS) Unsulphated chondroitin (C-O-S) and chondroitin-4-sulphate (C-4- 
S) ‘stubs’ (i.e. following chondroitinase digestion) showed labelling 
throughout graft tissue suggesting an association with aggrecan. 
Chondroitin-6-sulphate (C-6-S) ‘stubs’ were not detectable in graft 
ECM indicative of the immaturity of the engineered graft (Cheng et 
al., 1996).
Keratan Sulphate (KS) Present in pericellular matrix compartments, becoming more 
predominant with graft tissue depth. Similar observations found in 
native articular cartilage where KS associates with aggrecan 
(Hedlund etal., 1999).
Dermatan Sulphate (DS) Located at the surface zone of graft tissue, suggesting that this 
molecule is associated with decorin (Choi et a l, 1989, Miosge et 
al., 1994).
Table 3.4. Extracellular matrix composition of neo-cartilage grafts generated from an immature 
bovine chondrogenic source over a 4 weeks culture period (Hayes et al, 2007).
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Type I collagen Type II collagen
AggrecanVersican
Figure 3.9. Immunohistochemical labelling of extracellular matrix components of neo-cartilage 
generated using an in vitro Transwell culture system (Kindly donated by Dr Anthony Hayes).
A comparable study of neocartilage grafts produced using either an immature or 
mature chondrogenic source at optimal culture conditions revealed that the immature 
source produced a more alcianophilic, highly organised, stratified, hyaline tissue o f 
increased tissue weight and thickness than the mature source. There were marked 
differences in the synthetic capacity of chondrocytes obtained from both sources. 
Grafts produced from the immature source generated x3.3 fold more total s-GAG and 
xl.7  fold more total collagen than the mature source over a 4 week culture period. 
Interestingly, of the total s-GAG and collagen that was released to culture media from 
grafts generated by both an immature and mature source, a higher proportion o f s- 
GAG was released to the inner insert media than the outside media and the opposite 
was observed for collagen. These results suggest that grafts produced from an 
immature bovine chondrogenic source, due to their highly active synthetic nature, 
could effectively heal partial or full thickness defects supporting the studies o f Namba 
et al 1998.
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However, one potential problem is the integration o f neo-cartilage tissue to adjacent 
native articular cartilage within defects. Wang et al., 2004 showed that freshly 
isolated or passaged (PI) chondrocytes, have potential to adhere to different joint 
surfaces that they could be exposed to in a cartilage defect (i.e. mid-deep zone hyaline 
cartilage, calcified cartilage or bone). There is potential to improve integration 
between repair tissue and native cartilage at a defect site, as proteoglycans carrying 
dermatan sulphate GAG chains are thought to inhibit cell attachment. Following the 
debridement o f a defect site, and prior to implantation o f repair tissue to the defect 
site, dermatan sulphate could be removed from the surfaces o f the defect by 
enzymatic treatment (using Chondroitinase ABC) having the effect o f encouraging 
cell attachment (Brittberg 1999).
In the literature it was reported that the production of neo-cartilage grafts in Transwell 
culture systems involved two phases; (1) matrix accumulation (culture days 10-21) 
and (2) maintenance of the existing matrix (following culture day 35). It was found 
that both collagen and proteoglycan content within graft tissue increased with culture 
time and matrix accumulation was enhanced by increasing cell density in the presence 
of serum and ascorbate. Newly synthesised proteoglycan retained in graft matrices 
increased from 20% on culture day 6 to 85% on culture day 35. Following day 35 o f 
culture there were no further increases in proteoglycan and collagen content (Boyle et 
al., 1995). Potentially, this study could have been improved if the effects o f increased 
cell density and culture duration on matrix accumulation (i.e. sulphated 
glycosaminoglycan and collagen content) were taken into consideration.
Sun et al in 2002, utilized the Transwell culture system to generate grafts using an 
equine chondrogenic source and found that the tissue generated had more sulphated 
glycosaminoglycan and lower collagen content than native articular cartilage. An 
improvement upon this study would have been to analyse both the collagen and s- 
GAG content of the harvested native articular cartilage prior to enzymatic isolation 
for use o f chondrocytes in neocartilage graft production, so that the biochemical 
content of native tissue and engineered neocartilaginous graft tissue could have been 
compared more accurately.
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3.4 Chapter summary
• Neocartilage grafts produced from an immature bovine chondrogenic source 
were of an opaque, hyaline appearance at all cell densities and time points 
studied.
• Stratification into distinct zones approximating to the surface, middle and deep 
regions of native adult articular cartilage in vivo was evident within graft 
tissue following just 2 weeks o f culture and this morphological stratification 
became more apparent with time and increased cell seeding density.
• An increased culture period and cell seeding density produced grafts of 
increased thickness and cellularity, respectively.
• With respect to native adult articular cartilage, grafts made from 6 x 106 cells 
or above were too hypercellular and grafts produced from 2 x 106 cells were 
too thin.
• The optimal culture conditions for future analysis within this project was 
found to be a cell seeding density o f 4-6 x 106 cells over a 4 week culture 
duration determined by histological data alone.
• Neocartilage tissue generated from an immature chondrogenic source, utilising 
optimal culture conditions, showed immunofluorescent labelling o f major 
extracellular matrix components was similar to immature native articular 
cartilage.
• At optimal culture conditions neocartilage grafts produced from an immature 
chondrogenic source were more synthetically active compared to those 
produced from a mature chondrogenic source, generating significantly higher 
amounts of both total sulphated glycosaminoglycan and collagen.
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• A higher s-GAG and collagen content was retained within grafts generated 
from the immature chondrogenic source compared to mature; these findings 
were supported by graft weight, thickness and histology.
• Interestingly, more s-GAG was found to be released to inner insert media o f 
the Transwell culture system in comparison to outside media and the opposite 
was observed with collagen release.
• The Transwell culture system is advantageous over many other culture 
models, as neocartilage graft generation can be highly regulated in culture, as 
most non-gaseous graft metabolites produced throughout the culture duration 
can be monitored.
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4.0 THE EFFECT OF PASSAGE EXPANSION  
OF CH O NDROCYTES IN M O NOLAYER CU LTU R E, ON  
RESULTANT NEOCARTILAGE TISSUE A R C H ITEC TU R E  
USING AN IN  VITRO TRANSW ELL CULTURE SYSTEM .
An unavoidable and necessary step for the use o f human chondrocytes to assist in the 
healing of articular cartilage defects is cell expansion to increase the cell number 
because human chondrogenic sources utilized for clinical applications are o f limited 
supply. Animal chondrogenic sources are of a more plentiful supply, but are not 
practical due to immuno-rejection. Therefore, human chondrocytes are isolated from 
harvested cartilage from a low load bearing region o f a patient and multiplied in 
monolayer culture.
In monolayer culture the chondrocytes are placed into an alien 2-D culture 
environment in which modifications to the cytoskeleton occur. The chondrocytes 
lack the crucial influences of physiological cell-cell and cell-extracellular matrix 
interactions. As a result chondrocytes change in phenotype to a more fibroblastic 
state (Figure 4.1). The chondrogenic phenotype is rounded, whereas the fibroblastic 
phenotype is flattened and stretched out. The process in which a chondrocyte 
phenotype changes from chondrogenic to fibroblastic is termed de-differentiation.
Figure 4.1. Morphological changes that occur to a chondrogenic cell source resulting 
from passage expansion in monolayer culture.
De-differentiates
CHONDROGENIC
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FIBROBLASTIC
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De-differentiation is a process in which tissues that have undergone cell 
differentiation (a series o f events, involving the interactions o f growth factors leading 
to the development o f specialised cells having specific structural, functional and 
biochemical properties) can be made to reverse the process as to become a primordial 
cell again.
Like chondrocytes, fibroblastic tissue is derived from primitive mesenchyme and they 
express the intermediate filament vimentin, a marker illustrating mesenchymal origin. 
Fibroblasts are able to synthesise extracellular matrix molecules including: collagens, 
glycosaminoglycan, elastic fibres and glycoproteins. Fibrocartilage consists o f mostly 
Type I collagen fibres (unlike hyaline tissues that consist o f more type II collagen in 
comparison) with small amounts of type III and V collagens and less proteoglycan 
than hyaline cartilage (Eyre & Wu 1983).
This resultant phenotypic change of cells is a consequence o f proliferation in 
monolayer and is accompanied by the up-regulation o f type I collagen and versican 
{Fibroblastic markers) and the down regulation o f aggrecan, type II collagen and 
specific genes SOX 5, 6 and 9 {Cartilaginous markers). Re-differentiation o f the 
passaged cell source into a 3-D culture system or high cell density culture (i.e. 
alginate, agarose, pellet cultures or in vitro Transwell culture systems) may provide a 
solution to this problem.
However, stimulating re-differentiation o f chondrocytes may encourage the undesired 
effect o f hypertrophic differentiation and dramatically diminish chondrocyte ability to 
produce true hyaline tissue (Benya et al., 1978, Stokes et al., 2001, Yang et al., 2006). 
In the present study, we examined the effect of passage expansion o f chondrocytes 
from both immature and mature bovine sources, in monolayer culture, followed by re­
differentiation in a Transwell culture system, on the resultant tissue architecture.
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4.1 Methodology
Chondrocyte sources {i.e. immature (7 day bovine) and mature (18 month bovine)) 
designated for de-differentiation were serially passage expanded in monolayer culture 
using aerated 75cm2 flasks maintained in DMEM plus 50pg/ml gentamycin, 
containing 10% FBS. The cells were grown to confluence, then cultures were washed 
to remove surplus protein using serum free DMEM plus 50pg/ml gentamycin. The 
media was removed and Trypsin.EDTA (5ml) was added to the monolayer flasks for 
5 minutes at 37°C to allow cells to lose contact with the surface o f the flasks. With a 
higher passage number (P4 and P5), cell removal from the flasks became more 
challenging, so addition o f collagenase (lOOunits/ml) was also required for 30 
minutes at 37°C following a trypsin treatment.
Harvested chondrocytes were washed, counted, and seeded onto filter inserts 
{immature: 6xl06 cells/insert and mature: 4xl06 cells/insert) as described in section 
2.2. Neocartilage grafts were produced over a 6 week {immature) and 4 week 
{mature) culture period and were maintained and harvested following methodology 
also described in section 2.2.
The remaining cells harvested from the monolayer culture, were returned to 
monolayer culture at low density for further rounds of expansion. This procedure was 
repeated until passage number 5, by which time the growth rate in monolayer was 
insufficient to sustain sufficient cell numbers for further graft production.
Analyses: Grafts {i.e. immature and mature) were histologically and biochemically 
analysed using methodology previously described in chapter 2. Neocartilage grafts 
generated from expanded immature chondrogenic sources were immuno-labelled 
following the methods described in section 2.3.1.
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4.2 Results
4.2.1 Effect of passage expansion of immature chondrocytes, in monolayer 
culture, on resultant neo-cartilage tissue architecture using an in vitro 
Transwell culture system.
Immature bovine chondrocytes showed reduced ability to produce a true hyaline 
tissue resembling articular cartilage, using an in vitro Transwell culture system, 
following successive monolayer expansions. An increasing passage number of the cell 
source resulted in the generation o f neo-cartilage grafts with a decreasing thickness 
from approximately 500pm at P0 (primary chondrogenic source) to -3 0 0 pm at P5 
(grafts produced from a chondrocyte cell source that had been serially passaged 5 
times) (Figure 4.2).
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Figure 4.2. Thickness of neo-cartilage grafts produced at 6 weeks from an immature chondrogenic 
source with an increasing passage number. Data presented as mean SEM and significance was 
assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***).
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Histological organisation o f neo-cartilage grafts was progressively lost with an 
increased passage number, and alcian blue staining reduced, indicating diminished 
sulphated GAG content with successive passage (Figure 4.3). At PO, PI and P2 
grafts generated showed similarities to native adult articular cartilage; with distinct 
stratified regions of surface, middle and deep zones consisting of spheroidal 
chondrocytes in the mid to deep region and discoidal chondrocytes at the surface. 
Chondrocytes that had been passaged three times (P3) were unable to lay down an 
extracellular matrix, therefore cells were lost to culture medium at this stage resulting 
in a premature termination o f the Transwell filter insert cultures.
However, chondrocytes that were further passaged a fourth (P4) and fifth (P5) time 
regained their capacity to lay down an extracellular matrix. Although the resultant 
neo-cartilage grafts from both P4 and P5 lacked distinct zonal organisation, and their 
chondrocytes appeared to be less rounded in comparison to the chondrocytes observed 
from grafts generated at PO to P2. Neo-cartilage grafts generated from P4 and P5 
chondrocytes contained discrete clusters of cells in their basal portions (Figure 4.3 
(iarrow heads)) and histologically resembled fibrocartilage. This is suggestive that a 
phenotypic change from chondrogenic to fibroblastic occurs at very early stages of 
chondrocyte cell expansion.
PO p i P2 P4 P5
Figure 4.3. Neo-cartilaginous tissue produced using an in vitro Transvvell culture system from 
immature chondrocytes that were serially passage expanded (P0-P5) in monolayer culture. Alcian blue 
and haematoxylin/eosin. Scalebar represents 40pm.
107
These histological findings were supported by s-GAG analyses in that grafts produced 
at all passages generated significantly less total s-GAG compared to Control (PO) 
treated grafts (Table 4.1 & Figure 4.4). Decreased glycosaminoglycan retention 
within neocartilage grafts was observed between PO to P3, showing an approximate 
65.6% decrease between PO and P2 and a 100% decrease between PO and P3 (Table
4.1 & Figure 4.4). However, following further passages for a 4th and 5th time, the 
capacity o f grafts to retain s-GAG within matrices was restored to 36.5% and 41.3% 
of PO, respectively.
Passage
Number
Media Graft Residue Total GAG 
(pg)Insert Outside 4M GuHCl Pepsin Papain
PO 824.80tl2.61 393.35±3.60 1191.47il26.07 278.7±179.53 132.54il00.47 2820.89±366.17
PI 731.40±12.00 341.05±10.61 824.58±105.53 70.33±9.64 26.77±3.28
1994. M il 17.86 
(*)
P2 272.32±14.24 364.60±8.56 482.83±115.59 42.00i21.44 26.49±3.59
1188.24il23.99
P3 30.84±4.59 25.52±2.69 - - -
56.36i7.23
P4 738.33±5.38 302.37±6.11 483.89i51.48 60.73il9.49 41.05±6.75
1626.37i64.58
P5 655.52±12.05 216.22±7.62 425.62±65.89 210.03±33.24 26.19±4.42
1533.58i93.26
Table 4.1. Total sulphated glycosaminoglycan (s-GAG) generated by neocartilage grafts produced using an in 
vitro Transwell culture system, from an immature chondrogenic source that was serially passage expanded (P0-P5) 
in monolayer culture (n=3). Data presented as mean SEM and significance was assumed where P<0.05 (*), 
PO.Ol (**) or PO.OOl (***). All data compared relative to the Control.
Immunohistochemical (IHC) labelling o f grafts produced using successively passaged 
immature bovine chondrogenic sources, showed that Type II collagen was present 
throughout graft matrices regardless o f passage number (Figure 4.5). Grafts 
generated from a primary chondrogenic source (PO) showed IHC labelling within the 
superficial zone for type I collagen, similar to native articular cartilage where type I 
collagen is a minor component enriched in the ‘lamina splendins’ o f the superficial 
region (Figure 4.5). An increased passage number from PO to P2 extended collagen 
type I labelling from the graft surfaces towards the mid region. At P3, no graft was
108
Figure 4.5. Distribution of collagen types I & II in neo-cartilaginous graft tissues produced from serially 
expanded (P0-P5) chondrogenic sources in monolayer culture (scalebars = 80pm)
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produced as chondrocytes were unable to lay down an extracellular matrix leading to 
a premature termination of cultures at this stage. After chondrocytes were further 
passaged a 4th and 5th time, type I collagen labelling was present throughout the whole 
of graft matrices (Figure 4.5).
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Figure 4.4. Total sulphated glycosaminoglycan (s-GAG) generated by neocartilage grafts produced using an in 
vitro Transwell culture system, from an immature chondrogenic source that was serially passage expanded (P0-P5) 
in monolayer culture (n=3). Data presented as mean SEM and significance was assumed where P<0.05 (*), 
P<0.01 (**) or P 0.001 (***).
Aggrecan, a major constituent o f cartilage extracellular matrices was present 
throughout the whole o f the graft matrix regardless o f passage number (Figure 4.6). 
However, the staining intensity o f aggrecan labelling decreased with an increase in 
passage number (Figure 4.6).
Interestingly, versican labelling (a fibrocartilaginous marker) became predominant in 
the deep zones o f neo-cartilage grafts at both P4 and P5 (Figure 4.6). The labelling 
pattern for versican coincided spatiotemporally with the cell clusters observed 
histologically at the base o f the tissue, suggesting a fibrochondrocytic cell phenotype 
in this tissue zone (Figure 4.3 & Figure 4.6).
The IHC labelling results correlate with both the histological and biochemical 
findings, suggestive that between P0 and P3 there is a phenotypic shift from 
chondrogenic to fibroblastic. This is supported by a decreased staining intensity for 
aggrecan labelling and an increased labelling for both collagen type I and versican in 
neo-cartilage grafts following successive passages.
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Figure 4.6. Distribution of aggrecan and versican in neo-cartilaginous graft tissue produced from serially 
expanded (P0-P5) chondrogenic sources in monolayer culture. Scalebars=40pm
Aggrecan 
V
ersican
4.2.2 Effect of passage expansion of mature chondrocytes, in monolayer 
culture, on resultant neo-cartilage tissue architecture using an in vitro 
Transwell culture system.
Increasing passage number o f the mature cell source resulted in the generation o f neo­
cartilage grafts with a decreasing thickness from approximately 108pm at PO to 
~57pm at P5. Grafts at all passages were significantly thinner when compared to the 
Control (PO) graft, with the exception o f P2. A similar trend was observed using the 
mature cell source, to that found with the immature cell source. It appeared that 
neocartilage grafts generated from a cell source that had been serially expanded three 
times (P3) were the thinnest, suggestive o f a reduced capacity for the cells at this 
stage to lay down a matrix. This ability was slightly restored following further 
passages a 4th and 5th time, producing grafts o f increased thicknesses when compared 
to P3.
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Figure 4.7. Thickness of neo-cartilage grafts generated from a mature cell source of increasing 
passage number. Data presented as mean SEM and significance was assumed where P<0.05 (*), 
P<0.01 (**) or P0.001 (***).
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The histological organisation of neocartilage grafts produced from mature cell 
sources, lacked the distinct zonal stratification observed in native adult articular 
cartilage, regardless o f passage number (Figure 4.8). Chondrocytes present within 
the Control (PO) graft tissue appeared to be extremely hypercellular; all grafts 
appeared to be extremely cellular with very little matrix accumulation.
PO P1 P2 P3 P4 P5
Figure 4.8, Neo-cartilaginous tissue produced using an in vitro Transwell culture system 
from mature chondrocytes that were serially passage expanded (P0-P5) in monolayer culture. 
Alcian blue and haematoxylin/eosin. Scale bar represents 50pm.
These histological findings were supported by s-GAG analyses in that grafts produced 
at all passages generated significantly less total s-GAG compared to Control (PO) 
treated grafts (Table 4.2 & Figure 4.9). A 62.7% decrease in glycosaminoglycan 
retention within neocartilage grafts generated from mature cells was observed 
between PO to P3 (Table 4.2 & Figure 4.9). However, following further passages for 
a 4th and 5th time, the capacity o f grafts to retain s-GAG within matrices was restored 
to 50.3% and 57.5% o f PO, respectively.
The histological and biochemical findings for neocartilage grafts generated from 
serially expanded mature chondrogenic sources support a similar trend to what was 
observed using an immature chondrogenic source. This suggests that prior to P3 a 
phenotypic shift occurs within the cell source from a more chondrogenic to a more 
fibroblastic phenotype. After three passage expansions the chondrocytes show a 
reduced capacity to lay down extracellular matrices. Following a further 4th and 5th 
passage this ability is restored, however the neocartilage tissue generated appears to 
be more fibrocartilaginous.
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Passage
Number
Media Graft Residue Total GAG 
(Pg)Insert Outside 4MGuHCL Pepsin Papain
PO 769.15±6.10 265.68±6.83 1.26±0.47 0.90±0.08 16.61±8.19 1053.60±11.41
PI 387.28 176.85 2.31 0.07 7.17 573.68
P2 329.17±4.91 293.02±8.09 0 .00± 0.00 0.31±0.20 6.14±2.68 628.64±12.79
*^**^
P3 229.46±2.98 204.50±1.94 0.22±0.22 0.36±0.23 6.42±4.77 440.95±1.51
P4 169.29±1.46 163.28±1.76 O.OOiO.OO 0.87±0.19 8.57±2.44 342.01±4.43
*^**^
P5 216.55±2.13 198.19±2.51 0 .13±0.13 0.66±0.26 10.00±4.39 425.53±8.58
Table 4.2. Total sulphated glycosaminoglycan (s-GAG) generated by neocartilage grafts produced 
using an in vitro Transwell culture system, from a mature chondrogenic source that was serially 
passage expanded (P0-P5) in monolayer culture. Data presented as mean SEM and significance was 
assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***). All data compared relative to the Control.
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Figure 4.9. Total sulphated glycosaminoglycan (s-GAG) generated by neocartilage grafts produced 
using an in vitro Transwell culture system, from a mature chondrogenic source that was serially 
passage expanded (P0-P5) in monolayer culture. Data presented as mean SEM and significance was 
assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***).
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4.3 Discussion
These experiments involved tissue engineering articular cartilage grafts using 
chondrocytes isolated from immature and mature bovine full depth cartilage. It was 
shown that with an increasing passage number o f the chondrogenic source, the grafts 
that were generated increasingly lacked the distinct appearance and morphological 
stratification o f native articular cartilage. The immature cell source is excellent at 
producing large amounts o f extracellular matrix, but is not clinically relevant or even 
practical. The mature chondrogenic source has poor synthetic abilities in comparison 
to the immature cell source, and they produce grafts lacking a zonal architecture, with 
little matrix, appearing extremely cellular. An explanation for this possibly could be 
that in vivo the natural repair process as well as environmental factors change the 
phenotype o f the mature chondrocyte to a more fibroblastic state. Therefore mature 
chondrocytes de-differentiate in vivo prior to the cell isolation, expansion and seeding 
onto filter inserts for graft production, de-differentiated cells lose their zonal 
differences.
After both the immature and mature chondrogenic sources had been passaged three 
times (P3) they lost the ability to re-differentiate. No grafts were produced from the 
immature cell source and grafts produced from the mature source were very thin, 
suggesting that at this point the chondrocytes had undergone a phenotypic change and 
de-differentiated. The capacity o f  the chondrogenic sources to lay down an 
extracellular matrix was restored following successive passages o f the cells after P3, 
although the zonal organisation o f hyaline cartilage was not apparent appearing more 
fibrocartilaginous in nature.
Parallel results in other studies show similar phenotypic changes occur in cartilage 
chondrocytes between PO (utilising a primary cell source) and P4 (utilising a 
chondrogenic source that has been passaged four times). De Haart et al 1999 found 
that expansion o f bovine articular cartilage chondrocytes showed a decreased 
expression o f type II collagen following a third passage o f the cell source. 
Chondrocytes isolated from human nasal septum cartilage have also been shown to 
exhibit a similar impairment in their ability to proliferate at P3, they begin to acquire 
a more fibroblastic morphology (Chua et al., 2005). Honda et al., 2004 reported that 
multiplied chondrocytes in a new scaffold: Hybrid 75:25 Poly (L-Lactide-s-
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Caprolactone) sponge, that was coated with type I collagen generated cartilage tissue 
up to P2 but not beyond P4. The use o f subpopulations in monolayer showed that 
superficial zone chondrocytes had more SZP than mid/deep zones to begin with, and 
the mid/deep zones had more collagen type II than superficial zone to begin with. 
Following three passages these differences no longer existed (Darling and Athanasiou
2005). Interestingly, Fu et al 2005, expanded young rabbit chondrocytes to passage 3 
and then seeded the source on polylactic acid scaffolds (PLA) coated with lecithin and 
poly lysine modulated by bFGF and they reported observing histologically 
cartilaginous grafts.
A study analysing the effects o f monolayer expansion o f human articular 
chondrocytes reported the down-regulation in mRNA for aggrecan and type II 
collagen and an up-regulation o f both versican and type I collagen (Binette et al.,
1998). This was consistent with the immunolabelling data presented in this study.
To improve grafts generated from a passaged source it would be beneficial to 
optimise conditions for monolayer culture and re-differentiation encouraging 
chondrogenesis and inhibiting hypertrophic differentiation by adding the right factors 
at the appropriate moment. For example PTH/PTHrP has been found to inhibit 
chondrocyte hypertrophy, but insulin sends chondrocytes towards hypertrophy 
therefore addition o f the right factors are essential (Liu et al., 2007). Ideally 
conditions should encourage type II collagen and proteoglycan production, inhibit 
collagen type I, suppress type X collagen and delay the expression of alkaline 
phosphatase and calcium mineral accumulation (Liu et al., 2007). A detailed 
understanding o f intracellular signalling during chondrogenesis and the effects of 
monolayer culture on chondrocyte signalling would be advantageous, as improving 
basic knowledge in this area would help clinicians to intervene in attempt to prevent 
bio-artificial cartilage from losing its stability.
Yang et al., 2006 looked at the impact expansion and re-differentiation conditions had 
on the chondrogenic capacity o f cultured chondrocytes. During chondrocyte 
expansion they either supplemented media with or without bFGF, then analysed the 
re-differentiation abilities o f  the two expanded sources in either a pellet culture or 
filter inserts with type II collagen. An increased differentiation o f bFGF 
supplemented chondrocytes was observed in comparison to the non supplemented 
chondrocytes in monolayer culture, and the re-differentiation o f expanded 
supplemented chondrocytes was better than the non supplemented expanded
116
chondrocytes showing increased proteoglycan synthesis. It was found that expansion 
of supplemented chondrocytes and re-differentiation on collagen coated filters 
resulted in the most optimal chondrogenic conditions. Similar results were also 
observed when expanding goat chondrocytes supplemented with bFGF. There was 
increased chondrocyte proliferation and their post expansion chondrogenic capacity to 
re-differentiate onto HYAFF-M or polyactive foams was enhanced (Miot et al.,
2006).
Neighbouring cells can influence cell type and de-differentiation induced by 
passaging. A chondrogenic source that was passaged four times then mixed with a 
primary chondrogenic source and grown on filter inserts showed an increase in 
cartilage tissue formation and re-differentiation o f de-differentiated chondrocytes with 
addition o f increasing concentrations o f the primary chondrogenic source. Therefore, 
the quality o f in vitro cartilage tissue could be improved with the use o f  co-culturing 
both primary and passaged chondrocytes (Gan & Kandel 2007).
In vivo, articular cartilage is subjected to varying loads; mimicking in vivo conditions 
could enhance the synthesis o f important matrix components in vitro. The influence 
o f intermittent loading during re-differentiation o f chondrocytes in alginate culture 
was analysed and it was observed that collagen type II and glycosaminoglycan 
increased encouraging re-differentiation (Heyland et al., 2006). Staurosporin 
(described as a protein kinase C inhibitor) has been described as a potent re- 
differentiating agent o f articular chondrocytes that have been sub-cultured up to 
passage 2 (Borge et al., 1997). Chondrogenesis can also be promoted in human 
chondrocytes, but not fibroblasts, by responding to perlecan in vitro (French et a l,
1999) and enhancing the chondrogenic transcription factor, SOX 9 (Bell et al., 1997). 
The potential recovery o f  passaged chondrocytes to a more chondrogenic phenotype 
can be achieved through SOX 9 transduction to enhance the re-expression o f cartilage 
matrix genes (Tew et al., 2005). The transcription factor SOX 9 is an essential factor 
in chondrocyte differentiation functioning as a potent inhibitor o f chondrocyte 
hypertrophy. It has been reported that passaged human osteoarthritic chondrocytes 
show an increased collagen type II expression (in both mRNA and protein levels) in 
monolayer when transduced using adenoviral or retroviral vectors o f SOX 9 (Tew et 
al., 2005).
In this study the nature o f the engineered tissue generated was analysed utilizing 
aggrecan, versican, collagen types I and II markers. A problem is ‘what can be
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determined as a cartilaginous or fibroblastic specific marker?’ Recently it was 
reported that collagen type II might be a marker for the synthetic activity of 
chondrocytes rather than a de-differentiation marker (Goessler et al., 2006). The 
expression o f markers that define both the chondrogenic and fibroblastic phenotype 
should have been looked at over the various culture stages (i.e. following chondrocyte 
isolation, during monolayer culture and following re-differentiation in the Transwell 
cultures) as should have cell viability. Ideally, terminal differentiation markers such 
as type X collagen, alkaline phosphatase and osteopontin should have been used so 
that hypertrophic differentiation o f the cell source following re-differentiation in 
Transwell cultures could potentially be eliminated.
In 2001, it was reported that the monoclonal antibody II-fibrau was a useful marker to 
characterise chondrocyte differentiation, having the ability to discriminate between 
differentiated and de-differentiated chondrocytes by binding to de-differentiated 
chondrocytes only. It was found that the addition o f differentiated cells to alginate 
culture resulted in 90-95% o f the cells being II-fibrau negative, whereas the addition 
of de-differentiated cells to alginate in a chondrogenic favouring environment resulted 
in an increase in type II collagen but II-fibrau staining was positive. The placement 
of de-differentiated cells within a biomaterial into a nude mouse resulted in no 
apparent II-fibrau staining (Van Osch et al., 2001).
Alternatively, maybe the use o f  a chondrogenic source for tissue engineering cartilage 
isn’t the way forward. A possible avoidance measure to the obstacle that passaging 
creates could be the usage o f an immortalised cell line. However, this could prove 
disadvantageous as the use o f a tumour cell line would be required for this and the 
chondrocytes would grow not under the control o f the body, but under the control of 
the virus. Cell sources that show potential for future use are embryonic stem cells, 
mesenchymal stem cells and progenitor cells. To date knowledge o f these cell 
sources is minimal and each source provides impediments that need to be overcome, 
but they do provide optimism for the future.
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4.4 Chapter Summary
• Neocartilaginous tissues produced from immature primary chondrogenic cell 
sources showed similarities to native adult articular cartilage with distinct 
stratified zones approximating to the surface, middle and deep regions that 
were progressively lost with an increased passage number.
• Neocartilaginous tissues generated using mature cell sources were extremely 
cellular showing little matrix accumulation and lacked the distinct zonal 
stratification that is observed in native adult articular cartilage.
• Increasing passage number from 0-3 times o f the chondrocyte cell source 
(both immature and mature) used to generate neocartilage grafts showed a 
decreasing s-GAG retention within neocartilage grafts. Grafts produced from 
a chondrocyte source that had been serially expanded three times (P3) 
compared to Control (PO) treated grafts (in both immature and mature) 
showed large decreases in both graft thickness and total s-GAG generation.
• Chondrogenic cell sources (both immature and mature) that were serially 
passaged three times (P3) resulted in a reduced capacity to lay down an 
extracellular matrix (ECM). In the immature cultures, P3 cells were lost to 
culture medium resulting in premature termination o f Transwell filter inserts, 
and in mature cultures the thinnest neocartilage grafts were produced at this 
stage.
• Further passage o f the chondrogenic source (both immature and mature) a 4th 
and 5th time regained the capacity o f  cells to lay down an ECM. Neocartilage 
tissues produced from either P4 or P5 cells were thicker showing higher s- 
GAG retention within grafts compared to P3 generated graft tissues, but not in 
comparison to P0-P2 generated neocartilage tissues.
• Neocartilage grafts generated from an immature P4 or P5 chondrogenic source 
histologically contained discrete cell clusters within their basal portions, that
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IHC labelled spatiotemporally for versican (a fibroblast marker) suggestive 
that P4 and P5 graft tissue resembled a more fibrocartilaginous tissue. This 
was also supported by a decreased staining intensity for aggrecan labelling and 
increased labelling for type I collagen.
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5.0 THE EFFECTS OF DIFFERENT MOLECULAR WEIGHT 
HYALURONAN ON NEOCARTILAGE GRAFT 
METABOLISM UTILIZING AN IN VITRO TRANSWELL
CUTURE SYSTEM.
Hyaluronan (HA) is a glycosaminoglycan made up o f repeating disaccharide units o f 
[D-glucuronic acid (PI-3) N-acetyl D-glucosamine (pi-4)]n (Meyer 1934). HA is 
endogenously synthesised by chondrocytes (Gillard et al., 1975) and synovial 
membrane cells o f  the joint cavity (Baxter et al., 1973) and has been found to have a 
high rate of catabolism (Laurent and Fraser., 1992, Csoka et al., 2001). Hyaluronan is 
a relatively simple molecule, but has a wide range o f biological roles within articular 
joints and other tissues o f the body. Primarily HA provides a structural role in 
cartilage, as the major proteoglycan ‘aggrecan’ binds to HA chains stabilised by link 
protein, having the effect o f influencing the hydration properties o f cartilage 
(Hardingham & Muir, 1972). HA is also present within joint synovial fluid, and is 
involved in the regulation o f  metabolic exchange between cartilage and the synovial 
fluid functioning as a semi-permeable barrier, a lubricant and a shock absorber.
It has been reported that various sized HA polymers are known to trigger different 
functional responses. The low molecular weight (Mwt) hyaluronan appear to act as 
‘endogenous danger signals’ mediating cell signalling effects (Powel & Horton, 
2005). The smaller fragments are inflammatory, immuno-stimulatory and angiogenic 
(Sugahara et al., 2006) with the capability to activate macrophages, suppress 
proteoglycan sulphation (Sorlursh et al., 1980), displace proteoglycans from cell 
surfaces (Sorlursh et al., 1980) and compete with high Mwt HA for receptor binding 
(Stern et al., 2006).
High molecular weight HA is used clinically as an accepted viscosupplementation 
procedure in the treatment o f degenerative joint diseases (e.g. Osteoarthritis-OA). 
Viscosupplementation has been found to improve the visco-elastic properties o f the 
synovial fluid encouraging lubrication, shock absorbance, the formation of a semi- 
permeable barrier, decreasing both inflammatory and proliferative responses that 
occur within diseased joints. It has been found that pain reduction lasts considerably 
longer than the half life o f injected HA, suggestive that the high molecular weight HA 
injections potentially may have disease modifying activity (Goldberg & Bulkwater,
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2005). However, the mechanisms o f action of high Mwt HA in viscosupplementation 
at present are unclear but potential anti-inflammatory, anti-angiogenic, immuno­
suppressive effects with abilities to retard differentiation and impede cartilage matrix 
catabolism by certain catabolites [e.g. IL-1 (Yasui et al., 1992, Monfort et al. 2005) 
andfibronectinfragments (Kang et al., 1999)] have been implied for high Mwt HA in 
the literature.
The original objectives o f the present study were to examine the effects different 
molecular weight hyaluronans (ranging from 5kDa -  3000+kDa) had on: (1) normal 
neocartilage graft metabolism, and (2) IL-1 induced neocartilage graft matrix 
degradation utilising an in vitro Transwell culture system. However, under the 
experimental conditions used, minimal IL-1 effects were observed but interesting data 
was obtained from the ‘Control’ experimentation in this study. Thus, the focus of 
experimentation in this chapter will be the effects o f different Mwt HA on Transwell 
cartilage graft metabolism.
5.1 M ethods
5.1.1 Neocartilage g raft Transw ell culture protocol
4 Week culture 
period for graft 
generation
24 hour 
serum free 
period
Neocartilage grafts 
cultured in the 
presence or 
absence of HA
(molecular weights 
ranging from 5- 
3000+kDA for 5 
hours at 3mg/ml)
Cultured with 
HA in the 
presence or 
absence of IL- 
1 at 3ng/ml for 
48 hours
Figure 5.1. Schematic illustrating the culture protocol used to study the effect of different molecular 
weight hyaluronan on neocartilage grafts produced in Transwell culture.
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A schematic showing the different culture times used to study the effects of different 
molecular weight hyaluronan (ranging from 5kDa to 3000+kDa) on cartilage graft 
metabolism in the presence or absence o f 3ng/ml IL-1 is shown in Figure 5.1. In 
brief, neocartilage grafts were produced using an immature bovine chondrogenic 
source following 4 weeks o f Transwell culture as described in chapter 2.2. In most 
experiments these were then cultured for 24 hours in serum free media. They were 
then cultured for 5 hours in the absence or presence o f 3mg/ml o f varying molecular 
weight HA, followed by a 48 hour culture in the absence or presence o f IL-1 (3ng/ml) 
and in the presence or absence o f  3 mg/ml HA of different molecular weights. In 
these experiments low Mwt HA is defined as that being lower than the size of 
endogenous HA (i.e. 500-1000kDa (Hardingham & Fosang, 1992) and high Mwt HA 
as that greater than that o f endogenous HA.
5.1.2 Biochemical Analysis
Transwell culture media (both inner and outer well) was harvested at 48 hours and 
analysed for sulphated glycosaminoglycan (s-GAG) as described in section 2.5.1. 
Proteoglycan content was extracted from the neocartilage grafts with 4M GuHCl for 
48 hours, the extract was dialysed and s-GAG determined. The remaining 
neocartilage residue following proteoglycan extraction was papain digested and s- 
GAG was determined. Percentages o f s-GAG in replicate cultures (n=2 or n=3) of 
inner and outer media, graft extraction and graft residue were determined and 
subjected to statistics.
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5.2 Results
5.2.1 Evaluation of how the addition of different molecular weight hyaluronan 
(5kDa and 3000+kDa) affected normal graft metabolism and IL-1 induced 
neocartilage graft matrix degradation using an in vitro Transwell culture 
system.
The addition o f an extremely low molecular weight (5kDa) hyaluronan (HA) to 
neocartilage tissue generated in Transwell cultures, resulted in a significant increase 
(P<0.01) o f sulphated glycosaminoglycan (s-GAG) released into culture media {both 
inner and outer wells) in comparison to the Control (Table 5.1). In contrast, addition 
of a very high molecular weight (3000+kDa) hyaluronan had an opposite effect of 
5kDa HA and significantly decreased (P<0.001) percentage s-GAG released to culture 
media compared to the Control (Table 5.1).
TREATMENT
% Total GAG
INSERT OUTSIDE TOTAL
MEDIA MEDIA (Insert & Outside Media)
Control 20.35 ± 1.28 6.30 ±0 .37 26.66 ± 1.64
Control + 5kDa HA 25.76 ± 3 .44 11.02 ± 1.49 36.78 ±2.15
Control + 3000+kDa HA 3.22 ± 0 .94 1.30 ±0 .34 4.52 ± 1.27
(***^
IL-1 22.58 ± 0.29 6.30 ±0 .20 28.88 ±0.10
IL-1 + 5kDa HA 27.77 ± 1.32 9.15 ±0 .52 36.92 ± 1.80
IL-1 + 3000+kD aH A 3.69 ± 0 .2 2.62 ± 0.48 6.31 ±0.25
(P=0.08) (*) ^***^
Table 5.1. Effects of different molecular weight hyaluronan on proteoglycan release to media from 
neocartilage graft extracellular matrices in the presence or absence of IL-1 (n=3). Data presented as 
mean ± SEM. All data compared relative to Control, significance was assumed where P<0.05 (*), 
P<0.01 (**) or PO.OOl (***).
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The percentage s-GAG retained within Control neocartilage grafts was 73.3% ± 1.69. 
The addition o f an extremely low molecular weight (5kDa) hyaluronan significantly 
reduced sulphated glycosaminoglycan retention within grafts (Table 5.2). 
Interestingly, addition o f  the very high molecular weight (3000+kDa) hyaluronan to 
grafts significantly increased sulphated glycosaminoglycan retention by -20%  
compared to the Control (Table 5.2).
TREATMENT
% Total GAG
4M
GUANIDINE
PAPAIN
DIGEST
TOTAL RETAINED IN 
GRAFTS
Control 56.28 ±2 .95 17.07 ± 1.34 73.34 ± 1.69
Control + 5kDa HA 45.63 ±3.71 17.59 ± 1.86 63.22 ±2.15
Control + 3000+kDa HA 78.87 ± 6 .59 16.61 ± 5 .60 95.48 ± 1.27
IL-1 57.31 ± 0 .37 13.82 ±0 .28 71.12 ± 0.10
IL-1 ± 5kD aH A 46.99 ± 1.60 16.09 ±0 .42 63.08 ± 1.80
IL-1 + 3000+kDa HA 74.11 ± 0 .64  
(*)
19.58 ±0 .42 93.69 ±0.25 
^***^
Table 5.2. Effects of different molecular weight hyaluronan on proteoglycan retention in neocartilage 
graft extracellular matrices in the presence or absence of IL-1 (n=3). Data presented as mean ± SEM. 
All data compared relative to Control, significance was assumed where P<0.05 (*), P<0.01 (**) or 
PO.OOl (***).
Similar results were obtained in duplicate experiments [Experiment 1 shown above 
(n=3) and Experiment 2 (n=2)\ a summation o f the data from these two experiments 
is shown in Figure 5.2. It was apparent that IL -ip  at 3ng/ml resulted in minimal or 
no effect on inducing increased graft matrix degradation following a 48hour treatment 
period, due to the concentration o f IL -ip  used being too low i.e 3ng/ml. 
Consequently, all IL-1 data in the following experiments o f this chapter are not 
reported because no effects were observed due to the low concentrations.
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A 50 i
Treatment
Figure 5.2. Sulphated glycosaminoglycan (A) released to culture media and (B) retained in 
neocartilage graft matrices, following the addition of an extremely low (5kDa) and very high 
OOOO^ lcDa) molecular weight hyaluronan (n=5). Data presented as mean ± SEM. All data compared 
relative to Control, significance was assumed where P<0.05 (*), P<0.01 (**) or P<0.001 (***).
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The addition o f an extremely low molecular weight (5kDa) HA to neocartilaginous 
graft tissue significantly increased (PO.OOl) the release o f percentage s-GAG to 
culture media {to both inner and outer wells) in comparison to the Control (Figure
5.2 (A)). The increased amounts o f s-GAG released to culture media in the presence 
of 5kDa HA suggest that a considerable amount o f aggrecan {a major proteoglycan o f 
cartilage) within the graft extracellular matrix (ECM) must be present as non-link 
protein stabilised aggregates; i.e. the 5kDa HA can compete for binding and retention 
with some o f the aggrecan aggregates within the ECM thereby facilitating the 
‘extraction’ or release o f aggrecan from the graft tissue.
Addition o f a very high molecular weight hyaluronan (3000+kDa) significantly 
increased (P<0.001) the retention o f sulphated GAG within graft extracellular 
matrices (Figure 5.2 (B)). Thus, the addition o f high molecular weight HA appears to 
cause retention o f aggrecan within the tissue. This suggests that the high molecular 
weight HA is able to diffuse into the graft ECM and entrap the aggrecan monomers in 
very large aggrecan aggregates that remain within the graft tissue. Whether or not 
these larger aggregates were link protein stabilised was not determined in these 
experiments.
5.2.2 Addition of either a very low molecular weight (lOOkDa) or high 
molecular weight (2200kDa) hyaluronan to Transwell cultured 
neocartilage grafts and their effects on graft metabolism.
The addition o f a very low molecular weight (lOOkDa) hyaluronan to Transwell 
grafts, showed a significant increase o f  s-GAG release (Table 5.3 & Figure 5.3 (A)) 
to culture media (inner and outer well) and decreased s-GAG retention within 
neocartilage grafts compared to the Control (Table 5.4 & Figure 5.3 (B)). Therefore 
lOOkDa HA appears to have similar affects on neocartilage grafts as the extremely 
low molecular weight (5kDa) HA described earlier. The addition o f a high molecular 
weight HA (2200kDa) significantly decreased s-GAG release to culture media (inner 
and outer well) [Table 5.3 & Figure 5.3 (A)] and an increased s-GAG retention 
within grafts (Table 5.4 & Figure 5.3 (B », similar to that observed with 3000+kDa 
hyaluronan.
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TREATMENT
% Total GAG
INSERT
MEDIA
OUTSIDE
MEDIA
TOTAL 
(Insert & Outside Media)
Control 9.13 ± 0 .94 5.92 ± 0 .32 15.05 ± 1.23
Control + 1 OOkDa HA 12.79 ±0 .75 9.28 ± 0.38 22.07 ± 1.12 (**)
Control + 2200kDa HA 7.24 ±0.55 1.50 ± 0 .06 8.74 ±0.48 (**)
Table 5.3. Effects of different molecular weight hyaluronan on proteoglycan release from 
neocartilage graft extracellular matrices in the absence of IL-1 (n=3). Data presented as mean 
± SEM. All data compared relative to Control, significance was assumed where P<0.05 (*), 
P<0.01 (**) or PO.OOl (***).
TREATMENT
% Total GAG
4M
GUANIDINE
PAPAIN
DIGEST
TOTAL RETAINED IN 
GRAFTS
Control 77.15 ± 2 .9 7.8 ± 1.74 84.95 ± 1.23
Control ± lOOkDa HA 70.61 ± 1.41 7.32 ± 1.31 77.93 ± 1.12 (**)
Control + 2200kDa HA 84.32 ± 1.26 6.94 1.10 91.26 ±0 .48  (**)
Table 5.4. Effects of different molecular weight hyaluronan on proteoglycan retention in 
neocartilage graft extracellular matrices in the absence of IL-1 (n=3). Data presented as mean 
± SEM. All data compared relative to Control, significance was assumed where P<0.05 (*), 
P<0.01 (**) or PO.OOl (***).
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Control Con+100KDa Con+2200KDa
T r e a t m e n t  (Molecular W eigh t  Hya lu ronan)
O 80
a 60
« 20
Control Con+100KDa Con+2200KDa
T r e a t m e n t  (Molecular Weight Hya lu ronan)
Figure 5.3. Sulphated glycosaminoglycan (A) released to culture media and (B) retained in 
neocartilage graft matrices, following the addition of a very low (lOOkDa) and high 
(2200kDa) molecular weight hyaluronan (n=3). Data presented as mean ± SEM. All data 
compared relative to Control, significance was assumed where P<0.05 (*), P<0.01 (**) or 
PO.OOl (***).
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5.2.3 Addition of either a low molecular weight (250kDa) or high molecular 
weight (1600kDa) hyaluronan to Transwell cultured neocartilage grafts 
and their effects on graft metabolism.
The addition o f  either 250kDa or 1600kDa molecular weight hyaluronan, to 
neocartilage graft tissue generated in a Transwell culture system, had no significant 
effect on sulphated glycosaminoglycan retention within grafts (Tables 5.5, 5.6 & 
Figure 5.4).
TREATMENT
% Total GAG
INSERT
MEDIA
OUTSIDE
MEDIA
TOTAL 
(Insert & Outside Media)
Control 10.57 ± 0 .42 10.87 ± 1.03 21.44 ± 1.12
Control + 250kDa HA 12.37 ± 1.19 13.29 ±0.31 25.65 ± 1.33
Control + 1600kDa HA 9.98 ± 1.28 11.70 ± 0 .72 21.68 ± 1.89
Table 5.5. Effects of different molecular weight hyaluronan on proteoglycan release to Transwell 
culture media from neocartilage graft extracellular matrices in the absence of IL-1 (n=3). Data 
presented as mean ± SEM. All data compared relative to Control, significance was assumed where 
P<0.05 (*), P<0.01 (**) or PO.OOl (***).
TREATMENT
% Total GAG
4M
GUANIDINE
PAPAIN
DIGEST
TOTAL RETAINED IN 
GRAFTS
Control 64.53 ± 1.94 14.03 ± 1.5 78.56 ± 1.12
Control ± 250kDa HA 58.16 ± 3.78 16.19 ±2.73 74.35 ± 1.33
Control ± 1600kDa HA 62.9 ± 2.43 15.42 ±0 .56 78.32 ± 1.89
Table 5.6. Effects of different molecular weight hyaluronan on proteoglycan retention in neocartilage 
graft extracellular matrices in the absence of IL-1 (n=3). Data presented as mean ± SEM. All data 
compared relative to Control, significance was assumed where P<0.05 (*), P<0.01 (**) or P<0.001 
(***)
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Control Con +250KDa Con+1600KDa
Trea tm en t  (Molecular Weight Hyaluronan)
S 70
Control Con+250KDa Con+1600KDa
T r e a t m e n t  (Molecular Weight Hyaluronan)
Figure 5.4. Sulphated glycosaminoglycan (A) released to culture media and (B) retained in 
neocartilage graft matrices, following the addition of low (250kDa) and high (1600kDa) molecular 
weight hyaluronan (n=3). Data presented as mean ± SEM. All data compared relative to Control, 
significance was assumed where P<0.05 (*), P<0.01 (**) or PO.OOl (***).
5.3 Discussion
During this study, interesting information as to possible mechanisms o f action of 
exogenously added HA to Transwell neocartilage grafts, and its effects on cartilage / 
chondrocyte metabolism were concluded. The proteoglycan ‘aggrecan’ is one o f the 
major constituents o f native adult articular cartilage. Aggrecan monomers non-
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covalently associate with a central filament o f hyaluronan, self assembling into 
supramolecular aggregates that are stabilised by a glycoprotein referred to as link 
protein. The endogenous hyaluronan chains present within aggrecan aggregates in 
articular cartilage typically are o f molecular weight ranging between 500 - lOOOkDa 
(Hardingham & Fosang, 1992). The exogenous addition o f different molecular 
weight hyaluronan to neocartilage grafts in Transwell systems that ranged above and 
below the typical molecular weight o f endogenous hyaluronan found in aggrecan 
aggregates o f native articular cartilage were found to have opposing effects.
The addition o f hyaluronan to Transwell cultured grafts that had lower molecular 
weights than the typical Mr o f  endogenous HA found in native aggrecan aggregates 
(i.e. 5kDa, lOOkDa & 250kDa HA) resulted in increased release o f s-GAG to culture 
media (inner and outer wells) compared to experimental Controls (Table 5.7 & 
Figure 5.5). This result is consistent with the theory that ‘smaller’ molecular weight 
hyaluronan compete for newly synthesised and existing aggrecan that was either free 
or present in non-link protein stabilised aggregates, thereby facilitating the 
‘extraction’ or ‘release’ o f these aggrecan / smaller HA aggregates from graft 
extracellular matrices into the media o f the Transwell cultures. However, the addition 
of HA with similar molecular weight (i.e. 1600kDa) to that found in aggrecan 
aggregates releases a similar amount o f percentage s-GAG into culture media as the 
experimental Controls (Table 5.7 & Figure 5.5).
In contrast, addition o f HA to neocartilage grafts o f a significantly higher molecular 
weight (i.e. 2200kDa and 3000+kDa HA) than the typical molecular weight of 
endogenous HA found in aggrecan aggregates, showed decreased s-GAG release to 
media, and increased s-GAG retention within graft extracellular matrices compared to 
experimental Controls (Table 5.7 & Figure 5.5). This implies that the larger 
molecular weight hyaluronan can diffuse into the graft matrices and more efficiently 
‘trap’ newly synthesised and endogenous aggrecan in HA-aggrecan aggregates 
preventing the diffusion o f  this pool o f aggrecan out o f the cartilage graft ECM.
These results demonstrate that very high molecular weight HA can diffuse into the 
cartilage graft ECM and help to entrap newly synthesised and non-link protein 
stabilised ‘free aggrecan’ in its ECM. Thus the clinical use o f HA in 
viscosupplementation procedures for OA patients may be facilitating the retention of 
newly synthesised ‘repair aggrecan’ in the pathological cartilage and thereby slowing 
down the rate o f cartilage destruction through loss o f proteoglycan from the tissue.
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Molecular Weight %  GAG Released to
Hyaluronan Media (.Minus IL-lp) Comment
5kDa (1)
( 2 )
37 (27) 
43 (21) All hyaluronan of molecular weight
lOOkDa ( i )
( 2 )
22 (15) 
27 (25)
■>- <5 OOkDa have increased 
% GAG released to media 
compared to experimental
250kDa (1) 26 (21) Controls
1600kDa ( I > 22 (21) Similar to experimental Control values
2200kDa (1)
(2)
9 (15) 
17 (25) All these (> 1600kDa) 
have decreased % GAG 
release to media compared 
to experimental Controls
3000+kDa (!)
( 2 )
5 (27) 
8 (21)
Table 5.7. Sulphated GAG (%) released into Transwell culture media (inner and outer well) in the 
presence of different molecular weight HA in the absence of IL-1 p. In each case the experimental 
number ( I or 2) is indicated and the appropriate Control for each experiment is in (brackets) next to the 
% GAG released to media.
50
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8 .2 40
8  " 8  3 5  _® 2  35
— 2 30
§  5  2 5 -
0  O 20 -
1000 1000010 100 
Molecular Weight Hyaluronan (kDa) Log
a Hyaluronan Treatment (Expt 1) ♦ Hyaluronan Treatment (Expt 2) 
* Control (Expt 1) Control (Expt 2)
Figure 5.5. Sulphated GAG (%) released into Transwell culture media (inner and outer well) in the 
presence of different molecular weight HA in the absence of IL-1 p. In each case the experimental 
number (I or 2 as in Tabic 5.7) is indicated by the ▲ or ♦ symbols, respectively and the appropriate 
Control for each experiment is represented in grey.
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All o f these above conclusions were independent o f the studies seeking to find out if 
the addition o f varying molecular weight HA can abrogate IL -lp  induced cartilage 
matrix degradation. Regarding the IL -lp  component o f the studies, it appears that 
3ng/ml IL -lp  had minimal but some effects on increasing GAG release to the media 
in some but not all experiments (data not shown). Where this increase was evident, 
there appeared to be an abrogation / reduction in the ‘apparent’ IL -ip  induced GAG 
release with the addition o f  higher molecular weight hyaluronans (e.g. 2200 and 
3000+kDa). None-the-less, the protective mechanism o f high molecular weight 
hyaluronan is unknown and will require further analysis prior to any conclusions 
being made.
The results o f this study were obtained following a 48 hour incubation period of 
neocartilage grafts with the different molecular weight HA. A 24 hour incubation 
period appeared to be insufficient to elicit any s-GAG response, potentially a 
consequence o f delayed aggregation. Bayliss et al, in 1983 reported an initial delay in 
the formation o f link protein - stabilised aggrecan aggregates in human adult articular 
cartilage. At first the Bayliss results appeared to conflict with those previously found 
by Oegema (1980), who had suggested that synthesised proteoglycans in normal 
cartilage were just as capable o f aggregation at 4 hours as they were at 18 hours. 
However, the experimental procedures in both reports determining the ability to form 
aggregates were different. Oegema used mixed disaggregated proteoglycans with 
exogenous hyaluronic acid, but Bayliss allowed re-aggregation in the presence of 
endogenous hyaluronic acid and link protein.
Overall, these results show similarities to recent publications, in that low molecular 
weight hyaluronan is more likely to have detrimental effects on extracellular matrices 
(Solursh et al., 1980, Stern et al., 2006, Iacob & Knudson, 2006, Sugahara et al.,
2006) and high molecular weight HA tend to have beneficial effects (Kang et al., 
1999, Julovi e ta l., 2004, Monfort e ta l., 2005).
5.4 Chapter Summary
•  Interesting results were observed with ‘Control (absence o f IL-1)’ Transwell 
cultures exposed to different molecular weight hyaluronan for 48 hours. The
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IL-1 data has been omitted from this chapter as IL-1 at 3ng/ml resulted in 
minimal or no effect on inducing increased graft matrix degradation following 
a 48 hour treatment period, due to the concentration o f IL -lp used being too 
low.
• When neocartilage grafts were subjected to exogenous hyaluronan of a smaller 
Mwt (i.e. 5kDa, lOOkDa & 250kDa HA) than the typical Mr o f endogenous 
HA (500kDa-1000kDa range) found in native aggrecan aggregates, an 
increased release o f  s-GAG to Transwell media and decreased s-GAG 
retention within neocartilage grafts was observed. This is suggestive that the 
‘smaller’ molecular weight hyaluronan compete for newly synthesised and 
existing aggrecan that was either free or present in non-link protein stabilised 
aggregates, thereby facilitating the ‘release’ o f these aggrecan / smaller HA 
aggregates from graft extracellular matrices into the media o f the Transwell 
cultures.
• HA o f Mwt 1600kDa (slightly larger than endogenously produced HA) had no 
effect on increasing the s-GAG content o f the Transwell culture media.
• In contrast, addition o f HA to neocartilage grafts o f a significantly higher 
molecular weight (i.e. 2200kDa and 3000+kDa HA) than the typical molecular 
weight o f endogenous HA found in aggrecan aggregates, showed decreased s- 
GAG release to media, and increased s-GAG retention within graft 
extracellular matrices implying that the larger molecular weight hyaluronan 
can diffuse into the graft matrices and more efficiently ‘trap’ newly 
synthesised and endogenous aggrecan in HA-aggrecan aggregates preventing 
the diffusion o f this pool o f aggrecan out o f the cartilage graft ECM.
• Therefore, the clinical use o f HA in viscosupplementation procedures for OA 
patients may be facilitating the retention o f newly synthesised ‘repair 
aggrecan’ in the pathological cartilage and thereby slowing down the rate of 
cartilage destruction through loss o f proteoglycan from the tissue.
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6.0 THE GENERATION OF TRANSWELL NEOCARTILAGE 
GRAFT TISSUE IN THE PRESENCE OF DIFFERENT 
MOLECULAR WEIGHT HYALURONAN.
In the previous chapter interesting changes in properties o f Transwell neocartilage 
graft metabolism were observed from the addition o f different molecular weight 
hyaluronan to cartilage grafts following their generation in Transwell culture systems. 
This chapter describes related studies where cartilage grafts were produced over a 4 
week culture period whilst in the presence o f different molecular weight hyaluronan 
with a view to investigating potential beneficial effects o f hyaluronan on cartilage 
graft metabolism for tissue engineering applications.
6.1 Methods
Cartilage grafts were produced in Transwell culture systems using an immature 
chondrogenic source as described in chapter 2.2. However, when chondrocytes were 
added to Transwells they were incubated in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 50fig/ml gentamycin and 20% heat inactivated FBS 
supplemented with lOOpg/ml ascorbate and 5ng/ml TGFp2 (Control) or in the 
presence o f added 3mg/ml hyaluronan o f different molecular weights (i.e. 5kDa, 
490kDa and 3000+kDa). Media (inner and outer wells) was changed and harvested 
thrice weekly (as described in section 2.2). The harvested media was subjected to s- 
GAG analyses and stored at -20°C. Following a 4 week culture period, duplicate 
grafts were analysed for weight (n=2). One set was subjected to histological 
thickness studies and immunohistochemical labelling to assess the presence o f 
commonly found cartilage extracellular matrix molecules (described in section 2.3). 
The other set was subjected to 4M GuHCl extraction for 48 hours, the extract was 
dialysed and s-GAG determined. The remaining neo-cartilage residue following 
proteoglycan extraction was both pepsin and papain digested and s-GAG was 
determined.
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6.2 Results
6.2.1 Zonal M orphology of neocartilage graft tissue produced in the presence 
of different m olecular weight hyaluronan.
Histological zonal organisation approximating to the characteristic surface, middle 
and deep regions found in native adult articular cartilage were overtly evident in the 
Control, 490kDa HA and 3000+kDa HA treated neocartilage grafts, but not in the 
5kDa HA treated graft (F igure 6.1). Grafts produced in the presence o f the low 
molecular weight (5kDa) HA were less alcianophilic, suggestive o f lower 
proteoglycan content in comparison to the other treatments. Interestingly, the ‘mid- 
zone’ of the graft treated with 3000+kDa HA appeared to be thicker in comparison to 
the other treatments (F igure 6.1).
200nm
C o n tro l C o n tro l  + 5kD a C o n tro l + 4 9 0 k D a  HA C o n tro l + 3 0 0 0 +kDa HA
Figure 6.1. Effects of generating neocartilage grafts in the presence of different molecular weight 
hyaluronan upon the histological organisation of engineered constructs. Alcian blue and haematoxylin 
/eosin. Scale bar = 200pm.
The thinnest graft produced (-29%  thinner compared to Control) was that treated with 
the 5kDa HA (Table 6.1). Neocartilage graft tissue produced in the presence of 
490kDa HA was similar in weight to the Control treated graft, although it was
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approximately 11% thinner than the Control (Table 6.1). The addition o f a very high 
molecular weight (3000+kDa) HA during graft production, resulted in an increase in 
graft weight (-47% ) and graft thickness (10.9%) in comparison to the Control (Table 
6.1). A potential explanation o f  these results could be that the extremely low 
molecular weight 5kDa HA is competing for and binding non-link protein stabilised 
aggregates present within the graft extracellular matrix, facilitating the release o f very 
low Mwt link stabilised aggrecan HA aggregates from graft tissue into Transwell 
culture media.
Treatment Average Graft Weight
{mg) (n=2)
Graft Thickness
{piM) (n=l)
Control 22.00 ±2.30 188.71
Control + 5kDa HA 14.90 ±4.10 133.42
Control + 490kDa HA 22.40 ±8.40 168.00
Control + 3000+kDa HA 32.35 ±8.15 209.26
Table 6.1. Weights (n=2) and thicknesses (n=l) of neocartilage grafts produced in the presence of 
different molecular weight hyaluronan. Where applicable data represented as mean ± SEM.
6.2.2 Glycosaminoglycan metabolism in neocartilage graft tissue produced in 
the presence of different molecular weight hyaluronans.
Grafts produced in the presence o f  both 5kDa and 490kDa molecular weight HA 
resulted in an increased release o f sulphated glycosaminoglycan (s-GAG) into 
Transwell culture media (both inner and outer wells) when compared to the Control 
(Table 6.2). The addition o f the 490kDa HA had the greatest effect resulting in 5.23 
fold increase in s-GAG release to media compared to the Control (Table 6.2). The 
presence o f the very high molecular weight (3000+kDa) HA showed a decrease in s- 
GAG released to media in comparison to the Control graft (Table 6.2). Following all 
treatments, more s-GAG was released to the inner insert well compared to the outer 
well o f the Transwell culture system over the 4 weeks culture period. An exception 
was with neocartilage grafts generated in the presence o f  490kDA HA, where slightly 
more s-GAG was released into the outer well (Table 6.2).
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Transwell
Culture
Treatment
g a g  (pg) Total GAG 
release 
compared to 
Control (%)
Inner Well Outer Well Total
Control 731.68 388.76 1120.44 —
5kDa HA 1207.20 504.37 1711.57 52.8 t
490kDa HA 2868.94 2992.63 5861.57 423.4 t
3000+kDa HA 520.13 438.03 958.16 14.5 |
Table 6.2. Sulphated glycosaminoglycan (pg) released to Transwell culture media (inner and outer well) over a 4 
weeks duration by grafts produced in the presence of different molecular weight hyaluronan (n=l).
Neocartilaginous graft tissue produced in the presence o f both 5kDa and 490kDa HA 
retained less s-GAG than Control treated grafts by approximately 70.2% and 7.4%, 
respectively (Table 6.3 & Figure 6.2). Grafts generated in the presence o f a high 
molecular weight (3000+kDa) HA showed a 122.45% increase in s-GAG retention 
compared to the Control (Table 6.3). The presence o f all molecular weight 
hyaluronan treatments (i.e. 5kDa, 490kDa & 3000+kDa) resulted in an increased 
synthesis o f total s-GAG (Table 6.3 & Figure 6.2). Interestingly, grafts produced in 
the presence o f 490kDa HA showed a massive increase (x3.7 fold) in total s-GAG 
synthesis compared to the Control, suggestive that 490kDa HA inclusion within 
Transwell culture systems enhances proteoglycan biosynthesis (Table 6.3 & Figure 
6.2)
Trans well 
Culture 
Treatment
g a g  (pg)
Total GAG 
compared to 
Control (%)
Media
Total
Total in 
4M 
GuHCl
Residue
Total
Pepsin Papain
Control 1120.44 570.60 26.04 23.92 1741 100
5kDa HA 1711.57 144.45 15.47 24.86 1896.35 8.92 t
490kDa HA 5861.57 524.96 23.45 26.08 6436.06 269.68 f
3000+kDa HA 958.16 1328.25 28.96 23.15 2338.52 34.32 t
Table 6.3. Total sulphated glycosaminoglycan (pg) and GAG retention (pg) within neocartilage grafts produced 
over a 4 weeks culture period using a Transwell system in the presence of different molecular weight hyaluronan 
(n=l).
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Figure 6.2. Total sulphated glycosaminoglycan (pg) generated over 4 weeks culture duration by grafts 
produced in the presence of different molecular weight hyaluronan utilising a Transwell system (n=l).
6.2.3 Biochemical and im m unochem ical composition of neocartilage graft 
extracellular m atrices generated in the presence of different molecular 
weight hyaluronans.
Negative Controls showed no non-specific labelling with either primary or secondary 
antibodies (Figure 6.11). Immuno-histochemical labelling o f grafts generated in the 
presence of varying molecular weight hyaluronan revealed that the graft matrix had 
many similarities to immature native articular cartilage. A summary o f these findings 
are provided below.
A. Collagens
Collagen type I labelling was present at the surface and not in the underlying regions 
of all grafts regardless o f treatment (Figure 6.3), showing similarities to native 
articular cartilage (Figure 6.10a ). The band width o f type I collagen labelling within 
the surface region o f the grafts, increased with an increasing molecular weight
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hyaluronan (Figure 6.3). The largest and most diffuse band width of collagen type I 
labelling was observed in the grafts produced in the presence of 3000+kDa HA. The 
surface region o f the graft treated with the high molecular weight hyaluronan 
appeared to be extremely disorganised (Figure 6.3).
Figure 6.3. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of Type I collagen labelled with polyclonal Ab #70-XR90 in neocartilage graft tissue. 
Scalebar represents lOO^ im.
Type II collagen labelling was present throughout graft matrices following all 
treatments (Figure 6.4) as is observed in native articular cartilage (Figure 6.10b ), 
confirmatory o f the tissues hyaline nature. However, type II collagen labelling 
appeared more intense in the surface and deep zones, with less labelling within the 
mid zone (Figure 6.4). This was more apparent with the addition of the higher 
molecular weight hyaluronan (490kDa & 3000+kDa), potentially suggesting that the 
higher Mwt HA could be masking collagen type II labelling. However, all treatments 
were chondroitinase ABC and keratanase digested prior to labelling, eliminating this 
possibility showing that labelling is not affected by epitope masking.
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Control 5kDa HA 490kDa 3000kDa HA
Figure 6.4. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of collagen type II labelled with mAh CIICI in neocartilage tissue. Scalebar represents 
100 pm.
(B) G lycosam inoglycans
It would be expected that the chondroitin sulphate glycosaminoglycans would show 
similar distribution to aggrecan, suggestive o f their association with the large 
proteoglycan. Chondroitin-O-sulphate (C-O-S) labelling on chondroitinase generated 
neoepitope ‘CS-stubs’ (Caterson et al., 1990) were present throughout the whole o f 
the grafts, especially in the graft produced in the presence o f 5kDa HA (Figure 6.5). 
Although, labelling o f all grafts show a more intense labelling within the deep zone 
that occurs to a lesser extent in the 5kDa HA treated graft. This shows similarities to 
native articular cartilage as the highest concentration o f proteoglycan (i.e. aggrecan) 
in which CS associates is found within the deeper regions.
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Control 5kDa HA 490kDa 3000kDa HA
Figure 6.5. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of GAG (C-O-S) labelled with mAb l-B-5 in neocartilage tissue. Scalebar represents 
100 pm.
Immuno-labelling for chondroitin-4-sulphate (C-4-S) on chondroitinase generated 
neoepitope ‘CS-stubs’ was evident throughout the entire graft ECM, but appeared 
weaker in the presence o f 5kDa HA (Figure 6.6). This is expected, as the GAG (CS) 
would show similar distribution to aggrecan suggestive o f GAG association with large 
proteoglycans (Figure 6.10g ).
Control 5kDa HA 490kDa 3000kDa HA
Figure 6.6. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of GAG (C-4-S) labelled with mAb 2-B-6 in neocartilage graft tissue. Scalebar represents 
100 pm.
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Chondroitin-6-sulphate (C-6-S) ‘CS-stubs’ showed weak labelling throughout graft 
tissue extracellular matrix regardless of treatment, with a more predominant staining 
within the deep region (Figure 6.7). This is an indicative o f the immaturity of the 
neocartilage grafts and shows similar labelling as would be observed in immature 
native articular cartilage (Figure 6.1 On).
Control 5kDa HA 490kDa 3000kDa HA
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Figure 6.7. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of GAG (C-6-S) labelled with mAb 3-B-3 in neocartilage tissue. Scalebar represents 
100 pm.
(C) Small Leucine Rich Proteoglycans (SLRPs)
The class I small leucine rich proteoglycans, decorin (Figure 6.8) and biglycan 
(Figure 6.9) were detectable throughout graft tissue. Both SLRPs, but decorin in 
particular, were more predominant in the surface zone o f the tissue and diminished 
with depth, as occurs in native cartilage (Figures 6 .10c &d ) (Miosge etal., 1994). The 
grafts generated in the presence o f 3000+kDa HA showed a more intense thicker band 
width labelling at the surface zone for both decorin and biglycan in cpmparison to the 
other treatments (Figure 6.8 & Figure 6.9). The distribution of decorin is similar to 
that observed for Type I collagen (Figure 6.3) labelling, suggestive that decorin 
maybe associating with this collagen.
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Figure 6.8. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of decorin labelled with mAb 28.4 in neocartilage tissue. Scalebar represents 100pm.
I H
Figure 6.9. The effects of varying molecular weight hyaluronan present during graft generation on the 
distribution of biglycan labelled with mAb PR8A4 in neocartilage tissue. Scalebar represents 100pm.
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Figure 6.10. Positive Controls. Immunohistochemical composition of immature Native Bovine Articular Cartilage ECM. Sections have been labelled 
(green) with a panel of antibodies towards chief structural components of the extracellular matrix, i.e. Collagens (A&B), Proteoglycans (C&D) and 
glycosamnoglycans (E-H) in the presence or absence of chondroitinase enzyme. Cell nuclei have been counterstained red with propidium Iodide. C-O-S, 
Chondroitin-O-sulphate. C-4-S, Chondroitin-O-sulphate . C-6-S, Chondroitin-6-sulphate. Scalebars = 100pm.
Plus Minus
Enzyme Enzymes
Plus Minus
Enzyme Enzymes
•Figure 6.11. Negative Control neocartilage sections were incubated with PBS (Omit Primary), 10|jg/ml mouse immunoglobulins (Mlg), or Rabbit 
immunoglobulins (Rig) instead of Primary antibody, with or without the enzymatic digestion step. Scalebar represents lOOpm
6.3 Discussion
During this study, due to limited n number o f replicates it was difficult to make 
definitive conclusions o f  any significance from the data obtained. However, grafts 
produced in the presence o f different molecular weight hyaluronan utilising a 
Transwell culture system were found to have profound differences in graft 
extracellular matrix composition and biosynthetic capacity.
All treatments (i.e. Control, 490kDa HA and 3000+kDa HA) with the exception o f 
5kDa HA produced grafts that were stratified into well-defined cartilaginous zones 
that approximated with the superficial, middle and deep layers o f adult articular 
cartilage. However, neocartilage tissue generated in the presence o f  the 3000+ kDa 
HA appeared to have a thicker ‘mid zone’ in comparison to other treatments, with a 
more disorganised surface zone.
Immunofluorescent labelling patterns obtained with a panel o f  antibodies towards 
commonly found cartilage extracellular matrix molecules suggested that regardless o f 
treatment, all grafts showed a similar immunohistochemical distribution of; (1) 
collagens (Types I and II); (2) Glycosaminoglycans (C-O-S, C-4-S and C-5-S); and (3) 
The small leucine-rich proteoglycans (decorin and biglycan) to immature native 
articular cartilage. However, increasing the Mwt o f HA used in graft generation, 
resulted with less Type II collagen labelling within the ‘mid region’ o f grafts, and an 
increased (more diffuse) labelling o f Type I collagen, decorin and biglycan within the 
surface region o f grafts.
Similar to the results found in the previous chapter, neocartilage grafts produced in 
the presence o f an extremely low molecular weight (5kDa) HA caused increased 
levels o f s-GAG (i.e. presumably proteoglycan (aggrecan)) to be released into the 
Transwell culture media (inner and outer wells) and less s-GAG to be retained within 
the graft. The measurements obtained for graft weight and thickness corroborated 
with the s-GAG results, as did the histological findings that grafts produced in the 
presence o f  5kDa HA were the least alcianophilic. A potential explanation is that the 
5kDa HA oligomers compete for aggrecan binding, resulting in the release o f non-link 
protein stabilised aggrecan from graft extracellular matrices.
The presence o f  a very high molecular weight (3000+kDa) HA resulted in the 
production o f a more enriched graft, o f increased weight and thickness compared to
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all other treatments, with less s-GAG being released to media (inner and outer well) 
and more s-GAG being retained within grafts (as in previous chapter). The addition 
o f the very high molecular weight HA appears to cause retention o f  aggrecan within 
the tissue. This is suggestive that the high molecular weight HA is able to diffuse into 
graft extracellular matrices and entrap the aggrecan monomer in very large aggrecan 
aggregates. W hether or not these larger aggregates were link protein stabilised was 
not determined in this experiment.
Interestingly, grafts produced in the presence o f  a hyaluronan (i.e. 490kDa) with a 
similar molecular weight to endogenous HA were similar in weight and thickness to 
Control treated grafts, but resulted in a x3.7-fold increase in the total s-GAG 
synthesised over a 4 weeks culture period. This particular molecular weight HA 
appeared to increase the anabolic process o f neocartilage grafts and its inclusion in 
chondrocyte transplantation protocols may significantly improve cartilage repair in 
tissue engineering procedures. This study needs to be repeated with a larger range o f 
different molecular weight HA that are less than and greater than the 490kDa HA.
As discussed previously in chapter 5, injections o f  high molecular weight HA are 
used clinically as an accepted visco-supplementation procedure to treat degenerative 
joint diseases (e.g. OA) to eliminate pain and reduce the rate o f cartilage degradation. 
However, the mechanisms o f action o f  this H A  visco-supplementation treatment are 
at present unclear but potential anti-inflammatory and ‘anabolic’ effects o f HA on 
chondrocyte / cartilage metabolism have been implied in the literature. Collectively, 
this data suggest that HA visco-supplementation procedures should incorporate the 
use o f a mixture o f HA M wt sizes in the range o f 490kDa - 3000+kDa HA in order to 
provide optimal benefits o f  aggrecan retention and biosynthesis to OA patients 
receiving this treatment modality.
6.4 Chapter Summary
•  Neocartilage grafts produced over a 4 week culture period in the presence o f 
different molecular weight hyaluronan, support the previous conclusions 
obtained in chapter 5, where grafts were treated after they were generated 
with different molecular weight hyaluronan.
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• Neocartilage grafts subjected to exogenous hyaluronan o f a smaller Mwt (i.e. 
5kDa) than the typical Mr o f  endogenous HA (500kDa-1000kDa range) 
found in native aggrecan aggregates, showed an increased release o f s-GAG 
to Transwell media and decreased s-GAG retention within neocartilage grafts 
supported by graft weight thickness and histological findings. This is 
suggestive that the ‘sm aller’ molecular weight hyaluronan compete for newly 
synthesised and existing aggrecan that was either free or present in non-link 
protein stabilised aggregates, thereby facilitating the ‘release’ o f these 
aggrecan / smaller HA aggregates from graft extracellular matrices into the 
media o f the Transwell cultures.
•  In contrast, addition o f HA to neocartilage grafts o f  a significantly higher 
molecular weight (i.e. 3000+kDa HA) than the typical molecular weight of 
endogenous HA found in aggrecan aggregates, showed decreased s-GAG 
release to media, and increased s-GAG retention within graft extracellular 
matrices implying that the larger molecular weight hyaluronan can diffuse 
into the graft matrices and more efficiently ‘trap’ newly synthesised and 
endogenous aggrecan in HA-aggrecan aggregates preventing the diffusion o f 
this pool o f aggrecan out o f the cartilage graft ECM.
• Interestingly and additionally, this data provides evidence that chondrocytes 
exposed to exogenous hyaluronan o f  similar molecular weight (i.e. 490kDa) 
to the typical Mr o f  endogenous HA (500kDa-1000kDa range) found in 
native aggrecan aggregates resulted in a marked effect on the rate and 
amount o f aggrecan synthesised (3.7 fold greater) compared to Control 
grafts.
•  Collectively, the data obtained from both chapters 5 and 6 suggest that a 
potential improvement upon HA visco-supplementation procedures would be 
to incorporate a mixture o f M wt H A  ranging between 490kDa-3000+kDa as
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to provide optimal benefits o f aggrecan retention and biosynthesis to OA 
patients receiving this treatment modality.
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7.0 GENERAL DISCUSSION
There has been recent interest in cartilage repair strategies with a particular focus on 
cell based, tissue engineering approaches (Kim et al., 2000, Risbud and Sittinger., 
2002 and Kuo et al., 2006). This involves the delivery o f culture expanded 
autologous chondrocytes to  a cartilage lesion site either; (1) in suspension under a 
sutured covering i.e. autologous chondrocyte implantation (ACI) (Brittberg et a l, 
1994) or (2) utilising a biodegradable scaffold or carrier that provides a three- 
dimensional biomimetic environment that facilitates cell delivery (Hutmacher 2000, 
Hunziker 2001, M ahmoudifar and Doran., 2005, Geffre et al., 2008). The implanted 
chondrocytes within the defect synthesise and lay down an extracellular matrix, 
generating tissue that to a certain extent resurfaces the site o f injury and restores joint 
functionality (Brittberg et al., 1994).
These cell based therapies are an improvement upon preceding cartilage repair 
strategies, such as microfracture (Steadman et al., 2001) and mosaicplasty (Hangody 
et al., 1997 & 1998). However, it has been reported that sutured membrane coverings 
plus the injected chondrocytes in some circumstances are lost to the synovial cavity 
during the recovery period (Driesang and Hunziker 2000). There are also concerns 
that cartilage resurfacing is limited and unsatisfactory integration occurs between 
native cartilage and the repair tissue. The reparative tissue generated, remains 
problematic, as it consists o f mixed morphologies ranging between hyaline-like and 
fibro-like cartilage (Henderson et al., 2007, M oriya et al., 2007).
In 1995, Kandel et al reported a potentially improved approach over traditional cell 
based therapies, that involved engineering neo-cartilage grafts ex vivo {from high 
density primary chondrocytes seeded onto either porous, collagen coated synthetic 
membranes or as biphasic constructs consisting o f cartilaginous tissue generated 
upon a calcium polyphosphate substrate) using a Transwell culture system and 
implanting the developed graft within a defect site (Kandel et al., 1995). This 
strategy has potential advantages as; (1) there would be no requirement o f a 
periosteal/collagen covering or a scaffold carrier as the graft would exist as a fully 
differentiated matrix; (2) the initial generation o f cartilage grafts would be highly 
regulated in culture, as most non-gaseous graft metabolites produced throughout the 
culture duration can be monitored, which is impossible to achieve in a diseased or
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damaged joint; and (3) potentially a larger degenerate area o f the joint could be 
repaired and resurfaced, arthroscopically reducing a patients rehabilitation time.
The results o f this study add to previous data (e.g. chiefly arising from the Kandel 
laboratory) showing that neo-cartilage grafts generated ex vivo from immature 
chondrocytes seeded at high cell densities in Transwell cultures produced opaque, 
hyaline tissues with potential to  treat articular cartilage defects. All tissues generated 
from a primary immature chondrogenic source following just two weeks o f culture 
were stratified into distinct zones approximating to the superficial, middle and deep 
regions. This morphological stratification became more apparent with increased time 
and cell seeding density.
In our laboratory, cell tracker studies eliminated the possibility that zone specific cell 
sorting contributed to zonal formation in neo-cartilage grafts as minimal inter-zonal 
chondrocyte movement occurred (Hayes et al., 2007). The formation o f the distinct 
strata in Transwell cultured grafts could potentially be explained by: (1) the effects 
subjected on the grafts due to the environment o f the culture system, or (2) the 
generation o f a metabolic / morphological gradient (i.e. nutrient, oxygen or pH) 
occurring between the graft’s tissue surface and the basal region.
Although distinct cartilaginous zones were observed within the neo-cartilage grafts, 
no identifiable calcified zone was observed. In the literature, methodologies have 
been reported that encourage calcification in engineered constructs, such methods 
include the addition o f  phosphoethanolamine (PEA), P-glycerophosphate (P-GP) or 
adenosine triphosphate (ATP) to deep zone chondrocytes (Kandel et al., 1997). This 
is suggestive that the addition o f PEA, P-GP or ATP to outer Transwell culture media 
during graft generation could potentially promote the formation o f  a calcified zone 
similar to that observed in native articular cartilage. M ore recent advances involve 
the generation o f neo-cartilage tissue on bone substitute calcium polyphosphate 
(CPP); this has been found to  improve graft integration with bone within a cartilage 
defect (Waldman et al., 2007, Pilliar et al., 2007). The presence o f  a calcified zone in 
reparative tissues has been reported to increase both tissue stiffness and interfacial 
shear properties at the cartilage-CPP interface (Allan et al., 2007).
At both histological and ultrastructural levels chondrocyte morphology and collagen 
fibril organisation within neocartilage zones, showed a resemblance to mature native 
articular cartilage. In the superficial region chondrocytes were discoidal in 
appearance surrounded by a sparse, meshwork o f collagen fibrils that had a prominent
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horizontal organisation. Chondrocytes located in the mid region were small, 
spheroidal, pre-hypertrophic cells that were widely spaced within an extracellular 
matrix that was comprised o f well defined pericellular, territorial and interterritorial 
compartments. In the deep zone chondrocytes were large, hypertrophic cells that 
were densely packed together and appeared to acquire a more columnar organisation 
with an increased culture period. Collagen fibrils within the deep zone were 
vertically arranged with respect to the grafts superficial region. Similar to native 
articular cartilage, neo-cartilage grafts became progressively more alcianophilic with 
tissue depth from the superficial region to the basal portions, indicating increased 
proteoglycan content.
During this study, using a Transwell system, it appeared that an increased cell seeding 
density and culture duration generated grafts o f  increased cellularity and thickness, 
respectively. The optimal culture conditions required for neo-cartilage graft 
production for analyses throughout this project were determined histologically with 
respect to mature native articular cartilage, they were found to be a cell seeding 
density o f  4 -6x106 cells over 4 weeks culture duration. Potentially, this study could 
have been improved if  optimum culture conditions for graft production were not 
determined from histological data alone, but also from intensive biochemical analysis 
showing how both cell density and culture duration affected graft: (1) mRNA 
expression and protein levels (<identifying i f  any vital extracellular matrix (ECM) 
components are missing that may jeopardise the integrity o f the neo-cartilage graft 
matrix) (2) proteoglycan concentrations and (3) collagen concentrations compared to 
native articular cartilage.
At optimum culture conditions neo-cartilage graft tissues generated from an immature 
chondrogenic source were more synthetically active compared to those produced from 
a mature chondrogenic source, generating significantly higher amounts o f both total 
sulphated glycosaminoglycan (s-GAG) and collagen. A higher content o f both s- 
GAG and collagen were found to be retained within grafts produced from an 
immature chondrogenic source, in comparison to a mature chondrogenic source. 
Clinically, it is more likely that a mature cell source would be utilised in cell therapy 
treatments, therefore it would be desirable to identify culture conditions that 
potentially could improve the synthetic capacity o f mature chondrocytes. It would 
have been interesting to have compared how both s-GAG and collagen concentrations 
in both immature and m ature cartilaginous grafts, compared with the s-GAG and
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collagen concentrations o f  the native cartilage tissues to which the chondrogenic 
sources were originally isolated. An interesting characteristic o f the Transwell culture 
system was that more s-GAG was found to be released to the inner insert media in 
comparison to the outside media, and the opposite was observed for collagen release. 
Interestingly, immunohistochemical (IHC) labelling assessing the presence o f 
commonly found cartilage extracellular matrix molecules revealed that graft tissue 
composition closely resembled immature native articular cartilage, unlike the 
histological findings that resembled mature native articular cartilage. Type I collagen 
labelling was predominant at the surface o f the grafts and both aggrecan and type II 
collagen labelling were present throughout the whole depth o f  the graft tissue, as 
found in native articular cartilage. However, the immaturity o f the tissue was 
reflected by the fact both collagen type X and chondroitin-6-sulphate (C-6-S) ‘stubs’ 
were not detectable in neo-cartilage tissues following a 4 week culture period. 
Extension o f the graft culture period to more than 12 weeks resulted with weak 
association o f  type X collagen within the pericellular matrix o f hypertrophic 
chondrocytes within the basal zone. These findings are not particularly surprising, as 
grafts were generated over a four week time frame using an immature chondrogenic 
source.
The mechanical strength o f  neo-cartilage tissue generated during this study was not 
quantified, but graft pliability during handling indicated that they lacked the 
mechanical stiffness o f mature articular cartilage. In the literature, it has been reported 
that applying a force in Transwell culture greatly improved the mechanical properties 
and stimulated the synthesis o f  extracellular component proteins affecting the overall 
structure o f the engineered tissues (W aldman et al., 2003, 2006 & 2007). The 
application o f  mechanical forces during tissue engineering have been found to have 
many effects such as; altering sulphation patterns on chondroitin sulphate GAG 
chains (Sauderland & Steinmeyer 2007), increasing decorin concentrations suggestive 
that decorin through interactions w ith type II collagen may aid cartilage adaptation to 
increased loading (Visser et al., 1994), induces the down regulation o f BMP-3 an 
inhibitor o f cartilage differentiation enabling the induction o f  cartilage (Aspenburg et 
al., 2000), increases levels o f  chondrogenic markers such as aggrecan, Type II 
collagen and SOX 9 and decreases levels o f  more fibroblastic markers such as type I 
collagen (Miyanishi et al., 2006), Kawanishi et al., 2007). The application o f surface 
motion, but not axial m otion to  chondrocytes has been found to stimulate the
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production o f superficial zone protein (SZP), aiding the generation o f normal articular 
cartilage (Grad et al., 2005). It is known that load bearing tissue in the absence o f 
mechanical forces will atrophy. Therefore, applying a force to Transwell cultures 
during graft generation could potentially optimise the functional value o f the neo­
cartilage tissue for the repair process. Alternatively, the engineered constructs could 
be modified post-implantation by physiotherapy.
One potential problem for the use o f  grafts in the repair process is the integration o f 
neo-cartilage repair tissue to adjacent native articular cartilage within defects. Kandel 
et al in 1995 found that the absence o f  an adhesive was more productive than the 
presence o f  an adhesive, enhancing grafts to remain in position within full thickness 
defects. However, maintaining graft positioning within intra-chondral defects was 
poor and required further analysis. There is potential to improve integration between 
repair tissue and native cartilage at a defect site, as proteoglycans carrying dermatan 
sulphate GAG chains are thought to inhibit cell attachment. Following the 
debridement o f a defect site, and prior to implantation o f  repair tissue to the defect 
site, dermatan sulphate could be removed from the surfaces o f  the defect by 
enzymatic treatment (using Chondroitinase ABC) having the effect o f encouraging 
cell attachment (Brittberg 1999). A more recent suggestion is to use a biopolymer to 
develop a novel bio-adhesive that enables integration between both native cartilage 
and repair tissue. One proposed bio-adhesive is a chemically modified chondroitin 
sulphate that has both methacrylate and aldehyde groups on its polysaccharide 
backbone to chemically bridge biomaterials and tissue proteins via 2 fold covalent 
cross-links (Wang et al., 2007).
All neo-cartilage graft experimentation within this study utilised animal chondrogenic 
sources that were o f  plentiful supply. However, the use o f neo-cartilage grafts for 
clinical application would require human chondrogenic sources to minimise recipient 
rejection; these are o f  a more limited supply. Neo-cartilage grafts are produced ex 
vivo from high cell seeding densities and for clinical use an unavoidable necessary 
step would be to increase chondrocyte cell numbers using monolayer culture. Cell 
culture expansion results in the undesirable de-differentiation o f  chondrocytes to a 
more fibroblastic state, accompanied by the up-regulation o f type I collagen and the 
down regulation o f aggrecan, type II collagen and matrix specific genes SOX 5, 6, 
and 9 (Binette et al., 1998). It has been reported that re-differentiation of 
chondrocytes can be stimulated by placing them into 3-dimensional (<alginate or
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agarose) or high cell seeding density cultures (Transwell or pellet). Although, re­
differentiation potentially may encourage hypertrophic differentiation, dramatically 
diminishing chondrocyte ability to produce hyaline tissue (Benya et al., 1978, Stokes 
et al., 2001, Yang et al., 2006).
In this study, chondrocytes were isolated from both immature and mature bovine full 
depth cartilage and were culture expanded {passaged) from 0 (P0) to 5 (P5) times, 
then each chondrogenic source following each passage was seeded into high cell 
density Transwell cultures to find out if  the culture system encouraged re­
differentiation o f  de-differentiated chondrocytes. It was shown that with an 
increasing passage number o f  the chondrogenic source, the grafts generated 
increasingly lacked the distinct appearance o f  native articular cartilage. The immature 
cell source is excellent at producing large amounts o f extracellular matrix, but is not 
clinically relevant or even practical. The mature chondrogenic source has poor 
synthetic abilities in comparison to the immature cell source, and they produce grafts 
lacking a zonal architecture, with little matrix, appearing extremely cellular. One 
possible explanation for this could be that in vivo the natural repair process as well as 
environmental factors change the phenotype o f  the mature chondrocyte to a more 
fibroblastic state. Therefore mature chondrocytes de-differentiate prior to the cell 
isolation, expansion and seeding onto filter inserts for graft production, de­
differentiated cells lose their zonal differences.
After both the immature and mature chondrogenic sources had been passaged three 
times (P3) they lost the ability to re-differentiate. No grafts were produced from the 
immature cell source and grafts produced from the mature source were very thin, 
suggesting that prior to this point the chondrocytes had undergone a phenotypic 
change and de-differentiated. The capacity o f  the chondrogenic sources to lay down 
an extracellular matrix was restored following successive passages o f  the cells after 
P3, although the zonal organisation o f  hyaline cartilage was not apparent, appearing 
more fibrocartilaginous in nature. This was supported by IHC labelling showing that 
with an increased passage number neo-cartilage grafts showed decreased staining 
intensity for aggrecan labelling and increased labelling for type I collagen. 
Histological analysis o f neo-cartilage grafts generated from an immature source that 
had been passaged 4 and 5 times revealed that engineered grafts contained discrete 
cell clusters within the basal portion, that IHC labelled spatiotemporally for versican 
suggestive that P4 and P5 grafts resembled a more fibrocartilaginous tissue. Parallel
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results o f other studies in the literature support these findings, showing that 
phenotypic changes occur in culture expanded chondrocytes between PO (primary 
chondrogenic source) and P4 (chondrogenic source that had been passaged 4 times) 
(De Haart et al., 1999, Honda et al., 2004, Chua et al., 2005).
Therefore, there is still a need to discover ways o f bulking out chondrocyte numbers 
preventing the detrimental effects o f cellular de-differentiation. Ideally, the culture 
conditions utilised need to encourage chondrocyte differentiation ( if working with a 
cell source that is not committed to the chondrogenic lineage) and suppress 
chondrocyte hypertrophy. The transcription factor SOX-9 has been found to be an 
essential factor in chondrocyte differentiation functioning as a potent inhibitor of 
chondrocyte hypertrophy. It has been reported that passaged human osteoarthritic 
chondrocytes show an increased collagen type II expression in monolayer culture 
when transduced using adenoviral or retroviral vectors o f SOX 9 (Tew et al., 2005).
It would be advantageous if  a detailed understanding o f the effects various culture 
methodologies (i.e. following chondrocyte isolation, during monolayer culture and 
re-differentiation in Transwell culture) have on chondrocytes and the extracellular 
matrix in which they generate were established. Changes in cartilage matrix mRNA 
expression levels, protein levels and paracrine signalling molecules could be used as 
markers to determine the chondrocytic state at each culture stage; i.e. differentiated 
(CDMP-J, Wnt 5a &b, BMP-13 and B M P S down regulation, Type II collagen and 
aggrecan expression), de-differentiated (Monoclonal antibody II-fibrau, type I  
collagen up-regulation) or hypertrophic to terminally differentiated (BMP-6, Type X  
collagen, alkaline phosphatase, osteopontin, Wnt 5a and b). An improved basic 
knowledge in this area would help clinicians intervene in attempt to prevent bio- 
artificial cartilage from losing its stability.
The optimisation o f culture conditions as to  prevent the de-differentiation o f 
chondrocytes will play an imperative role in future advancement o f  Transwell 
cultured neo-cartilage grafts. It has been reported that low oxygen conditions in 
culture help maintain the stability o f  a chondrocytes phenotype and stimulates the re­
differentiation o f  de-differentiated chondrocytes (Brittberg 1999). Recently, it has 
been reported that the amount o f  collagen cross-links present within neo-cartilage 
grafts are affected by oxygen concentrations. During this study, there were 
indications that neo-cartilage graft matrices were loosely packed together, as quite 
high amounts o f s-GAG were released to culture media in Control treated grafts. The
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lack o f collagen cross-linking in neo-cartilage grafts may be a consequence o f the 
highly potent mitotic TGF-P2 being present in Transwell media, an agent known to 
decrease the number o f  collagen cross-links within extracellular matrices (Jenniskens 
et al., 2006). Therefore, it would be interesting to investigate the effects varying 
oxygen tensions in Transwell culture have on graft generation.
The presence o f  serum in culture media has been found beneficial for increasing cell 
numbers, but consequentially serum containing media decreases cartilage matrix gene 
expression (Malpeli et al., 2004), altering chondrocyte morphology encouraging them 
to become more fibroblastic (Chua et al., 2005). The presence o f serum within 
culture media could potentially impede culture analyses, as serum contains exogenous 
growth factors that hinder the identification and quantification o f  the growth factors 
generated from cultured chondrocytes (Kita et al., 2006). In future analyses, 
decreasing serum concentrations used in Transwell culture systems could potentially 
prevent any recipient immune reactions against engineered neo-cartilage grafts due to 
the presence o f foreign bodies or viral proteins (Chua et al., 2005). One potential step 
towards a serum free environment would be to develop chemically defined serum 
supplements (Heng et al., 2004). Some cells are unable to  proliferate in serum free 
environments and require supplementation w ith Insulin-Transferrin-Selenium (ITS), 
FGF or TGF-p in the presence o f  a small percentage o f serum.
It is important to add the right factor at the right moment during the various culture 
stages as to optimise culture media. In the literature, it has been reported that addition 
o f FGF-2 to culture media stimulates chondrocyte differentiation, proliferation 
(Takahashi et al, 2005, Jingushi et al., 2006 & M iot e ta l ., 2006), re-differentiation o f 
expanded chondrocytes (M iot et al., 2006) and inhibits the hypertrophic state 
(Tchetina et al., 2006). Parathyroid hormone / parathyroid hormone related protein 
(PTH/PTHrP) have also been found to inhibit the hypertrophic state, whereas insulin 
sends chondrocytes to  hypertrophy (Liu et al., 2007). In the future, investigating the 
effects addition o f various factors to Transwell culture media have on neo-cartilage 
grafts could potentially improve tissue quality.
There are alternate cell sources other than chondrocytes that show potential for future 
generation o f  Transwell cultured grafts these include; stem cells, progenitor cells and 
spore-like cells. Both adult stem cells and spore-like cells have been reported to be 
activated in normal tissue turnover, by injury or disease, possibly acting as a body’s 
natural repair mechanism. I f  these particular cells were found to be located in
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articular cartilage {i.e. to date a progenitor cell has been located in the surface zone o f 
articular cartilage (Dowthwaite et al., 2004)), then future cartilage repair therapies 
may minimise patient operations excluding the need for autologous chondrocyte 
implantations or the generation o f tissues ex vivo, alternatively activating these cells 
in situ inducing a cartilage repair response. There are three types o f  stem cells i.e. 
totipotent (<obtained from the earliest stages o f development), pluripotent {embryonic 
stem cells (ESC) and embryonic germ cells) and multipotent {Adult stem cells found in 
specialised organs after birth, such as: bone marrow, blood, skin, GI tract, dental 
pulp, retina o f the eye, skeletal muscle, liver, pancreas and the brain), all o f which are 
found at various stages throughout development. Stem cells that are obtained in the 
later stages o f development are more functionally inept in comparison to stem cells 
found in earlier developmental stages.
There are both moral and ethical considerations that arise surrounding the use of 
pluripotent embryonic stem cells. They are an immortal cell source with the ability to 
provide an unlimited supply o f  chondrocytes (Heng et al., 2004). However, there is 
no evidence that ESCs can consistently be driven down the correct lineage resulting in 
the generation o f a mixed population o f  cells. Adult stem cells are limited to produce 
one or more lineages o f  specialised cells depending on the potential o f the source, 
where it originated and environmental cues to which the source is subjected. They 
have the ability to self renew and last throughout a lifetime o f  an organism, this 
proving advantageous in medical transplantations, as adult stem cells would supply an 
unlimited donor material. However, the ability o f adult stem cells to self replicate and 
proliferate diminishes w ith age (Redman 2005).
Mesenchymal stem cells are a multipotent stem cell source that has been o f  recent 
interest in the literature for future tissue engineering applications. They originate 
from the mesodermal layer o f  a blastocyst in a developing embryo and have the 
capacity to develop into cartilage, bone, tendon, adipose tissue and muscle (Redman
2005). Transdifferentiation to  a chondrogenic lineage from another tissue type (i.e. 
bone, tendon, adipose tissue or muscle) have been reported, but is a rare and sporadic 
event proving difficult to cross boundaries and maintain a desired phenotype. 
Specific environmental cues acting upon the cell source are responsible for the 
maintenance o f a desired cell lineage, changes in the environmental cues in which a 
cell source is subjected would drive the cell source down an undesired lineage as 
would occur at the transplantation site.
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Progenitor cells occur in foetal and adult tissues and are committed to a cell lineage 
(Vacanti 2004); they are generated by condensations o f stem cells and are unable to 
self renew. They are parent cells that give rise to a distinct cell lineage by a series o f 
cell divisions that are coupled with cell maturation o f  the specialised cell. Progenitor 
cells have similar properties to stem cells with an undifferentiated nature and a 
capacity to proliferate. An articular cartilage progenitor has been isolated from the 
superficial zone o f  bovine articular cartilage (Dowthwaite et al., 2004). These surface 
zone progenitor cells are thought to allow appositional growth o f articular cartilage 
from the surface (Hayes et al., 2001).
Spore-like cells are ubiquitous and are found in a dormant form dispersed throughout 
the parenchyma o f  most tissues. They are small cells ranging less than 5 pm, there are 
concerns as to whether 5pm  diameter cells could contain the whole genome and the 
concept o f a minimal genome is beginning to emerge (Vacanti 2004). Spore-like cells 
are small undifferentiated cells that contain a nucleus, a small amount o f cytoplasm, a 
few mitochondria and a coating o f  glycolipid and mucopolysaccharide. They also 
have a mitotic cleft which is supportive o f cell division. These cells have the ability 
to withstand hostile conditions such as a low oxygen environment and extreme 
temperature, still maintaining the capacity to  proliferate and differentiate. Spore-like 
cells have the ability to differentiate into mature cells o f the tissue from which they 
were isolated (Vacanti et al., 2001). As the cells possess the ability to replicate, 
differentiate and survive extreme temperatures and hypoxic conditions, they may have 
many potential clinical uses in the future (Vacanti et al., 2001).
Therefore, it can be concluded that there is significant potential in the continued 
development o f autologous chondrocyte grafts for the repair o f human articular 
cartilage defects. However, there is still immense room for improvement o f the 
Transwell culture system by: optimising both Transwell culture medium and 
methodologies, utilising gene therapy and investigating the potential o f new cell 
sources as to minimise the deleterious effects o f cellular de-differentiation.
The latter half o f  this study utilised the Transwell system as a culture model to 
determine how the addition o f  exogenously added hyaluronan (o f varying molecular 
weights (Mwt) ranging from 5-S000fkDa), during and post neo-cartilage graft 
generation affected cartilage / chondrocyte metabolism. The size o f  endogenous 
hyaluronan (HA) produced by chondrocytes to form aggrecan aggregates in hyaline 
articular cartilage is in the range o f  500kDa to lOOOkDa (Hardingham & Fosang,
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1992). Interestingly, when neocartilage grafts were subjected to exogenous 
hyaluronan o f  a smaller M wt {i.e. 5kDa, lOOkDa & 250kDa HA) than the typical Mr 
of endogenous HA {500kDa-1000kDa range) found in native aggrecan aggregates, an 
increased release o f  s-GAG to Transwell media and decreased s-GAG retention 
within neocartilage grafts was observed. This is suggestive that the ‘smaller’ 
molecular weight hyaluronan diffuse into the graft extracellular matrix and compete 
for newly synthesised and existing aggrecan that was either free or present in non-link 
protein stabilised aggregates, thereby facilitating the ‘extraction’ or ‘release’ o f these 
aggrecan / smaller H A  aggregates from graft extracellular matrices into the media o f 
the Transwell cultures.
However, HA o f  M wt 1600kDa {slightly larger than endogenously produced HA) had 
no effect on increasing the s-GAG content o f  the Transwell culture media. In 
contrast, addition o f  HA to neocartilage grafts o f a significantly higher molecular 
weight {i.e. 2200kDa and 3000+kDa HA) than the typical molecular weight o f 
endogenous HA found in aggrecan aggregates, showed decreased s-GAG release to 
media, and increased s-GAG retention within graft extracellular matrices implying 
that the larger molecular weight hyaluronan can diffuse into the graft matrices and 
more efficiently ‘trap’ newly synthesised and endogenous aggrecan in HA-aggrecan 
aggregates preventing the diffusion o f  this pool o f aggrecan out o f the cartilage graft 
ECM.
Interestingly and additionally, it was found that chondrocytes exposed to exogenous 
hyaluronan o f  similar molecular w eight {i.e. 490kDa) to the typical Mr o f endogenous 
HA {SOOkDa- l  OOOkDa range) found in native aggrecan aggregates resulted with a 
marked effect on the rate and amount o f aggrecan synthesised (3.78 fold greater) 
compared to Control grafts. This is suggestive that the inclusion o f 490kDa HA 
within Transwell cultures greatly enhances proteoglycan biosynthesis. Overall, these 
results show similarities to  recent publications, in that low molecular weight 
hyaluronan are more likely to  have detrimental effects on extracellular matrices 
(Solursh et al., 1980, Stern et al., 2006, Iacob & Knudson, 2006, Sugahara et al.,
2006) and high molecular weight HA tend to have beneficial effects (Kang et al., 
1999, Julovi et al., 2004, M onfort et al., 2005).
High molecular weight HA is used clinically as an accepted viscosupplementation 
procedure in the treatm ent o f  degenerative joint diseases (i.e. Osteoartritis-OA). This 
procedure has been found to  improve the visco-elastic properties o f  the synovial fluid
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encouraging lubrication, shock absorbance, the formation o f  a semi-permeable 
barrier, decreasing both inflammatory and proliferative responses that occur within 
diseased joints. It has been found that pain reduction lasts considerably longer than 
the half life o f injected HA, suggestive that the high molecular weight HA injections 
potentially may have disease modifying activity (Goldberg & Bulkwater, 2005). The 
mechanisms o f action o f exogenous high molecular weight hyaluronan in 
viscosupplementation at present are unclear, but data obtained in this study suggest 
that high molecular weight hyaluronan may be facilitating the retention o f  newly 
synthesised ‘repair aggrecan’ in the pathological cartilage and thereby slowing down 
the rate o f cartilage destruction through loss o f proteoglycan from the tissue. A 
potential improvement upon HA visco-supplementation procedures would be to 
incorporate a mixture o f  M wt HA ranging between 490kDa-3000+kDa as to provide 
optimal benefits o f aggrecan retention and biosynthesis to  OA patients receiving this 
treatment modality.
For future experimentation, it would be o f  interest to determine the endogenous levels 
o f hyaluronan present within neo-cartilage grafts in comparison to native articular 
cartilage. It would also be beneficial to fluorescently trace the penetration o f 
exogenously added HA {of varying molecular weights) into neo-cartilage grafts, and 
also determine if the major proteoglycan present in cartilage (aggrecan) is in an 
aggregated or non-aggregated form within graft tissue or Transwell media, as to 
determine the modes o f action and mechanisms involved with the addition o f each 
Mwt HA. Overall, it can be concluded that the Transwell culture system does not 
only show significant potential in the continued development o f autologous 
chondrocyte grafts for the repair o f human articular cartilage defects, but also 
provides an ideal culture model for scientific investigations as it enables high 
regulation and monitoring o f  most non-gaseous graft metabolites produced throughout 
the culture duration.
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S U M M A R Y  Recent advances in tissue engineering offer considerable promise for the  repair 
of focal lesions in articular cartilage. Here we describe (1) the  macromolecular organization of 
tissue-engineered neocartilage grafts a t light and electron microscopic levels, (2) their in vitro 
development, and (3) the effect of chondrocyte dedifferentiation, induced by monolayer 
expansion, on their resultant structure. We show th a t grafts produced from primary cultures 
of chondrocytes are hyaline in appearance with identifiable zonal strata as evidenced by cell 
morphology, matrix organization, and immunohistochemical composition. Like native articu­
lar cartilage, their surface zone contains type I collagen, surface zone proteoglycan, biglycan 
and decorin with type II collagen, aggrecan, chondroitin sulfate, chondroitin-4-sulfate, and 
keratan sulfate, becoming more prom inent with depth. Assessment of cell viability by Live/ 
Dead staining and cell-cyde analysis with BrDU suggest th a t the  in vitro tissue has a high 
cellular turnover and develops through both appositional and interstitial growth mecha­
nisms. Meanwhile, cell-tracker studies with CMFDA (5-chloromethyl-fluorescein diacetate) 
demonstrate th a t cell sorting in vitro is not involved in their zonal organization. Finally, 
passage expansion of chondrocytes in monolayer culture causes progressive reductions 
in graft thickness, loss of zonal architecture, and a more fibrocartilaginous tissue histol­
ogy, consistent with a dedifferentiating chondrocyte phenotype.
(J Histochem Cytochem 55:853-866, 2007)
cytes have the potential to synthesize and secrete new 
extracellular matrix (ECM) material, thereby resurfac­
ing the lesion and restoring functionality to the joint 
(Brittberg et al. 1994).
Although this type of therapy has shown significant 
progress (Brittberg et al. 2003), it has still not fully lived 
up to expectations (Wood et al. 2006). The reported 
loss of periosteal/collagen membranes, together with 
their underlying cells, into the synovial cavity remains 
an issue; and the development of a fibrocartilaginous 
repair tissue, which lacks the appropriate organiza­
tion and material properties to the original hyaline tis­
sue, remains problematic. Additional concerns yet to be 
resolved include imperfect cartilage resurfacing, unsatis­
factory integration of the new tissue with the surrounding 
matrix, and inadequate assimilation/remodeling of the 
carrier or scaffold (reviewed in Hunziker 2002; Wood 
et al. 2006).
Considering some of these problems, an alterna­
tive and potentially improved approach would be to
R e c e n t l y , there has been considerable interest in the 
application of novel, cell-based tissue-engineering stra­
tegies to articular cartilage repair (Kuo et al. 2006). In 
essence, utilizing this technology, culture-expanded au­
tologous chondrocytes can be delivered to a cartilage 
lesion site either (1) in suspension, beneath a periosteal 
patch or biodegradable membrane sutured to the wound 
margins, i.e., autologous chondrocyte transplantation 
(ACT) (Carticel; Genzyme, Cambridge, MA) (Brittberg 
et al. 1994,2003) or (2) immobilized within a biodegrad­
able, biomimetic, three-dimensional carrier or scaffold 
(Hutmacher 2000). Following implantation, and under 
favorable rehabilitative conditions, implanted chondro-
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the long term, rigorous evaluation of their macromo­
lecular composition and in vitro growth characteristics 
is clearly essential. Furthermore, to generate sufficient 
quantities of cells for an autologous human application, 
harvested chondrocytes would require proliferation in 
monolayer growth conditions. Crucially, this type of cul­
ture induces their dedifferentiation (Benya et al. 1978), 
characterized by a change in their cellular morphology, 
a downregulation of cartilage-specific genes (e.g., Sox 
5, 6, and 9, aggrecan, and type II collagen), and a re­
duced ability to produce hyaline cartilage (Stokes et al. 
2001; Yang et al. 2006). Whereas chondrocytes can be 
partially redifferentiated by their transferral to a three- 
dimensional culture model more conducive toward 
chondrogenesis, e.g., high density or agarose (Benya 
and Shaffer 1982; Watt 1988); the subsequent ability of 
these cells to synthesize genuine hyaline tissue remains 
ambiguous. Thus, in the present study, we (1) describe 
the macromolecular composition and organization of 
scaffold-free neocartilage tissues grown on synthetic 
filter membranes at light- and electron-microscopic 
levels, (2) explore their in vitro growth characteristics, 
and (3) examine the effect of passage expansion of 
chondrocytes, in monolayer culture, on resultant tis­
sue architecture.
Materials and Methods
Cell Culture
Full-depth slices of articular cartilage were obtained from 
the hock joints of 7-day-old bovines under sterile conditions. 
Cartilage slices were digested in 7 U/ml pronase (Roche; 
Hertfordfshire, UK) for 3 hr at 37C followed by overnight 
digestion in 100 U/ml type II collagenase (Worthington 
Biochemical Co.; Berkshire, UK). To obtain enriched sub­
populations of cells from each cartilage zone for tracker stud­
ies, the tissue was first subdissected into surface, middle, and 
deep layers and corresponding layers pooled prior to the above 
digestion steps. The resultant cell suspensions were filtered 
through a 40-pm cell strainer (BD Falcon; Erembodegem, 
Belgium), washed in DMEM containing 4500  mg/liter glu­
cose and L-glutamine (DMEM; Gibco BRL, Paisley, UK), and 
seeded at high density in 0.5-ml volumes (see below) onto type 
II collagen-coated (0.5 mg/ml; Sigma-Aldrich, Dorset, UK) 
0.6 cm Millipore filter inserts (0.4-|xm pores; Millipore, 
Billerica, MA) (Kandel et al. 1995). Initially, to investigate the 
effect of cell-seeding density on graft histology, chondrocytes 
were seeded at a range of cell densities: 2 ,4 ,6 ,  8 ,1 0 , and 12 X 
106 cells/insert (i.e., 4, 8, 12, 16, 20, and 24 X 106 cells/ml). 
To assess the effect of culture time on graft thickness, cells 
were cultured for 2-, 4-, 6-, and 8-week periods. Subsequently, 
grafts were made with 6 X 106 cells per insert and typically 
cultured for 4 weeks. Cultures were fed three times weekly on 
DMEM containing 20% heat-inactivated FBS, TGF |32 
(5 ng/ml; PeproTech, London, UK), and ascorbate (100 |xg/ml) 
and were maintained at 3 7C in a humidified atmosphere con­
taining 5% CO 2 as described by Kandel et al. (1995). To 
study the effect of dedifferentiation on the histological orga­
nization of the graft tissue, chondrocytes were serially passage 
expanded in monolayer culture in DMEM containing 10% 
FBS. Briefly, cells were grown to confluency in aerated 75-cm2 
flasks before passage with trypsin-EDTA (Gibco BRL). 
Harvested chondrocytes were washed, counted, and seeded 
at a density of 6 X 106 cells per filter insert and grown for 
4 weeks in culture as described above. Meanwhile, the re­
maining cells were returned to monolayer culture at low den­
sity for further rounds of expansion. This procedure was 
repeated until passage number five, by which time the growth 
rate in monolayer was insufficient to sustain sufficient cell 
numbers for further graft production.
Histology
Cartilage grafts were fixed in 2% paraformaldehyde and 
processed into paraffin wax using standard histological 
methods. Six-pan transverse sections were cut through the 
diameter o f the graft and mounted on HistoBond (R.A. Lamb; 
Eastbourne, UK) slides. Sections were stained for proteogly­
can (PG) content in 1% (w/v) alcian blue 8GX (pH 2.5) and 
Mayers hematoxylin/eosin or for collagen fiber organization 
by staining in 0.1% (w/v) sirius red F3B in saturated aqueous 
picric acid. Tissue organization was evaluated using bright- 
field, differential interference contrast (DIC), and polarizing 
optics. Graft thickness was measured at 10 arbitrary points 
across the diameter of the tissue on three different tissue 
sections, i.e., 30 measurements per graft.
Electron Microscopy
For ultrastructural investigation, grafts were processed for 
both scanning and transmission electron microscopy. For 
transmission electron microscopy, tissue was fixed in 2% 
glutaraldehyde in 0.05 M cacodylate buffer, pH 7.4, contain­
ing 0.7% ruthenium hexamine trichloride (RHT; Sigma- 
Aldrich) for 2 hr, followed by postfixation in 1% O s04  in
0.1 M  cacodylate, pH 7.4, containing 0.7% RHT for 2 hr. 
Samples were subsequently processed into Spurr’s resin (Agar 
Scientific; Essex, UK) using routine methodology. Ultrathin 
sections were cut and then stained with uranyl acetate and 
lead citrate before examination in a Philips EM 208 trans­
mission electron microscope (Philips Electron Optics; Eind­
hoven, The Netherlands). For scanning electron microscopy, 
RHT was omitted from the fixatives to prevent PG retention 
within the tissue. After the primary fixation step, samples 
were macerated in 10% NaO H  for 1 week at 4C to facilitate 
an appraisal of the collagenous network. After maceration, 
the tissue was processed for scanning electron microscopy 
using routine methodology and viewed in a Philips XL-20 
scanning electron microscope (Philips Electron Optics).
Immunohistochemical (IHC) Analysis of Graft ECM
Cartilage grafts were fixed in cold 75% ethanol, cryopro- 
tected in PBS containing 5% sucrose, and snap frozen onto 
cryostat chucks in Cryo-M-Bed tissue mountant (Bright 
Instruments; Cambridgeshire, UK). Grafts were cryosectioned 
at 10 |xm and frozen sections collected onto Histobond (R.A. 
Lamb) slides for immunostaining. Sections were labeled by 
standard indirect immunofluorescence procedures using pri­
mary antibodies to a wide range of ECM components (see 
Table 1). All immunoreagents were diluted in 0.05 M PBS
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between unlabeled deep- and surface-zone fractions, allowing
3 hr between the addition of successive cell subpopulations 
to minimize the extent o f initial cell mixing. Additionally, 
to identify the potential for zonal cell sorting during the cul­
ture period, labeled surface-, middle- or deep-zone cells were 
first mixed with their unlabeled counterparts before seed­
ing into filter inserts at a density o f 6 X 106 cells per insert 
(i.e., 2 X 106 cells from each layer). After 4 weeks of culture 
the grafts were harvested, fixed, and processed into paraffin 
wax, as described previously. W ax sections were cut and 
counterstained with propidium iodide (0.5 |xg/ml; Molecular 
Probes, Invitrogen) to impart nuclear context to the tissue 
or were immunofluorescently labeled with a monoclonal an­
tibody toward chondroitin sulfate to allow visualization of 
the ECM.
Results
Primary Culture
Macroscopically, all neocartilage graft tissues produced 
in this study had a glassy, hyaline appearance (Figure 2A). 
Based upon histological, ultrastructural, and IHC cri­
teria, the grafts were stratified into well-defined carti­
laginous zones that approximated with the superficial, 
middle, and deep layers of mature articular cartilage, 
although no calcified zone was identifiable (see below). 
In primary culture, this histological zonal organization 
was apparent at all cell-seeding densities and all culture 
periods studied (Figure 2, Figure 3, and Figure 4).
Cell Density and Culture Duration 
Cell-seeding density and culture period were important 
factors in determining the thickness of the resultant 
neocartilage tissues. Increasing cell number from 2 to
4 X 106 yielded a highly significant increase (p<0.001) 
in the thickness of neocartilage grafts produced at all 
culture periods examined. Increasing cell number > 4  X 
106 cells per insert provided subtle increases of variable 
significance in resultant graft thickness (Figures 2B and 
2C). Consistent with an increase in cell-seeding density 
was a concomitant increase in graft tissue cellularity; 
thus, seeding > 6  X 106 cells per insert yielded a tissue 
with a high cell-to-matrix ratio characterized by an ex­
cessively hypercellular appearance. The effect of in­
creasing the duration of culture from 2 to 8 weeks was a 
steady increase in the thickness of the cartilage grafts 
produced at all cell-seeding densities (Figures 2B and 
2C). This appeared to result from a combination of cell 
proliferation, hypertrophy, and progressive accumula­
tion of ECM material (see below). Interestingly, at each 
time point examined, the zonal proportions of the graft 
appeared relatively constant, suggesting that in vitro 
growth occurred uniformly throughout the tissue dur­
ing culture. Furthermore, with advancing time the cells 
in the basal part of the tissue (i.e., those closest to the 
filter membrane) appeared to acquire a more columnar 
organization (Figure 2C; see below).
Graft Organization
Light and electron microscopic examination of neo- 
cartilaginous grafts showed the surface zone to be 
weakly alcianophilic (Figure 3A), consisting of discoi- 
dal cells surrounded by a sparse, fibrillar meshwork of 
collagen (Figures 3A, 3B, and 3E). In this zone, both 
cells and matrix had a prominent horizontal organiza­
tion that was clearly apparent under Nomarski DIC 
and polarizing optics (Figures 3H and 31). The under­
lying mid-zone was strongly alcianophilic, indicating a 
higher PG content than the surface zone, and contained 
spheroidal chondrocytes that were separated by signifi­
cant amounts of ECM (Figures 3A, 3C, and 3F). Ul­
trastructural observation of this zone showed that its 
ECM comprised pericellular, territorial, and interterri­
torial matrix compartments, each with distinct collagen 
fiber densities and organizations, similar to that of 
articular cartilage (Figures 3C and 3F). The subjacent 
deep zone of the tissue was more cellular in appear­
ance than the overlying cartilage. Chondrocytes in this 
zone had an ovoid, hypertrophic morphology and were 
densely packed together, with some cells occurring in 
columnar arrays separated by thin septa of alciano­
philic ECM (Figure 2C, Figures 3A, 3D, and 3H). The 
interterritorial matrix of these septa, evident at the 
ultrastructural level, consisted of prominent longitu­
dinal fibrils that were arranged vertically with respect 
to the graft surface (Figures 3D and 3G). Observa­
tion with both Nomarski DIC and polarizing optics 
indicated that tissue organization in the deep zone 
(Figures 3H and 3J) was perpendicular to that occur­
ring at the graft surface (Figures 3H and 31).
Composition o f Graft ECM
Negative controls showed no nonspecific labeling with 
either primary or secondary antibodies (data not shown). 
Immunofluorescent labeling patterns obtained with anti­
bodies toward the chief ECM components suggested 
that after 4 weeks of primary culture the graft tissue 
was immunohistochemically similar to immature native 
articular cartilage (refer to Figure 1).
Collagens. Type I collagen was strongly detectable at 
the surface of the graft but was absent from the under­
lying connective tissue (Figure 4A) as occurs within the 
superficial zone of articular cartilage, whereas type II 
collagen was identifiable throughout the graft matrix 
(Figure 4B), confirmatory of the tissue’s hyaline nature. 
Type X collagen was not detectable in grafts after 
4 weeks of culture, reflecting the immaturity of the 
ECM; however, it became weakly associated with the 
pericellular matrix of hypertrophic chondrocytes in 
the basal zone after extended culture periods (i.e., 
>12 weeks; data not shown); its location correspond­
ing to that occurring in articular cartilage.
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Figure 3 Histological and ultrastructural organization of neocartilage tissue. (A) Wax histology. The graft is composed of three histologi­
cally distinct zones that approximate to the surface, middle, and deep zones of native adult cartilage (dashed lines demarcate boundaries 
between each cartilage zone). Alcian blue and hematoxylin/eosin. (B-D) Transmission electron micrographs demonstrating cell morphology 
and matrix organization associated with each graft zone (top to bottom), p, pericellular matrix; t, territorial matrix; i, interterritorial matrix; 
arrowheads in D denote position of interterritorial matrix. (E-G) Scanning electron micrographs showing topographic detail of collagenous 
organization in graft zones (top to bottom). (H) Nomarski differential interference contrast image showing distinct tissue organizations 
associated with each zonal strata (arrows denote predominant orientation of cells and matrix). Picrosirius red. (I,J) Polarized light microscope 
images showing (I) horizontal organization of collagen fiber bundles at the graft surface and (J) vertical organization of collagen associated 
with the interterritorial matrix of deep-zone chondrocytes. Bars represented in pm.
(> 12  weeks) it became more prominent at the surface 
of the graft (Figure 4H), having a similar organization 
to that of articular cartilage.
Glycosaminoglycans (GAG s). Unsulfa ted chondroi­
tin (C-O-S) and C-4-S “stubs” (i.e., after chondroitinase 
digestion) were prominent throughout the graft ECM 
and had a similar distribution to aggrecan, suggestive 
of their association with this PG (Figures 41 and 4J, 
respectively). Chondroitin-6-sulfated “stubs” were not 
detectable in the graft ECM (Figure 4K), indicative of the 
immaturity of the engineered tissue. Keratan sulfate 
was weakly present in the pericellular matrix compart­
ment, becoming more prominent with depth (Figure 4L) 
as occurs in articular cartilage, where it is associated 
with aggrecan. In contrast, dermatan sulfate was pres­
ent predominantly in the surface zone of the graft tissue 
(Figure 4M), suggesting that this molecule was asso­
ciated with decorin that was similarly located and to 
which it has known association in articular cartilage.
In Vitro Growth Characteristics
Assessment of cell viability with a fluorescent Live/ 
Dead Viability/Cytotoxicity Kit (Molecular Probes, 
Invitrogen) showed the majority of cells in thin 
(M).25 mm) living sections of graft tissue were viable,
i.e., had stained green after 4 weeks of culture (Figure 5A). 
During the same time period, dead cells (both necrotic
and apoptotic) evident by their red nuclei had accumu­
lated throughout the graft tissue; however, there was no 
distinct zone of cell death per se. Cell-cycle analysis with 
BrDU revealed strong incorporation of this thymidine 
analog in proliferating cells both at the graft surface and 
in the underlying cartilage tissue (Figure 5B), the high 
levels of BrDU incorporation probably reflecting the 
known effect transforming growth factor has on chon­
drocyte proliferation. Comparison with control sections 
incubated with naive immunoglobulin or antibody dilu­
ent instead of BrDU antibody confirmed that there was no 
nonspecific labeling (data not shown). Cell-tracker stud­
ies with CMFDA (5-chloromethyl-fluorescein diacetate) 
showed that after 4 weeks of culture the labeled mid-zone 
subpopulation largely retained its intermediate position 
in tri-layered composites, indicating there was little inter­
zonal movement of chondrocytes (Figure 5C). When 
grafts were made by mixing a single fluorescently labeled 
subpopulation with its unlabeled counterparts from 
the adjacent zones, in all cases the labeled chondrocytes 
were randomly distributed throughout the tissue depth 
(Figures 5D-5F). Although there was no compelling evi­
dence of zonal cell sorting mechanism per se, occasionally 
there appeared to be slightly more labeled deep zone cells 
in the basal part of the tissue (Figure 5F). This was pos­
sibly due to the hypertrophic cells of the deep zone being 
larger (mean cell volume ±  SEM of 1689 ±  145 iaitT) 
and therefore settling more readily during the initial cell-
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Figure 5 In vitro growth characteristics of 
neocartilaginous grafts. (A) Viability staining 
with calcein AM (live cells; green) and ethidium 
homodimer (dead cells; red) in living sections 
of graft tissue. The majority of chondrocytes 
in the graft are viable after 4 weeks of cul­
ture; however, dead cells (both apoptotic and 
necrotic) are observable throughout the tis­
sue depth. (B) Immunolocalization of bromo- 
deoxyuridine (90-min exposure) shows strong 
incorporation of this thymidine analog in pro­
liferating cells both at the surface and within 
the subjacent cartilaginous tissue (brown 
staining). Note that the matrix has been 
counterstained with alcian blue for tissue 
context. (C) Cell-tracker studies with CFDA (5- 
chloromethyl-fluorescein diacetate) show 
that the labeled mid-zone subpopulation of 
chondrocytes (yellow) largely retains its inter­
mediate position in tri-layered constructs. 
Note that cell nuclei have been counter­
stained red for cellular context. (D-F) Fluores- 
cently tagged subpopulations of surface- (sz) 
(D), middle- (mz) (E), and deep-zone (dz) chon­
drocytes (F). Green cells when mixed with their 
unlabeled counterparts show no compelling 
evidence of zone-dependent cell sorting in 
vitro. Matrix has been immunofluorescently 
labeled red for tissue context. Bar = 25 ^m.
v. < v
sz cells mz cells dz cells
zonally stratified neocartilage grafts potentially useful 
for the biological repair of intrachondral lesions of ar­
ticular cartilage. All tissues engineered from a primary 
chondrocyte source in this study showed histological, 
ultrastructural, and IHC similarities to native articular 
cartilage. The neocartilage tissues comprised three his­
tologically distinct zones that resembled the superficial, 
middle, and deep zones of native articular cartilage, and 
within these zones there were striking similarities in cell 
morphology, collagen fiber organization, and matrix 
composition to that o f native articular cartilage. Inter­
estingly, whereas the histological organization of the 
tissue closely resembled that of mature articular car­
tilage, the composition o f its ECM suggested closer 
similarities with immature, fetal-like hyaline cartilage: 
there was no detectable chondroitin-6-sulfate; type X 
collagen was initially absent, and there was no calcified 
cartilage matrix. This was not altogether surprising, 
however, given that the matrix was synthesized de novo 
over a short, 4-week period. Furthermore, although we 
did not specifically quantify the mechanical strength 
of the tissue, the pliability of the neocartilage evident
during handling indicated that it lacked the mechanical 
stiffness of mature articular cartilage.
Previous studies, chiefly by Waldman and colleagues, 
indicate that media supplementation and/or mechanical 
stimulation have the potential to add functional value 
to neocartilage grafts. Media supplementation has been 
successfully used to improve the quality of tissue- 
engineered cartilage, resulting in a more mature tissue 
phenotype, (3-glycerophosphate, for example, induces 
deep zone chondrocytes to calcify their cartilage ma­
trix (Kandel et al. 1997; Waldman et al. 2002), and 
N a H C 0 3 supplementation has been shown to improve 
the histological quality of neocartilage, resulting in 
more flattened cells resembling superficial zone chon­
drocytes at the graft surface (Waldman et al. 2004a). 
Biomechanical loading regimes, both compressive and 
shear (long and short term) have also been used to 
increase matrix deposition, improve matrix composi­
tion, and increase the thickness and biomechanical 
properties of the engineered cartilage (Waldman et al. 
2003b,2004b,2005). Indeed, the importance of utiliz­
ing appropriate biomechanical kinematics in articular
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Figure 7 Effect of monolayer expansion upon the distribution of collagen types I and II in neocartilaginous tissue. Note progressive increase 
in immunolabel for type I collagen with successive passage (P). Qualitative changes in the distribution of type II collagen were not apparent. 
Bar = 80 p.m.
largely by the culture environment. At the surface of the 
graft, chondrocytes would begin to flatten out, prolif­
erate, and undergo dedifferentiation, as occurs in mo­
nolayer culture (Benya et al. 1978; Stokes et al. 2001). 
These changes might not only explain the change in cell 
morphology from spheroid to discoid, but also account 
for the high levels of BrDU incorporation in cells at the 
surface of the tissue. It would also drive the expression 
of molecules typically associated with the superficial 
zone, such as collagen type I (Benya et al. 1978). Addi­
tionally, as the cells spread and assume a more fibro­
blastic morphology, collagen fibrils would be secreted 
more across the surface of the graft tissue, as occurs 
in monolayer culture. Deeper within the tissue the 
spheroid/ovoid chondrocyte morphology would be pre­
served as the cells are constrained at high density in 
three dimensions by neighboring cells. This environ­
ment would be conducive toward chondrogenesis (Watt 
1988) as reflected in the presence of increased amounts 
of sulfated PG, type II collagen, and aggrecan deeper 
within the tissue, potentiated further by the presence 
of transforming growth factor in the culture medium. 
During the initial period of growth, effete chondro­
cytes are probably crushed by the growing tissue and 
undergo necrosis/apoptosis as evidenced by the red 
nuclear staining seen with ethidium homodimer-1. Pro­
gressive deposition and accumulation of ECM between 
stacks of densely packed cells at the base of the culture 
might also generate the interstitial septa seen in this 
zone, as occurs in the developing growth plate (Eggli 
et al. 1985). Also, because the tissue is constrained lat­
erally by the walls of the culture vessel, growth would 
proceed in a predominantly vertical direction, made 
manifest as an increase in tissue thickness as seen in 
this study.
It is conceivable that the distinct strata might also 
arise partly through metabolic/morphogenic gradients 
occurring within the developing tissue. These might 
arise spontaneously as a result of a differential between 
the metabolic conditions cells experience at the surface 
of the developing tissue and its base. For instance, at the 
base of the culture competition for metabolites would 
probably be greatest because, in this region, cells are 
most densely packed and depend upon diffusion of 
metabolites through the underlying filter membrane and 
the overlying cells and matrix. It is known that oxygen
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cartilage repair purposes, the deleterious effects of 
chondrocyte dedifferentiation resulting from multiple 
passages still remain a major obstacle. Chondrocytes 
differentiated from stem cells would clearly obviate the 
necessity to perform multiple expansions of primary 
cells; thus, stem cell technology currently offers con­
siderable promise. A number of recent studies, for ex­
ample, have identified chondroprogenitor/stem cell 
populations within the superficial zone of articular 
cartilage (e.g., Dowthwaite et al. 2004). These cells 
have been shown to be highly proliferative, exhibit 
phenotypic plasticity in their differentiation pathway, 
and can undergo multiple rounds of passage without 
loss of chondrogenic phenotype (Dowthwaite et al. 
2004; Martin et al. 2005), showing significant poten­
tial for future cartilage-engineering applications.
In summary, results of this study add to previous 
data demonstrating that high-density primary cultures 
of full-depth chondrocytes grown on Millipore filter 
membranes produce a zonally stratified hyaline carti­
lage tissue with histological, ultrastructural, and IHC 
features of immature articular cartilage. These features 
arise spontaneously in primary culture and are pro­
gressively lost after chondrocytes have been passage 
expanded in monolayer growth conditions. The resul­
tant changes in graft thickness, organization, and com­
position thus reflect the cellular phenotypic changes 
that occur through chondrocyte dedifferentiation. 
Thus, significant potential exists in the continued devel­
opment of autologous chondrocyte grafts for the repair 
of intrachondral lesions of human articular cartilage. 
There is, however, a pressing need to accommodate re­
cent advancements in cartilage stem cell technology 
(Dowthwaite et al. 2004), new defined growth me­
dium (Jakob et al. 2001; Chua et al. 2005), cell culture 
methodologies (Murphy and Polak 2004; Barbero et al. 
2006), and gene therapy (Tew et al. 2005) that will 
allow bulking of chondrocyte numbers without the 
deleterious effects of cellular dedifferentiation.
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engineer a neocartilaginous repair tissue completely 
ex vivo and then implant the mature construct within the 
intrachondral lesion site (Kandel et al. 1995). The po­
tential advantages of this approach would be 3-fold: (1) 
growth conditions would be subject to a high degree of 
regulation in vitro, otherwise impossible within a dis­
eased or damaged joint; (2) there would be no require­
ment for a periosteal/collagen flap or carrier because 
the engineered repair tissue would already possess a 
mature, fully differentiated cartilage matrix; and (3) 
this would make the repair and resurfacing of greater 
and more degenerative lesions a possibility, potentially 
without the requirement for open knee surgery. Thus, 
providing the appropriate technologies for implant 
fixation were in place (Kandel et al. 1995), these po­
tential advantages would translate to an improvement 
in the scope and success of the repair and, significantly, 
a reduction in patient rehabilitation time.
Articular cartilage would appear well suited to an ex 
vivo regeneration strategy of the type described: it is a 
relatively simple tissue with a low cell-to-matrix volume 
ratio; it contains a single cell type, the chondrocyte, 
and it has no innervation, blood, or lymphatic sup­
plies (reviewed by Poole et al. 2001). Yet the superficial 
simplicity of articular cartilage belies its underlying 
complexity. The mature tissue is both structurally and 
functionally heterogeneous and consists of four dis­
tinct zones: superficial/tangential, middle/transitional/
intermediate, deep/radial, and a zone of calcified carti­
lage. Each of these zones has striking differences in chon­
drocyte morphology, gene expression, biochemical 
composition, and collagen fiber organization (refer to 
Figure 1). Collectively, these attributes allow the tissue 
to resist and dissipate biomechanical load while provid­
ing smooth, low-friction joint articulation for movement.
Over the last decade there have been a number of 
interesting publications, chiefly from the Kandel labo­
ratory, describing neocartilaginous tissues engineered, 
scaffold-free, from high-density primary chondrocytes 
(Boyle et al. 1995; Kandel et al. 1995,1997,1999; Peel 
etal. 1998; Sun and Kandel 1999; Adkisson etal. 2001; 
Waldman et al. 2002,2003a,b,2004a,b,2005; Park 
et al. 2006; Allan et al. 2007). Primarily, cartilage tis­
sues have been fabricated either upon porous, collagen- 
coated synthetic membranes or as biphasic constructs 
consisting of a cartilaginous tissue grown upon a calcium 
polyphosphate substrate. Interestingly, the engineered 
tissues have been shown to possess broad similarities 
with native articular cartilage and have been used for 
allogeneic transplantation in animal models with vari­
able success rates (Kandel et al. 1995,2006; Peel et al. 
1998; Park et al. 2006; Allan et al. 2007).
Significant potential exists in the further develop­
ment of these types of neocartilaginous tissues for the 
repair of human intrachondral lesions. However, to 
ensure their successful integration and functioning in
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Figure 1 Schematic summarizing the 
m acrom olecular organization of ma­
tu re  articular cartilage. The tissue con­
sists o f four distinct zones: superficial 
(SZ); m iddle (MZ), deep  (DZ), and a 
zone of calcified cartilage matrix (CZ), 
below  which is th e  subchondral bone 
(SB). Each zone is distinct in terms of 
its cell m orphology (left panel), colla­
gen  fiber o rganization  (middle panel), 
and  th e  biochemical composition of 
its extracellular matrix (ECM) (right 
panel). Matrix constituents of each 
cartilage zone are  presented as mo­
lecular schematics.
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Table 1 Antibodies used for immunohistochemistry
Hayes, Hall, Brown, Tubo, Caterson
Antibody (dilution) Clone (isotype) Pretreatment Specificity Source/Reference
#70-XR90 (1:200) P ABC/K Type I collagen Fitzgerald Industries International; Concord, MA
CIICI (1:5) M (lgG2a,K) ABC/K Type II collagen DSHB/Holmdahl et al. (1986)
aType X (1:100) P ABC/K Type X collagen Gibson et al. (1996)
6B4 (1:20) M (lgG1) ABC/K Aggrecan (interglobular domain) Caterson et al. (2000)
12C5 (1:5) M (lgG1) ABC/K Versican (HA-binding region) DSHB/Asher et al. (1991)
28.4 (1:20) M (lgG1) ABC/K Decorin (core protein) Bidanset et al. (1992)
PR8A4 (1:20) M (IgG) ABC/K Biglycan (core protein) Roughley et al. (1993)
1B5 (1:500) M (IgG 1k ) ABC/K Unsulfated chondroitin Couchman et al. (1984)
Caterson et al. (1985)
2B6 (1:20) M (IgG 1) ABC/K Chondroitin-4-sulfate and dermatan sulfate Couchman et al. (1984)
B/K Dermatan sulfate Caterson et al. (1985)
3B3 (1:20) M (IgM) ABC/K Chondroitin-6-sulfate Caterson et al. (1985)
5D4 (1:20) M (lgG1) None Keratan sulfate Caterson et al. (1983)
MCA2060 (1:200) M (lgG2a) HCI Bromodeoxyuridine (BrDu) AbD Serotec
ABC, chondroitinase ABC; B, chondroitinase B; K, keratanase; DSHB, Developmental Studies Hybridoma Bank; HA, hyaluronic acid.
containing 0.1% Tween 20 (Sigma-Aldrich), which was also 
used for each washing step. Where necessary, either to gen­
erate a neo-epitope or to improve antibody penetration, sec­
tions were enzymatically deglycosylated by pretreatment 
with either 0.5 U/ml chondroitinase ABC or chondroitinase B 
(both from Sigma-Aldrich) and 0.5 U/ml keratanase (AMS 
Biotechnology; Oxon, UK) in 100 mM Tris-acetate buffer 
(pH 7.4) for 1 hr at 37C (see Table 1). After washing, sections 
were treated with blocking serum (Dakopatts Ltd.; High 
Wycombe, UK) at 1:20 dilution for 30 min at room tempera­
ture before overnight incubation at 4C with primary antibody 
(see Table 1). After a second wash, sections were fluorescently 
labeled with FITC-conjugated goat anti-mouse or swine anti­
rabbit Fab fragments (Dakopatts Ltd.), recognizing either 
mouse or rabbit species, for 30 min at room temperature. Sec­
tions were counterstained with propidium iodide (0.5 |xg/ml; 
Molecular Probes, Invitrogen, Paisley, UK) for 5 min to im­
part nuclear context and then mounted in Vectashield fade- 
retarding mountant (Vector Laboratories Ltd.; Peterborough, 
UK). Control sections were incubated with PBS, 10 p-g/ml 
mouse immunoglobulins (Sigma-Aldrich), or non-immune rab­
bit serum (Sigma-Aldrich) instead of primary antibody, with 
or without the enzymatic digestion step. Sections were viewed 
and photographed using a Leitz fluorescent microscope (Leica; 
Wetzlar, Germany) equipped with digital image acquisition.
Cell Viability Assay
To determine cell viability and identify the presence and 
distribution of dead cells within the neocartilage tissue, grafts 
were incubated in the presence of 2 p.m calcein AM and 4 p,M 
ethidium homodimer solution (Live/Dead Viability/Cytotoxicity 
Kit; Molecular Probes, Invitrogen) for 30 min. After incuba­
tion with the above reagents, grafts were washed in PBS, cut 
transversely into thin (~0.25 mm) slices using a sharp razor 
blade to minimize cell death, and mounted under coverslips in 
PBS. Sections were photographed immediately under epifluo- 
rescence optics as described previously.
Cell Proliferation
To identify proliferating cells and study the role of cell pro­
liferation on tissue reorganization, neocartilage grafts were
incubated with bromodeoxyuridine (BrDU, 1:1000; Amersham, 
Buckinghamshire, UK) in complete tissue culture medium for 
90 min at 37C. Grafts were then fixed and processed for 
paraffin wax histology as described previously. A rat mono­
clonal antibody toward BrDU (AbD Serotec; Oxford, UK) 
(see Table 1) was used to localize proliferating cells using 
immunoperoxidase labeling in conjunction with DAB stain­
ing. This procedure was, in essence, similar to that described 
previously with the following modifications. After sections 
had been dewaxed and rehydrated they were incubated in 
1 M HC1 at 60C for 10 min to denature the DNA and improve 
antibody access. Endogenous peroxidase labeling was then 
irreversibly inhibited using 1.5% hydrogen peroxide (Sigma- 
Aldrich) in 100% methanol for 1 hr, followed by washing in 
PBS prior to the antibody blocking stage using rabbit serum 
(1:20). Sections were incubated with the anti-BrDU antibody 
(1:100) for 1 hr, washed in PBS, and then treated with a rabbit 
anti-rat biotinylated secondary antibody (1:200; Vector Labo­
ratories Ltd.) for 30 min at room temperature. To check for 
nonspecific labeling with primary and secondary antibodies, 
respectively, tissue sections were incubated with either naive 
rat immunoglobulin or antibody diluent (i.e., PBS) instead of 
the anti-BrDU antibody. After washing in PBS, sections were 
incubated with avidin/biotin/peroxidase complex (ABC; 20 p.1 
avidin DH, 20 pi biotinylated enzyme, and 1 pi PBS) for 
30 min. The ABC complex was localized using a DAB kit 
(Vector Laboratories Ltd.) including nickel chloride in the 
reaction substrate to produce a black/brown reaction prod­
uct. As a further check for nonspecific staining, the ABC 
complex or DAB staining steps were omitted. Sections were 
counterstained with 1% (w/v) alcian blue 8GX (pH 2.5) to 
impart tissue context and then photographed using bright- 
field optics.
Cell-Tracker Studies
To follow the in vitro kinetics of graft development, enriched 
chondrocyte subpopulations from each cartilage zone were 
labeled with a green fluorescent cell-tracker probe (Vybrant 
CFDA cell tracer kit; Molecular Probes, Invitrogen). To de­
termine the extent of interzonal cell movement occurring dur­
ing culture, a labeled mid-zone subpopulation was layered
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PGs. Aggrecan, the large aggregating PG of cartilage, 
was detectable throughout the ECM of the graft tis­
sue (Figure 4C); however, versican was not evident 
(Figure 4D). The small leucine-rich PGs biglycan and 
decorin were also detectable throughout the graft tissue 
(Figures 4E and 4F, respectively), but decorin, in par­
ticular, was more prominent in the surface zone of the 
tissue and diminished with depth, as occurs in articular 
cartilage. Superficial zone proteoglycan (SZP/lubricin/ 
PRG4/MSF precursor protein) was weakly immuno- 
located to cells of the graft surface after 4 weeks of cul­
ture (Figure 4G); however, with advancing culture time
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seeding step than the comparatively smaller cells of the 
middle and surface zones (mean cell volumes ±  SEM of 
567 ± 1 4  pm 3 and 467 ±  8 |xm3, respectively).
Effect of M onolayer Expansion
Successive passage expansion o f chondrocytes in m ono­
layer conditions led to striking changes in tissue depth, 
histological organization, and IHC composition of the 
resultant tissue (Figure 6-Figure 8). There were sig­
nificant deceases in graft thickness from > 5 0 0  pm at P0 
to < 3 0 0  pm at P5 and a steady reduction in the extent 
of alcian blue staining after successive passage, indic­
ative of a reduced sulfated GAG content (Figures 6A 
and 6B). Furthermore, histological organization of the 
tissue became less apparent with a progressive loss of 
zonal architecture (Figure 6B). At P3, chondrocytes had 
a profoundly reduced ability to lay down ECM, re­
sulting in a progressive loss o f cells to the medium and 
premature termination of the cultures at this stage. Inter­
estingly, this capacity was restored following succes­
sive passage of cells, although the resultant grafts 
lacked any semblance o f zonal organization, contained 
discrete clusters o f cells in the basal portion o f the tis­
sue, and appeared histologically similar to fibrocarti- 
lage (Figure 6B). IHC labeling of the grafts also showed 
a qualitative increase in the extent of labeling for type I 
collagen and versican and an overall decrease in the ex­
tent o f aggrecan immunolabeling with increasing pas­
sage number (Figure 7 and Figure 8), also indicative of a 
switch to a more fibrous cartilage phenotype. The label­
ing pattern for versican was particularly interesting be­
cause it coincided spatiotemporally with the cell clusters 
at the base of the tissue after P3, clearly suggestive of a 
fibrochondrocytic cell phenotype in this tissue zone.
Discussion
Tissue O rganization
This study adds to previous data (e.g., Kandel et al. 
1995) demonstrating that chondrocytes grown at high 
density upon porous filter membranes can produce
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cartilage engineering cannot be overstated. For exam­
ple, recent data show that chondrocytes require stim­
ulation by applied surface motion, but not axial 
compression, to upregulate production of SZP and to 
generate a normal articular surface (Grad et al. 2005). 
Provision for these factors may thus be important in 
optimizing the functional value of neocartilage tissues 
generated for repair purposes. It is worthwhile consid­
ering, however, that although an engineered construct 
with similar mechanical properties to mature articular 
cartilage may be desirable from a biomechanical stand­
point, an immature tissue phenotype may facilitate 
better integration with the host tissue and could be 
mechanically conditioned in situ, i.e., postimplantation, 
via a prudent exercise regimen.
Cellular Growth Mechanisms
Together our data suggest that the engineered tissues 
have a high cellular turnover and develop through a 
combination of appositional and interstitial growth 
mechanisms. Appositional growth would appear to 
occur principally at the graft surface, as evidenced by 
prominent BrDU incorporation at this site, and inter­
stitial growth in the underlying cartilage tissue via a 
combination of cell proliferation and matrix accumu­
lation. Our cell-tracker studies strongly suggest that 
zone-specific cell sorting does not play a role in the 
establishment of the distinct strata in vitro. Instead, our 
data suggest that chondrocytes divide or differentiate 
according to their potential and position in the devel­
oping tissue and that these behaviors are dictated
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tension, for example, plays an important regulatory 
role during cartilage growth by promoting chondrocyte 
differentiation and cartilage matrix synthesis while sup­
pressing terminal chondrocyte differentiation (Hirao 
et al. 2006). Oxygen tension may play a similar role in 
the current context: its physiological effects manifesting 
in the zonal organization of cells and matrix within the 
in vitro-generated tissue.
Effect of Passage Expansion
Although chondrocytes are readily obtainable from 
animal models to generate allogeneic grafts for experi­
mental purposes, to obtain sufficient cell numbers for a 
clinical application would necessitate multiple expan­
sions of autologous chondrocytes in monolayer culture. 
It is well established that this type of culture causes their 
cellular dedifferentiation to a more fibroblastic pheno­
type: downregulation of cartilage-specific genes such as 
Sox-5, 6, and 9, aggrecan, and type II collagen and up- 
regulation of type I collagen (Benya et al. 1978; Stokes 
et al. 2001; Yang et al. 2006). Although there is some 
evidence that passage-expanded chondrocytes can par­
tially redifferentiate when transferred to culture models 
more conducive to chondrogenesis (e.g., agarose or 
high-density cultures) (Benya and Shaffer 1982; Watt 
1988), in this study we have shown that their ability to 
produce true hyaline tissue resembling articular carti­
lage becomes dramatically reduced.
Other studies have shown similar phenotypic changes 
to occur in human articular chondrocytes between P0 
and P4 in monolayer culture, with profound changes 
identifiable at the mRNA level identifiable as early as 
PI (Darling and Athanasiou 2005). Chondrocytes iso­
lated from human nasal septum cartilage have been 
shown to exhibit a similar impairment in their ability to 
proliferate at P3, whereupon they begin to acquire a 
fibroblastic dedifferentiation morphology (Chua et al. 
2005). Binette et al. (1998) have also noted a similar 
downregulation of mRNA for aggrecan and type II col­
lagen and an upregulation of versican and collagen type 
I hy human articular chondrocytes after monolayer 
expansion, consistent with the IHC data presented in 
this study.
Thus, at present, although significant potential ex­
ists for the use of autologous chondrocyte grafts for
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